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Drug Use and the Risk of Motor Vehicle Collision in Adults 65 Years of Age and Older 
 
Toni Marie Rudisill, MS 
 
Introduction: The population of adults 65 years of age and older is growing at an exponential rate in the 
United States.  The current generation of older adults is more mobile and driving much later in life 
compared to previous cohorts.  While the current generation of older adults is living longer, they are not 
necessarily healthier.  Older adults consume roughly 30% of all written prescriptions, are the largest 
consumers of over-the-counter medications, and report a higher prevalence of lifetime licit and illicit drug 
use compared to previous generations.  There is concern that many older adults will drive while taking 
drugs—either illicit or licit—that will interfere with their ability to safely operate a motor vehicle.  Licit 
and illicit drug use is largely understudied in this population of drivers, particularly in the United States.   
 
Methods:  This study employed a systematic review to discern which individual licit drugs were 
associated with increased risk/odds of motor vehicle collision, a cross-sectional analysis of a national 
traffic fatality database to discern which types of licit and/or illicit drugs and combinations were most 
prevalent among fatally injured senior drivers compared to middle-aged drivers, and a case-crossover 
study using electronic medical records to assess the risk that individual licit drugs pose to drivers 65 years 
of age and older in West Virginia who were admitted to medical treatment following a motor vehicle 
collision. 
 
Results:  Among the 53 specific medications investigated by the 27 studies included in the systematic 
review, 15 medications (28.3%) were associated with an increased risk of motor vehicle collision.  The 
medications that were associated with an increased risk of collision were: Buprenorphine, Codeine, 
Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, 
Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and Zopiclone.  In the cross-sectional 
analysis, licit and illicit drug use among senior drivers occurred in 17.8% of those tested.  Among drug-
positive senior drivers, benzodiazepines and narcotics were frequent.  The rates of testing positive for any 
drug, multiple drugs, combined drug and alcohol, and alcohol use alone among seniors were 47% (Rate 
ratio, RR=0.53, 95% CI 0.50, 0.57), 57% (RR=0.43, 95% CI 0.39, 0.48), 88% (RR=0.12, 95% CI 0.10, 
0.15) and 79% (RR=0.21, 95% CI 0.19, 0.24) less, respectively, compared to middle-aged drivers.  In the 
case-crossover study, few drivers tested positive for drugs.  Of those testing positive, benzodiazepines and 
opiates were the most common.  After adjusting for the number of medications a driver was consuming 
during case and control periods, cases consuming Tramadol (Odds ratio, OR: 11.41; 95% CI 1.27, 
102.15), were at a significantly increased risk of motor vehicle collision if they consumed these 
medications 14 days before the collision compared to control periods.  Numerous other medications, 
including Clopidogrel, Gabapentin, Citalopram, Insulin, Hydrochlorothiazide, Metoprolol, Zolpidem, and 
Nitroglycerine, were trending towards being associated with motor vehicle collision, but were not found 
statistically significant.   
 
Conclusions: The findings of this research pose numerous clinical and research implications.  As many 
of the licit drugs included in this analysis are widely prescribed, patients should be informed that their 
driving ability may be affected.  Further exploration into this area is research is necessary as older adults 
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Chapter 1: Literature review 
1.1 The ‘graying’ of United States drivers  
Due to increases in both life expectancy and fertility post-World War II, the United States (U.S.) 
is experiencing an unprecedented demographic shift with the number of adults 65 years of age and older 
increasing faster than any other age group (Centers for Disease Control and Prevention 2003).  This 
translates into a one million person per year increase in the 65 and older age group as projected through 
2030 (Centers for Disease Control and Prevention 2003).  The current generation of older adults is living 
their lives quite differently than previous cohorts.  Quality of life is highly valued (Rappaport 2009), and 
compared to their predecessors, the older adults of today are increasingly mobile and heavily engaged in 
their personal and professional lives (Becton, Walker et al. 2014).  In a 2010 survey of 225 older adults, 
most reported that they planned to continue working later in life and intended to increase their travel and 
civic engagements (MaloneBeach and Langeland 2010).  Overall, the current generation of older adults is 
wealthier, better educated, and more likely than their predecessors to remain employed (Topiwala, Patel 
et al. 2014).  Between 1977 and 2007, the number of adults who continued to work past 75 years of age 
increased 172% (Tang, Choi et al. 2013), which has been attributed to gaps in health insurance, 
educational attainment burdens, and decreases in pension plans (Mermin, Johnson et al. 2007).     
The current demographic shift is not without consequence.  Despite higher socio-economic status 
and advancements in healthcare, the current generation of older adults is not markedly healthier than their 
predecessors, though they are living longer (Martin, Freedman et al. 2009).  Consequently, it is projected 
that this generation of older adults will experience increases in chronic disease and complex medical 
conditions which will burden the healthcare system (Dall, Gallo et al. 2013).  It is projected that this 
demographic shift will cause a 14% increase in demand for primary care physicians (Dall, Gallo et al. 
2013) along with increases in the length of hospital stays and number of hospital admissions (Pallin, 
Allen et al. 2013; Pallin, Espinola et al. 2014).  Emergency department capacity and hospital admission 
rates will need to increase 10% and 23%, respectively, faster than the population grows in order to keep 
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up with demand (Pallin, Allen et al. 2013; Pallin, Espinola et al. 2014).  Therefore, meeting the healthcare 
demands of this generation of older adults is one of the largest public health hurdles to date.  
Besides the increased demands on the healthcare system, the demographic shift has also placed 
additional strain on the transportation system.  Because older adults are continuing to work and travel, 
they are also driving later in life compared to previous generations.  Agencies, such as the U.S. 
Department of Transportation, have been proactively working to develop a national agenda to promote 
safe mobility due to increasing number of older drivers (Stutts 2005).  These measures have included 
ways to make roads safer through engineering pursuits, to promote safer drivers thru stricter relicensing 
measures, and encouraging the motor vehicle industry to create safer vehicles (Oxley, Langford et al. 
2010).  Such agencies acknowledge that driving is inherent to American culture and many depend solely 
on personal transportation for their mobility.  Reliance on public transportation in the U.S. is declining 
among older adults while their number of trips taken and miles traveled continue to increase (Rosenbloom 
2003).  Approximately 79% of older adults reside in rural or suburban areas (Rosenbloom 2003), causing 
many of these individuals to rely on their personal vehicles for transportation purposes (Schwarzlose, 
Mjelde et al. 2014).     
1.2 The importance of mobility on health and well-being 
Mobility is broadly defined as an individual’s ability to move about their environment (Webber, 
Porter et al. 2010).  While individuals can navigate their environment various ways, such as walking, 
taking public transportation, riding as a passenger, or driving, most Americans equate mobility with 
driving a personal vehicle (King, Meuser et al. 2011).  It is widely accepted that driving is associated with 
freedom and independence.  Dickerson et al investigated the importance of instrumental activities of daily 
living (IADL) in a group of 30 seniors who were returning home after receiving extensive rehabilitation; 
when asked to rate the importance, being able to drive and manage medications, respectively, were the 
first and second most valued tasks (Dickerson, Reistetter et al. 2013).  A significant body of literature 
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exists regarding the importance of mobility and its effect on individual health and well-being.  Driving 
cessation has been linked to various negative health outcomes, which can be categorized as 
physical/tangible measures, including unmet leisure needs (Bonnel 1999; Marottoli, de Leon et al. 2000; 
Haustein and Siren 2014), reduced social networks (Mezuk and Rebok 2008; Pekmezaris, Kozikowski et 
al. 2013), even mortality (Edwards, Perkins et al. 2009), or poorer emotional/mental health (Johnson 
1999; Fonda, Wallace et al. 2001; Ragland, Satariano et al. 2005; Gagliardi, Marcellini et al. 2010; King, 
Meuser et al. 2011; Al-Hassani and Alotaibi 2014). 
Three studies investigated the effects of driving cessation on unmet leisure needs.  A qualitative 
study conducted by Bonnell et al investigated the effects of driving cessation on 15 women through focus 
group sessions (Bonnel 1999).  Driving cessation is an important issue to older women’s health as more 
women live alone (41%) as age increases (Bonnel 1999).  Virtually all participants reported that they gave 
up social outings, missed doctor’s appointments, church and family gatherings, meals, volunteering 
opportunities, and leisure activities (such as shopping) when they ceased driving.  Many sought out other 
means of transport which included walking, relying on family and friends, services vans, and public 
transportation (Bonnel 1999).  A study by Haustein and Siren investigated how important a driving 
license is for seniors to fulfill their mobility needs (Haustein and Siren 2014).  Data were collected in 
2012 from 863 individuals born in either 1939 or 1940 via telephone interviews.  The study compared 
those that were currently licensed, had never been licensed, or gave up their licenses. Both never having a 
license and having given up a license significantly affected unmet mobility needs (Haustein and Siren 
2014).  A study by Marotolli et al was designed to test the hypothesis that driving cessation leads to a 
decline in out-of-home activity levels (Marottoli, de Leon et al. 2000).  Participants came from the New 
Haven Established Populations for Epidemiologic Studies of the Elderly (EPESE) cohort. After adjusting 
for potential demographic and health-related variables, driving cessation was significantly associated with 
decreased out-of-home activity levels (Marottoli, de Leon et al. 2000). 
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Two studies have investigated the effects of driving cessation on social isolation.  A study by 
Mezuk et al evaluated the impact of driving cessation on social integration and perceived support from 
relatives and friends among older adults (Mezuk and Rebok 2008).  Data came from the population-based 
Baltimore Epidemiologic Catchment Area Study.  Social integration and perceived social support were 
assessed at two interviews staged over the course of 13 years.  The use of public transportation was 
investigated as a potential mediator.   Driving cessation was significantly associated with a reduced 
number/network of friends that was not mediated by the use of public transportation (Mezuk and Rebok 
2008).  A study by Pekmezarius et al surveyed 1,151 seniors to examine the needs of seniors living in a 
large suburban community across two counties in New York State (Pekmezaris, Kozikowski et al. 2013).  
Findings revealed that seniors over 85 years of age and those who do not drive were more socially 
isolated even though public transportation was readily available (Pekmezaris, Kozikowski et al. 2013).  
One study investigated if driving cessation was a predictor of mortality (Edwards, Perkins et al. 
2009).  In a 2000-2004 prospective study of 660, community-dwelling, adults over 63 years of age, being 
a non-driver at follow up was significant predictor of three year survival (Edwards, Perkins et al. 2009). 
Six studies investigated the effects of driving cessation on mental health.   In a study by Al-
Hassani et al a questionnaire was sent to 114 community dwelling seniors regarding their driving status 
and mental health.  Results showed that for non-drivers, driving cessation created feelings of dependency 
and loss of control (Al-Hassani and Alotaibi 2014).  A study by Gagliardi et al investigated association 
between mobility and positive well-being in two sample populations of older adults from Germany (n = 
1518) and Italy (n = 600) who were part of the MOBILATE European cohort study. Results showed that 
in both countries the driving car is an important predictor of well-being, mobility, health, and life 
satisfaction (Gagliardi, Marcellini et al. 2010).  A study by Johnson investigated the effects of licensure 
forfeiture in a convenience sample of 285 urban dwelling adults who had stopped driving within the past 
year in an undisclosed city in the Western U.S.  Approximately 80% of respondents reported feelings of 
loneliness after drivers license forfeiture and felt their mobility was compromised even though public 
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transportation was available (Johnson 1999).  A study by King et al investigated attitudes, beliefs, values, 
and emotions associated with real or anticipated changes in mobility status in a convenience sample of 30 
adults over 57 years of age in an undisclosed Midwestern city (King, Meuser et al. 2011).  Participants 
were separated into focus groups by age and disability status.  Fear of dependence was an important 
feeling in all groups.  Many said they experienced an array of emotions such as devastation, resentment, 
anger, frustration, loneliness, and isolation after they could no longer drive (King, Meuser et al. 2011).  A 
study by Fonda et al investigated whether changes in driving patterns (i.e. limiting driving distances or 
driving cessation) were associated with depressive symptoms among older adults (Fonda, Wallace et al. 
2001).  The participants in this study (n=4,102) were individuals from the Asset and Health Dynamics 
among the Oldest Old (AHEAD) cohort.  Results showed that respondents who stopped driving had 
greater risk of worsening depressive symptoms. Interestingly, having a spouse available to drive those 
who no longer drove did not mediate this effect (Fonda, Wallace et al. 2001). A study by Ragland et al 
evaluated clinical depression in former drivers compared with active drivers. Participants were part of a 
cohort of 1,953 residents of Sonoma County, California, aged 55 years and older, as part of a community-
based study of aging and physical performance (Ragland, Satariano et al. 2005). Results showed that after 
controlling for age, sex, education, health, and marital status, former drivers reported higher levels of 
depression than did active drivers. Increased depression was substantially higher in men that no longer 
drove compared to women who no longer drove (Ragland, Satariano et al. 2005). 
Findings from these studies show how important driving is to an individual’s health and well-
being.  While the ability to drive is highly revered among older adults, findings from the Bonnell et al 
study report that pressure from adult children to cease driving, decreases in reflexes, fear of liability, car 
repair costs, and safety concerns are some of the reasons why some seniors choose to no longer drive 
(Bonnel 1999).  Respondents from the Johnson study reported that mandatory license revocation or 
pressure from family and friends were the primary reasons for driver’s license forfeiture (Johnson 1999). 
1.3 Crash risks among older adult drivers 
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While maintaining mobility is crucial for older adults’ health and well-being, driving cessation is 
unavoidable for many.  Deciding when to cease driving is not always clear.  Due to the increasing number 
of older adult drivers, the crash risk that older drivers pose to themselves and others has generated much 
research interest. To date, this issue has been investigated numerous ways, but can generally be grouped 
into the following categories: 1) trend analyses of older driver crash rates, 2) comparisons of fatal and 
non-fatal crash rates between different age groups of drivers, 3) hospitalization or injury rates of elderly 
drivers, passengers, and/or pedestrians, and 4) where and how older driver collisions occur.    
As for trend analyses, one study has been conducted to date (Cheung and McCartt 2011).  Cheung 
et al investigated fatal and non-fatal crash rates of older drivers using crash data from 13 states between 
1997 and 2008.  The findings from this analysis reveal that both fatal and non-fatal crash rates have 
declined considerably in the U.S. among older adult drivers during this 12-year period (Cheung and 
McCartt 2011).    
While crash rates appear to be declining among older adult drivers, they are not necessarily low.  
In 2011, the National Highway Traffic Safety Administration reports that 17% of all traffic fatalities were 
among adults aged 65 years and older (National Highway Traffic Safety Administration 2013).  Three 
studies have been conducted in the U.S. using national crash data to compare rates between different age 
groups (Massie, Campbell et al. 1995; Li, Braver et al. 2003; Williams and Shabanova 2003).  Li et al 
compared older drivers age 60 and over, 16-19, 20-29, and 30-59 year old drivers.  Results showed that 
older drivers had much higher death rates per vehicle miles traveled compared to other age groups (Li, 
Braver et al. 2003).  Massie et al compared fatal crash involvements per million miles traveled in 16-19, 
20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, and ≥70 year old drivers.  Findings 
show that the oldest drivers had the highest fatal crash involvement rates compared to all other age groups 
(Massie, Campbell et al. 1995).  Williams et al compared the rates of drivers in fatal crashes involving 
one or two passenger vehicles per 100,000 license holders, by driver age group and gender.  The authors 
also investigated driver fault.  Findings showed that the oldest drivers were more likely than any other 
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group to be responsible for their fatal crashes (Williams and Shabanova 2003).  The findings from the 
U.S. studies are similar to those conducted in Australia (Ryan, Legge et al. 1998; Keall and Frith 2004; 
Keall and Frith 2006; Langford, Bohensky et al. 2008; Langford, Koppel et al. 2008; Langford, Charlton 
et al. 2013) and Canada (Lefrancois and D'Amours 1997; Myrick 2001).  The findings from the 
Australian and Canadian studies have also found drivers over 70 to be involved in more fatal and non-
fatal collisions per vehicle miles traveled and drivers who drive less miles per year to be at heightened 
crash risk (Lefrancois and D'Amours 1997; Ryan, Legge et al. 1998; Myrick 2001; Keall and Frith 2004; 
Keall and Frith 2006; Langford, Bohensky et al. 2008; Langford, Koppel et al. 2008; Langford, Charlton 
et al. 2013). 
As for injury or hospitalization rates of older adult drivers and their passengers, three studies have 
investigated these topics (Tavris, Kuhn et al. 2001; Braver and Trempel 2004; Dellinger, Kresnow et al. 
2004).  Tavris et al studied the differences in gender and hospitalization rates for drivers and passengers 
involved in motor vehicle collisions in Wisconsin using administrative claims data.  Results showed that 
males were hospitalized 33% more than females and that hospitalizations of drivers increased 
significantly in men starting at age 70.  Passenger injury rates were highest in women over 85 years of age 
(Tavris, Kuhn et al. 2001).  Braver et al used insurance data to calculate the injury rates per driver for 
various road users.  Results of this analysis showed that older drivers pose a 152% increased risk of 
fatality to their passengers who also tend to be aged (Braver and Trempel 2004).  Dellinger et al assessed 
the risk of fatality and non-fatal injury to other road users (i.e. cyclists, pedestrians, etc) by drivers over 
65 years of age and compared these rates to various other age groups.  The findings showed that drivers 
over 74 years of age posed more risk of death to others and that drivers ≥85 years of age posed the most 
risk of injury to other road users per million miles driven (Dellinger, Kresnow et al. 2004).   
Four studies have investigated which type of road conditions or driving situations pose the most 
risk to older adult driver safety (McGwin and Brown 1999; Bedard 2000; Laing 2003; Surapaneni 2006).  
Bedard et al studied every fatal traffic incident from 1975-1998 using U.S. crash data and found that 
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drivers over 80 years of age were eight times at risk for committing driving errors associated with road 
signs or warnings, six times the risk of collision for entering or exiting traffic flow, and seven times are 
risk to commit errors at intersections compared to drivers aged 40-49 (Bedard 2000).  Laing et al 
investigated collisions in British Columbia by age between 1996 and 2000 and found that drivers over 65 
years of age have higher collision rates at intersections (Laing 2003).  Mcgwin et al studied traffic 
collisions by different age groups in Alabama during 1996.  Findings from their analysis showed that 
older drivers experienced more collisions at intersections or during turns or lane changes and often failed 
to yield the right of way or heed traffic control devices compared to other age groups (McGwin and 
Brown 1999).  Surapaneni investigated collisions of older adult drivers (≥75 years) compared to various 
other age groups in Clark County, Nevada.  Based on rates per million vehicle miles traveled, older 
drivers had higher rates of collisions involving turns, failure to yield, and lane changes compared to other 
ages (Surapaneni 2006). 
As evident from the reviewed literature, older adult drivers do appear to be at higher risk of 
collision compared to younger age groups, especially when taking the amount they drive (i.e. miles driven 
daily, weekly, etc) into account.  Older drivers seem to be at higher risk of hospitalization or injury 
compared to younger drivers possibly due to fragility.  Older drivers do appear to pose an increased risk 
to their passengers.  Collisions occurring at intersections, turning, and lane changes appear problematic to 
many older drivers. 
1.4 Aging and fitness-to-drive 
Part of the reason why older adult drivers may experience more collisions than younger drivers is 
due the natural course of aging.  Cognitive and psychomotor declines, decreases in vision and/or hearing, 
and physical limitations could potentially lead to driving errors or increased risk of motor vehicle 
collision.  The following sub-sections discuss the extant research on the association with aging and the 
ability for a driver to safely operate a motor vehicle (e.g. fitness-to-drive).   
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1.4.1 Cognition and fitness-to-drive 
Three studies have investigated the associations between cognitive declines, driving errors, and/or 
driving restrictions (McKnight and McKnight 1999; Anstey and Wood 2011; Rapoport, Naglie et al. 
2013).  All three studies revealed that decreased cognition is associated with more driving errors.  Antsey 
et al evaluated the association age, cognitive function, and driving errors in a group of drivers (n=266) 
aged 70-88 years. Participants performed several laboratory tests which evaluated their visual attention, 
processing speed, inhibition, reaction time, task switching along with an actual driving assessment.  The 
authors determined that all error types increased with age of participants (Anstey and Wood 2011).  
Mcknight et al studied the association between cognitive function and unsafe driving incidents in 407 
elderly drivers 62 year of age and older using several laboratory assessments and a driving test (McKnight 
and McKnight 1999).  The authors found a significant association between participants with lower 
cognitive function and unsafe driving actions (McKnight and McKnight 1999).   Rapoport et al examined 
the association between cognitive performance, driver perceptions, and self-reported driving restriction in 
a cohort of 928 drivers aged 70-94 years across several Canadian cities (Rapoport, Naglie et al. 2013).  
Cognition was evaluated laboratory assessment while driver perceptions were assessed using a scaled 
instrument.  Those with lower cognitive functioning moderately reduced their driving frequency and 
avoidance of complex driving environments (Rapoport, Naglie et al. 2013).   
Two studies have investigated how cognitive training can actually improve driver performance or 
prolong driving (Edwards, Delahunt et al. 2009; Ball, Edwards et al. 2010).  Ball et al tested a 
randomized, cognitive intervention on 908 community dwelling seniors to see if increased cognitive 
training decreased the incidence of motor vehicle collisions (Ball, Edwards et al. 2010).  Findings from 
the study showed that cognitive speed-of-processing and reasoning training resulted in a lower at-fault 
MVC rate in older drivers compared to controls (Ball, Edwards et al. 2010).   Edwards et al also 
performed a cognitive function intervention (n=276) to assess whether drivers with cognitive deficits who 
partook in the training would drive longer/later in life compared to controls (Edwards, Delahunt et al. 
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2009).  The results showed that drivers receiving the training were 40% less likely to cease driving 
compared to controls (Edwards, Delahunt et al. 2009).  
1.4.2 Psychomotor function and fitness-to-drive 
Three studies have investigated the relationship between psychomotor function and fitness-to-
drive (McKnight and McKnight 1999; Horswill, Pachana et al. 2009; Dawson, Uc et al. 2010).   Dawson 
et al assessed the neuropsychological abilities in a laboratory setting and in an instrumented vehicle of 
older adults with no cognitive impairments (n=111) compared to middle-aged adults (n=80) (Dawson, Uc 
et al. 2010).   After adjusting for age, education, and sex, older drivers psychomotor functioning was 
significantly less than those of middle-aged adults (Dawson, Uc et al. 2010).  A study conducted by 
Horswill et al also compared psychomotor function in young, middle and older adults and found that 
older adults had reduced response to perceived hazards compared to the other age groups (Horswill, 
Pachana et al. 2009).  Mcknight et al conducted a psychomotor assessment and on the road driving 
assessment of 407 drivers over 62 years of age.  The results showed that significant correlations were 
found between poor psychomotor functioning and unsafe driving errors (McKnight and McKnight 1999).   
1.4.3 Vision and fitness-to-drive 
The association between visual impairment and increased motor vehicle collision, decreased 
driving ability, and/or driving cessation has been extensively studied in the literature (Ivers, Mitchell et al. 
1999; McGwin Jr, Chapman et al. 2000; Satariano, MacLeod et al. 2004; Ross, Anstey et al. 2009; Green, 
McGwin et al. 2013; Sandlin, McGwin et al. 2014). Green et al investigated the association between 
visual impairments and motor vehicle collision in a population based sample of 2,000 licensed drivers 
over 70 years of age in Alabama.  Those with declines in contrast sensitivity were at a significantly higher 
risk of motor vehicle collision (Green, McGwin et al. 2013).  A study by Ivers et al in examined the 
association between decreased visual acuity and motor vehicle collision in a cohort of individuals 
(n=3,654) in Australia (Ivers, Mitchell et al. 1999).  Compared to younger drivers, drivers over 80 years 
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of age experienced significant more motor vehicle collisions if they experienced a decrease in visual 
acuity (Ivers, Mitchell et al. 1999).  Mcgwin et al evaluated the association between visual function and 
driving difficulty in a group of drivers (n=384) (McGwin Jr, Chapman et al. 2000).  Individuals with 
decreased visual acuity and contrast sensitivity were more likely to be involved in self-reported high-risk 
driving situations (McGwin Jr, Chapman et al. 2000).  A study by Ross et al found that in an Australian 
cohort of adults over 65 years of age (n=5,206), those with self-reported poor vision were more likely to 
cease driving compared to those with better self-reported vision (Ross, Anstey et al. 2009).  A study by 
Sandlin et al examined the relationship between visual impairments and the amount that a person drives in 
a population-based sample of older adults in Alabama 70 years of age and older (Sandlin, McGwin et al. 
2014).  The results of the analysis showed that those with impaired contrast sensitivity reduced the 
number of trips and annual mileage compared to those with normal contrast sensitivity (Sandlin, McGwin 
et al. 2014).  A study by Satariano et al also examined the relations between self-reported visual problems 
and driving cessation in a community-based study of adults (n=1,840) over 55 years of age in Sonoma, 
California (Satariano, MacLeod et al. 2004).  The results showed that drivers with more self-reported 
vision problems were more likely to reduce their driving trips/mileage (Satariano, MacLeod et al. 2004). 
1.4.4 Hearing and fitness-to-drive 
Three studies have investigated the relationship between hearing loss and fitness-to-drive (Ivers, 
Mitchell et al. 1999; Hickson, Wood et al. 2010; Green, McGwin et al. 2013).  Green et al investigated 
the association between hearing impairment and motor vehicle collision in a population based sample of 
2,000 licensed drivers over 70 years of age in Alabama (Green, McGwin et al. 2013).  Drivers with 
hearing impairments were 52% more likely to be involved in a motor vehicle collision (RR = 1.52, 95% 
CI = 1.01-2.30) (Green, McGwin et al. 2013).  Hickson et al investigated the effects of hearing 
impairment on older adults driving ability and distractibility in a laboratory setting and an actual driving 
assessment (Hickson, Wood et al. 2010).  It was found that older adult drivers with hearing impairments 
(both self-reported and clinically confirmed) had significantly poorer driving performance compared to 
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those without impairments (Hickson, Wood et al. 2010).  A study by Ivers et al in examined the 
association between hearing loss and motor vehicle collision in a cohort of individuals (n=3,654) in 
Australia (Ivers, Mitchell et al. 1999).  Compared to younger drivers, drivers over 80 years of age 
experienced significant more motor vehicle collisions if they experienced moderate hearing loss of loss of 
hearing in their right ears (Ivers, Mitchell et al. 1999).  Therefore, declines in hearing may lead to increase 
in motor vehicle collision. 
1.4.5 Physical limitations and fitness-to-drive 
Two studies have investigated the relationship between physical limitations and fitness-to-drive 
(Reimer, D'Ambrosio et al. 2008; Antin, Lockhart et al. 2012).  A study by Antin compared 49 drivers 
and non-drivers 65 years of age and older on various physical and mental assessments (Antin, Lockhart et 
al. 2012).  Results showed that non-drivers had more physical and cognitive limitations than those who 
continued to drive (Antin, Lockhart et al. 2012).  A study by Reimer et al investigated the effects of 
flexibility on safe vehicle operation in younger and older drivers (Reimer, D'Ambrosio et al. 2008). 
Results showed that while older drivers were less flexible than younger drivers, many had developed 
compensatory measures (i.e. bracing) to overcome flexibility limitations to prolong their driving (Reimer, 
D'Ambrosio et al. 2008).  
1.5 Medical conditions associated with motor vehicle collision risk 
While declines in cognition, psychomotor function, vision, hearing, and physical limitations 
associated with the normal aging process may pose a risk to drivers’ safety, numerous medical conditions 
have been linked to increased motor vehicle collision risk and/or decreased driving ability.  
Alzheimer’s/dementias (Fitten, Perryman et al. 1995; Tuokko, Tallman et al. 1995; Cox, Quillian et al. 
1998; Duchek, Carr et al. 2003; Frittelli, Borghetti et al. 2009; Eby, Silverstein et al. 2012),  
anxiety/depression (Sagberg 2006; Wingen, Ramaekers et al. 2006), arrhythmias (Stewart 1993; Gresset 
and Meyer 1994), cataracts (Owsley, Stalvey et al. 1999; Owsley, McGwin Jr et al. 2002), glaucoma 
13 
 
(Haymes, Leblanc et al. 2007), chronic obstructive pulmonary disease (Karakontaki, Gennimata et al. 
2013), cardiovascular diseases (Koepsell, Wolf et al. 1994; Guibert, Potvin et al. 1998; Lundqvist, Gerdle 
et al. 2000; Sagberg 2006; Hours, Fort et al. 2008), diabetes (Hansotia and Broste 1991; Koepsell, Wolf et 
al. 1994; McGwin, Sims et al. 1999; Sagberg 2006; Redelmeier, Kenshole et al. 2009; Signorovitch, 
Macaulay et al. 2013), epilepsy (Hansotia and Broste 1991; Beaussart, Beaussart-Defaye et al. 1997), 
Parkinson’s disease (Lings and Dupont 1992; Classen, Brumback et al. 2014), and sleep apnea (George, 
Boudreau et al. 1996; Mulgrew, Nasvadi et al. 2008; Gieteling, Bakker et al. 2012) are all associated with 
increased risk of motor vehicle collision and/or decreased driving ability. 
The associations between Alzheimer’s disease/dementias (AD) and motor vehicle collision risk 
and/or affected driving ability have been studied using driving simulators, instrumented vehicles, or 
collision rates.  Cox et al performed a matched case control study of 29 patients with Alzheimer’s disease 
(AD) using a driving simulator to understand how driving is related to mental status (Cox, Quillian et al. 
1998).  Those with AD performed much worse than controls (Cox, Quillian et al. 1998).  Frittelli et al 
also assessed the driving performance of 20 AD patients, 20 patients with mild cognitive impairment, and 
20 healthy controls using a driving simulator.  Those with AD performed significantly worse than those 
with mild cognitive impairments and controls (Frittelli, Borghetti et al. 2009).  Duckeck et al assessed the 
driving performance of AD patients with mild/early symptoms to those of healthy controls in a 
longitudinal study (Duchek, Carr et al. 2003).  Those with early AD were significantly more likely to 
experience decreased driving performance compared to controls.  These findings suggest even at early 
disease onset, those with AD may have compromised driving ability (Duchek, Carr et al. 2003).  Eby et al 
assessed the driving performance of early stage dementia patients (n=17) compared to healthy controls 
(n=26) using instrumented vehicles (Eby, Silverstein et al. 2012).  While driving performance did not 
differ vastly between groups, those with dementia did not drive as far and were more likely to become 
lost than controls (Eby, Silverstein et al. 2012).  Tuokko et al retrospectively assessed the driving records 
of patients receiving treatment for dementia (n=249) and compared these to a matched cohort of patients 
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at the same clinic without diagnosed dementia (Tuokko, Tallman et al. 1995).  The authors found that 
those with dementia had a collision rate 2.5 times greater than the control group (Tuokko, Tallman et al. 
1995).  Consequently, there is evidence that AD affects driving ability, but it may be dependent on the 
severity of cognitive impairment more than diagnosis (Fitten, Perryman et al. 1995).     
Two studies have assessed the relationship between anxiety/depression, motor vehicle collision, 
and/or affected driving ability (Sagberg 2006; Wingen, Ramaekers et al. 2006).  Sagberg et al 
administered a self-reported questionnaire to older drivers (n=4,448) to assess which medical conditions 
and symptoms may be associated with motor vehicle collision.  Patients who reported being anxious or 
depressed had significantly higher odds of motor vehicle collision (Sagberg 2006).  Wingen et al assessed 
the driving performance of clinically depressed patients compared to healthy controls. Those with 
depression had poorer driving performance and were more likely to weave within driving lanes and have 
slower reaction times compared to controls (Wingen, Ramaekers et al. 2006).     
Two studies have investigated the relationship between arrhythmias and motor vehicle collision 
or affected driving ability (Stewart 1993; Gresset and Meyer 1994).  Gresset et al conducted a matched 
case control study of men aged 70 years or older residing in Quebec who had been involved in motor 
vehicle collisions (Gresset and Meyer 1994).  The purpose was to assess which self-reported medical 
conditions were associated with higher odds of collision.  Those with heart arrhythmias were 1.63 times 
more likely to be involved in collisions (OR=1.63, CI: 1.00-2.65) (Gresset and Meyer 1994).  Stewart et 
al assessed the risk of motor vehicle collision by self-reported medical conditions in a cohort of Florida 
residents (Stewart 1993).  Heart arrhythmias were a statistically significant predictor of motor vehicle 
collision in this population (Stewart 1993). 
Three studies have investigated the association between motor vehicle collision and optometric 
diseases such as cataracts (Owsley, Stalvey et al. 1999; Owsley, McGwin Jr et al. 2002) and glaucoma 
(Haymes, Leblanc et al. 2007).  Owsley et al compared the collision data of those with and without 
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cataracts in a population of older drivers in Alabama (Owsley, Stalvey et al. 1999).  Those with cataracts 
were 2.5 times more likely to be involved in an at-fault motor vehicle collision compared to those without 
the disease (Owsley, Stalvey et al. 1999).  Additional studies by the same research group showed that 
cataract surgery can actually reduce collision risk (Owsley, McGwin Jr et al. 2002).  Haymes et al 
conducted a matched case control study to investigate the odds of motor vehicle collision in a group of 
patients with glaucoma compared to a control group (Haymes, Leblanc et al. 2007).  After adjusting for 
annual miles driven, glaucoma patients were involved in motor vehicle collisions 6 times more than 
controls (Haymes, Leblanc et al. 2007). 
One study has investigated the effects of chronic obstructive pulmonary disease (COPD) on skills 
related to driving performance.  COPD patients (n=35) and healthy controls (n=10) underwent a battery 
of psychomotor testing related to driving skills.  COPD patients performed significantly worse than 
controls on all measurements (Karakontaki, Gennimata et al. 2013).   
Several studies have assessed the relationship between cardiovascular ailments (i.e. heart attack, 
stroke, hypertension, coronary artery disease) and motor vehicle collision (Koepsell, Wolf et al. 1994; 
Guibert, Potvin et al. 1998; Lundqvist, Gerdle et al. 2000; Sagberg 2006; Hours, Fort et al. 2008).  The 
findings are often mixed.  Guibert et al conducted a population-based case control study in Quebec, 
Canada to assess whether male drivers with self-reported cardiovascular disease were more likely to be 
involved in a motor vehicle collision. After adjusting for annual miles driven, those with cardiovascular 
disease experienced fewer motor vehicle collisions (Guibert, Potvin et al. 1998).  Sagberg et al 
administered a self-reported questionnaire to older drivers (n=4,448) to assess which medical conditions 
and symptoms may be associated with motor vehicle collision.  Patients who reported having a previous 
heart attack had significantly higher odds (OR: 1.77) of motor vehicle collision (Sagberg 2006).  
Lundqvist et al conducted a case control study to assess the effects of stroke on driving performance using 
psychomotor testing, a driving simulator, and actual driving assessment.  Stoke patients performed worse 
than controls in all testing environments (Lundqvist, Gerdle et al. 2000).  Koepsell et al conducted a case 
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control study to assess which medical conditions may be associated with motor vehicle collision in a 
group of drivers over 65 years of age living in Washington State.  Those diagnosed with coronary heart 
disease were 40% more likely to be involved in a motor vehicle collision (OR: 1.4; 95% CI 1.0, 2.2) 
(Koepsell, Wolf et al. 1994).  Hours et al also conducted a nested case control study to assess which 
medical conditions were associated with motor vehicle collision in a cohort of individuals living in 
Rhone, France.  Those with hypertension were at a significantly increased risk of motor vehicle collision 
(OR: 3.82, 95% CI 1.42, 10.24) (Hours, Fort et al. 2008).  
Several studies have investigated the relationship between type-1 or type-2 diabetes and the 
odds/risk of motor vehicle collision (Hansotia and Broste 1991; Koepsell, Wolf et al. 1994; McGwin, 
Sims et al. 1999; Sagberg 2006; Redelmeier, Kenshole et al. 2009; Signorovitch, Macaulay et al. 2013).  
The findings of these studies are often mixed.  Hansotia et al conducted a population-based retrospective 
cohort study (n= 30,420) of adults with and without diabetes in Marshfield, Wisconsin.   Those with 
diabetes experienced 32% more collisions and 14% more moving violations compared to those without 
the condition (Hansotia and Broste 1991).  Mcgwin et al conducted a population-based case control study 
of drivers over 65 years of age in Alabama to assess if those with diabetes experienced more motor 
vehicle collisions.  Those with diabetes were not at a higher risk of collisions or at-fault collisions 
compared to controls (McGwin, Sims et al. 1999).  Koepsell et al conducted a case control study to assess 
which medical conditions may be associated with motor vehicle collision in a group of drivers over 65 
years of age living in Washington State.  Those diagnosed with diabetes were 2.6 times more likely to be 
involved in a motor vehicle collision (OR: 2.6; 95 % CI 1.4, 4.7) (Koepsell, Wolf et al. 1994).  
Redelmeier et al studied that association between glycosylated hemoglobin, diabetes and motor vehicle 
collision via a population-based case control study.  Findings suggested that even with tight glycemic 
control (i.e. improved glycosylated hemoglobin levels), the odds of motor vehicle collisions were still 
higher than controls (Redelmeier, Kenshole et al. 2009).  Sagberg et al administered a self-reported 
questionnaire to older drivers (n=4,448) to assess which medical conditions and symptoms may be 
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associated with motor vehicle collision.  Patients who reported non-medicated diabetes had 3.08 higher 
odds of motor vehicle collision (Sagberg 2006).  Signorovitch et al assessed the association between 
motor vehicle collision and those who had type-2 diabetes that were not treated with insulin via a 
retrospective cohort study using a medical claims database (n=5582).  Those admitted for hypoglycemic 
attacks were also at a higher risk of being admitted for motor vehicle collisions (HR 1.82; 95% CI 1.18, 
2.80) (Signorovitch, Macaulay et al. 2013).  
Two studies have investigated the association between epilepsy and motor vehicle collisions 
(Hansotia and Broste 1991; Beaussart, Beaussart-Defaye et al. 1997).  Beaussart et al conducted a 
longitudinal study of epileptic patients to assess the relationship between motor vehicle collision and 
epileptic seizures while driving (Beaussart, Beaussart-Defaye et al. 1997).  Results showed that the 
incidence of seizures was very low and severities of collisions were minor. Hansotia et al conducted a 
population-based retrospective cohort study (n= 30,420) of adults with and without epilepsy in 
Marshfield, Wisconsin.   Those with epilepsy experienced 33% more collisions compared to those 
without the condition (Hansotia and Broste 1991). 
Two studies have investigated how driving ability is affected by Parkinson’s disease (PD) (Lings 
and Dupont 1992; Classen, Brumback et al. 2014).  Classen et al compared the driving ability of PD 
patients (n=101) to healthy controls (n=138) via an actual driving assessment.  PD patients made 
significantly more driving errors overall compared to controls (Classen, Brumback et al. 2014).  Lings et 
al used a driving simulator to assess the driving ability of PD patients (n=28) compared to healthy 
controls (n=109).  Those with PD had more driving errors, such as failure to react, reduced strength, and 
increased reaction times, compared to controls (Lings and Dupont 1992).  
Three studies have investigated how sleep apnea affects motor vehicle collision risk and/or 
driving ability (George, Boudreau et al. 1996; Mulgrew, Nasvadi et al. 2008; Gieteling, Bakker et al. 
2012).  Mulgrew et al investigated the association between obstructive sleep apnea and motor vehicle 
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collision via a case-control study (n=783).  Those with sleep apnea were at a significantly increased risk 
of collision (Mulgrew, Nasvadi et al. 2008).  George et al investigated the driving ability of male patients 
with sleep apnea (n=21) matched by sex and age to those without the condition (n=21) using a driving 
simulator.  Patients with sleep apnea performed worse on all tests compared to controls (George, 
Boudreau et al. 1996).  Geiteling et al also investigated the driving ability of sleep apnea patients (n=18) 
compared to a control group (n=18) and a group of patients with periodic limb movement disorder (n=18) 
via a driving simulation experiment.  Those with sleep apnea and periodic limb movement disorder 
performed slightly worse than controls over the course of the experiment, particularly regarding vigilance 
(Gieteling, Bakker et al. 2012). 
1.6 Licit drugs and motor vehicle collision risk 
While the natural aging process and existing medical conditions can influence motor vehicle 
collision risk and/or driving ability, so can prescription or over-the-counter medication usage.  It is well-
established in the literature that medication usage increases with age.  While the number of prescription 
and over-the-counter medications (i.e. licit drugs) taken each day can vary between individuals, it is 
estimated that approximately 60% of all adults 65 years of age and older consume one prescription 
medication daily (Fulton and Allen 2005), while only 20% use three or more prescriptions each day 
(Jorgensen, Johansson et al. 2001).  Current research also suggests that adults 65 years of age an older 
consume approximately 30% of annual written prescriptions (Bushardt, Massey et al. 2008).  This age 
group is also the largest consumers of over-the-counter medications based on retail drug sales (Fulton and 
Allen 2005).  Unfortunately, both prescription and over-the-counter medication may produce side effects 
that interfere with safe driving.  Numerous medications have been associated with motor vehicle collision 
risk and/or decreased driving ability.  The following sections review the current research pertaining to this 
issue.  
1.6.1 The effects of licit drugs on motor vehicle collision risk 
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Most of the research pertaining to the relationship between licit drug use and motor vehicle 
collision risk has grouped and analyzed these drugs as broad categories.  The majority of drugs studied 
have included psychotropic drugs, which include antidepressants, antipsychotics, benzodiazepines and z-
drugs (i.e. sleep medications).  Narcotic analgesics have also been studied extensively, in addition to anti-
diabetic drugs.  
At least twelve studies have investigated the risk posed by antidepressant medication (Ray, 
Fought et al. 1992; Leveille, Buchner et al. 1994; Bramness, Skuytveit et al. 2008; Hours, Fort et al. 2008; 
Rapoport, Herrmann et al. 2008; Coupland, Dhiman et al. 2011; Meuleners, Duke et al. 2011; Rapoport, 
Zagorski et al. 2011; Ravera, van Rein et al. 2011; Orriols, Queinec et al. 2012; Chang, Wu et al. 2013; 
Orriols, Wilchesky et al. 2013).  The results of these studies are often mixed.  Bramness et al found that 
sedating (Incidence ratio, IR 1.4; 95% Cl 1.2, 1.6) and non-sedating (IR 1.6; 95% CI  1.5, 1.7) 
antidepressants were associated with increased collision risk in a retrospective cohort of drivers aged 18-
69 years in Norway  (Bramness, Skuytveit et al. 2008).  In a matched case-control study in Taiwan using 
claims data, Chang et al found that antidepressant use one week or one month was significantly associated 
with motor vehicle collisions (Chang, Wu et al. 2013).  In a large cohort study (n=60,746) of clinically 
depressed adults over 65 years of age conducted in England using claims data, Coupland et al found that 
only certain individual antidepressants were associated with collision risk (Coupland, Dhiman et al. 
2011).  In a case-control study conducted in France, Hours et al found that antidepressant use was 
significantly associated with at-fault motor vehicle collisions (OR 3.6; 95% CI 1.3, 10.0) (Hours, Fort et 
al. 2008).  In a case control study conducted in Seattle, WA of drivers over 65 years of age, Leveille et al 
found that tricyclic antidepressant use was associated with a 2.3 increased risk of collision (Leveille, 
Buchner et al. 1994).  In a population-based case-crossover study conducted in Australia, Meuleners et al 
found that men who were prescribed an antidepressant were at an increased risk of collision while females 
were not (Meuleners, Duke et al. 2011).  In a population-based case-crossover study conducted in France, 
Orriols et al found that when antidepressant medications were initiated or changed, those who consumed 
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these medications were at a 49% and 32%, respectively, higher risk of motor vehicle collision (Orriols, 
Queinec et al. 2012).  In a case-crossover study conducted in Quebec, Canada among drivers over 65 
years of age (n=109,406), drivers who consumed antidepressants one month before their crash were at a 
higher risk of collision compared to antidepressant use that occurred 4-8 months before the collision 
(Orriols, Wilchesky et al. 2013).  In a case-crossover study conducted in Ontario, Canada among adults 
over 65 years of age diagnosed with dementia, Rapoport et al found that second generation antidepressant 
use (i.e. newer antidepressant medication) was associated with a higher collision risk than first generation 
antidepressants (i.e. older antidepressant medications) (Rapoport, Herrmann et al. 2008).  In a 
retrospective cohort study conducted in Ontario, Canada among adult driver over 65 years of age, second 
generation antidepressants were associated with a modest increase (i.e. 10%) in motor vehicle collision 
(OR 1.10; 95% CI 1.07, 1.13) (Rapoport, Zagorski et al. 2011).  In a case control study conducted in the 
Netherlands, Ravera et al found that younger female drivers who were prescribed second generation 
antidepressants were at an increased risk of collision (Ravera, van Rein et al. 2011).  In a retrospective 
cohort study of Medicaid enrollees over 65 years of age in Tennessee, Ray et al found that tricyclic 
antidepressant use was associated with a two-fold increase of motor vehicle collision (relative risk, RR 
2.2; 95% CI 1.3, 3.5) (Ray, Fought et al. 1992). 
At least eight studies have investigated the association between motor vehicle collision and 
benzodiazepine use; all studies show that benzodiazepine use is associated with motor vehicle collision 
(Ray, Fought et al. 1992; Barbone, McMahon et al. 1998; Neutel 1998; England, Skurtveit et al. 2007; 
Rapoport, Herrmann et al. 2008; Meuleners, Duke et al. 2011; Orriols, Philip et al. 2011; Chang, Wu et 
al. 2013).  In a cohort study conducted in Norway of 18-70 year old drivers (n=3.1 million), those 
receiving a prescription for benzodiazepine tranquilizers or hypnotics were at a significantly increased 
risk of motor vehicle collision (England, Skurtveit et al. 2007).  Barbone et al conducted a case-crossover 
study of driver over 18 years of age in Scotland and found that benzodiazepine use was associated with a 
62% increased risk of collision (OR 1.62; 95% CI 1.24, 2.12) (Barbone, McMahon et al. 1998).  In a 
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matched case-control study in Taiwan using claims data, Chang et al found that benzodiazepine use one 
week or one month was significantly associated with motor vehicle collision (Chang, Wu et al. 2013).  In 
a population-based case-crossover study conducted in Australia of drivers 60 years of age and older, 
Meuleners et al found that both men and women who were prescribed a benzodiazepine were at an 
increased risk of collision (Meuleners, Duke et al. 2011).  In a cohort study conducted in Saskatchewan, 
Canada (n=225,796) which compared driver over 60 years of age to those under 60, Neutel et al found 
that regardless of age, benzodiazepine use increased the risk of motor vehicle collision (≤ 60 years:  OR 
3.2; 95% CI 1.3, 3.8;  >60 years:  OR 2.8; 95% CI 1.0, 8.4) (Neutel 1998).  In a population-based 
retrospective cohort study conducted in France, Orriols et al found that benzodiazepine hypnotic use was 
significantly associated with a 39% higher risk of motor vehicle collision (Orriols, Philip et al. 2011). In a 
case-crossover study conducted in Ontario, Canada among adults over 65 years of age diagnosed with 
dementia, Rapoport et al found that benzodiazepine use was associated with a higher collision risk 
(Rapoport, Herrmann et al. 2008).  In a retrospective cohort study of Medicaid enrollees over 65 years of 
age in Tennessee, Ray et al found that benzodiazepine use was associated with a 50% increase of motor 
vehicle collision (Ray, Fought et al. 1992). 
At least three studies have investigated antihyperglycemic drugs and motor vehicle collision risk; 
the findings are often mixed (Hemmelgarn, Lévesque et al. 2006; Lonnen, Powell et al. 2008; Skurtveit, 
Strøm et al. 2009).  In a nested case-control study conducted in Quebec, Canada, those taking insulin 
were at an increased risk of collision while those taking sulfonylurea or metformin were not 
(Hemmelgarn, Lévesque et al. 2006).  In a retrospective cohort study conducted in England, Lonnen et al 
found that those taking insulin were not at an increased risk of motor vehicle collision (Lonnen, Powell et 
al. 2008).  In a cohort study conducted in Norway of 18-70 year old drivers (n=3.1 million), those 
receiving a prescription for insulin or glucose-lowering agents were at a 40% and 20%, respective, 
increased risk of motor vehicle collision (Skurtveit, Strøm et al. 2009). 
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At least three studies have investigated the relationship between hypnotics (i.e. z-drugs) and 
motor vehicle collision risk; all three studies have determined an increased risk of motor vehicle collision 
with their use (Gustavsen, Bramness et al. 2008; Yang, Lai et al. 2011; Chang, Wu et al. 2013).  In a 
matched case-control study in Taiwan using claims data, Chang et al found that the use of z-drugs for one 
week or one month was significantly associated with motor vehicle collision (Chang, Wu et al. 2013).  In 
a cohort study conducted in Norway of 18-70 year old drivers (n=3.1 million), those receiving a 
prescription for z-drugs were at an increased risk of motor vehicle collision (OR 2.3; 95% CI 2.0, 2.7) 
(Gustavsen, Bramness et al. 2008).  In randomly selected cohort of 1 million people established using 
medical claims data in Taiwan, Yang et al found that taking one dose of a z-drug was associated with a 
74% increased risk of collision (Yang, Lai et al. 2011). 
At least eight studies have investigated the relationship between narcotic use and motor vehicle 
collision risk; most show that narcotic use is associated with motor vehicle collision risk (Leveille, 
Buchner et al. 1994; England, Skurtveit et al. 2007; Bachs, Engeland et al. 2009; Majdzadeh, Feiz-Zadeh 
et al. 2009; Meuleners, Duke et al. 2011; Bramness, Skurtveit et al. 2012; Corsenac, Lagarde et al. 2012; 
Gomes, Redelmeier et al. 2013).  In a cohort study conducted in Norway of 18-70 year old drivers (n=3.1 
million), those receiving a prescription for opioids were at a significantly increased risk of motor vehicle 
collision (England, Skurtveit et al. 2007); this study was repeated by Bachs et al, but for codeine or 
Tramadol specifically, and these two drugs were found to be associated with increased collision risk 
(Bachs, Engeland et al. 2009).  Bramness et al repeated the Bachs et al study for methadone and found 
that only methadone use in men were associated with increased collision risk (IR 2.4; 95% CI 1.5, 3.6) 
(Bramness, Skurtveit et al. 2012).  Corsneac et al performed a population based case control study in 
France (n=72,865) and found that buprenorphine or methadone use were both associated with an 
increased risk of collision (OR 2.0; 95% CI 1.4, 2.9) (Corsenac, Lagarde et al. 2012).  Gomes et al 
conducted a population-based nested case control study of patients aged 18 to 64 years who received at 
least one publicly funded prescription for an opioid and determined that the higher the opioid dose, the 
23 
 
higher risk of motor vehicle collision (Gomes, Redelmeier et al. 2013).  In a case control study conducted 
in Seattle, WA of drivers over 65 years of age, Leveille et al found opioid use was associated with a 88%  
increased risk of collision (Leveille, Buchner et al. 1994).  In a case-crossover study of drivers injured in 
motor vehicle collision who required medical treatment in Kerman, Iran, those using opium six hours 
before the collision were at an increased risk of collision (Majdzadeh, Feiz-Zadeh et al. 2009).  In a 
population-based case-crossover study conducted in Australia of drivers 60 years of age and older, 
Meuleners et al found that those taking narcotic analgesics were at an increased risk of collision (OR 1.5;  
95% CI 1.0-2.3) (Meuleners, Duke et al. 2011).   
1.6.2 The effects of licit drugs on actual driving ability 
While numerous licit drugs have been associated with increased motor vehicle collision risk, 
many others have been evaluated in experimental studies to determine if the drugs affect actual driving 
ability.  Most of the research involving drugs and driving ability have centered on antidepressants, 
antihistamines, benzodiazepines, hypnotics (i.e. z medications), and opioids.  The results of the 
experimental studies need to be interpreted with caution as the sample sizes are often small and limited to 
younger or healthier participants; hence, the findings may not be generalizable to older populations with 
complex medical conditions or multiple medication use. 
At least ten experimental, placebo controlled, cross-over studies have investigated specific 
antidepressant medications and their effects on driving ability; the findings from these studies are often 
dependent on the drug and/or population being tested (Ramaekers, Swijgman et al. 1992; Ramaekers, 
Muntjewerff et al. 1995; Ramaekers, Ansseau et al. 1997; O'Hanlon, Robbe et al. 1998; Ramaekers, 
Muntjewereff et al. 1998; Ridout and Hindmarch 2001; Ridout, Meadows et al. 2003; Wingen, Bothmer 
et al. 2005; Wingen, Ramaekers et al. 2006; Theunissen, Street et al. 2013).  O’hanlon et al found that 
Venlafaxine did not impair driving performance among 37 healthy volunteers (O'Hanlon, Robbe et al. 
1998).  Ramekers et al found that the driving performance of 41 clinically depressed patients was actually 
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improved with use of Moclobemide or Fluoxetine (Ramaekers, Ansseau et al. 1997).  Raemakers et al 
also found that among 18 healthy volunteers, nocturnal doses of Mirtazapine or Mianserin did not affect 
driving performance as much as when given during the daytime (Ramaekers, Muntjewereff et al. 1998).   
Raemakers et al found that driving performance of 18 healthy volunteers was not affected by Dothiepin or 
Fluoxetine (Ramaekers, Muntjewerff et al. 1995).  Raemakers et al found that among 17 healthy 
volunteers, Mianserin affected driving performance while Moclobemide had not effects (Ramaekers, 
Swijgman et al. 1992).  In a study of 12 healthy volunteers conducted by Ridout et al, Tianeptine did not 
affect performance any different than placebo, but Mianserin did impair driving performance (Ridout and 
Hindmarch 2001).  In a study of 16 healthy volunteers conducted by Ridout et al, Paroxetine did not 
affect performance any different than placebo, but Mirtazapine did impair driving performance (Ridout, 
Meadows et al. 2003).  In a study of 24 healthy subjects, Theunissen et al determined that Mirtazapine 
effects driving performance while Vortioxetine did not compared to placebo (Theunissen, Street et al. 
2013).  Wingen et al performed a study using 18 healthy subjects and found Mirtazapine affected driving 
performance while Escitalopram did not compared to placebo (Wingen, Bothmer et al. 2005).  Wingen et 
al tested the driving performance of clinically depressed patients compared to healthy participants; 
depressed patients taking second generation antidepressants performed worse on all measure compared to 
controls (Wingen, Ramaekers et al. 2006). 
Three, experimental, placebo controlled, cross-over studies have assessed the effects of narcotics 
on driving ability (Byas-Smith, Chapman et al. 2005; Verster, Veldhuijzen et al. 2006; Amato, Marie et 
al. 2013).  Amato et al assessed the effects of increasing doses of codeine/paracetamol on sixteen healthy 
volunteers and found no performance deficits compared to placebo (Amato, Marie et al. 2013).  Byas-
Smith et al compared the driving ability of chronic pain patients taking opioid analgesics to healthy 
volunteers and found no significant differences in performance between the groups (Byas-Smith, 
Chapman et al. 2005).  Verster et al compared the driving ability of 18 patients taking Bromfenac, a non-
steroidal anti-inflammatory, and the opioid oxycodone/paracetamol and found no significant impairment 
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between oxycodone/paracetamol and placebo in a standardized road test (Verster, Veldhuijzen et al. 
2006). 
Five, experimental, placebo controlled, cross-over studies have investigated the effects of z-drugs 
(i.e. hypnotics) on driving performance; results show that some drugs are more impairing than others 
(Vermeeren, Danjou et al. 1998; Vermeeren, Riedel et al. 2002; Verster, Volkerts et al. 2002; Leufkens, 
Lund et al. 2009; Mets, Vries et al. 2011).  Leufkens et al conducted a study with 28 healthy volunteers to 
assess the effects of Gaboxadol, Zopiclone, and Zolpidem on driving performance and found that all three 
drugs impaired performance (Leufkens, Lund et al. 2009).  Mets et al conducted a study with 30 healthy 
volunteers to evaluate the effects of Ramelteon and Zopiclone on driving performance and found both to 
be impairing (Mets, Vries et al. 2011).  Vermeeren et al conducted two studies with 28 and 30 healthy 
volunteers to evaluate the effects of Zaleplon and Zopiclone on driving performance and found that 
Zopiclone was impairing but Zaleplon is probably safe if taken at least five hours before driving in both 
studies (Vermeeren, Danjou et al. 1998; Vermeeren, Riedel et al. 2002).  Verster et al conducted an 
experiment with 30 healthy volunteers to assess the effects of Zaleplon and Zolpidem on driving 
performance and found that Zolpidem impairs performance while Zaleplon is relatively safe if taken 
several hours before driving (Verster, Volkerts et al. 2002). 
Seventeen, experimental, placebo controlled, cross-over studies have been conducted to assess the 
effects that antihistamines have on actual driving ability using instrumented vehicles; some antihistamines 
appear driver impairing while others are not (Hindmarch 1976; Ramaekers, Uiterwijk et al. 1992; 
Volkerts, Van et al. 1992; Ramaeker and O'Hanlon 1994; Vuurman, Uiterwijk et al. 1994; Vermeeren and 
O'Hanlon 1998; Vermeeren, Ramaekers et al. 1998; Vermeeren, Ramaekers et al. 2002; Potter, Schepers 
et al. 2003; Ridout, Shamsi et al. 2003; Verster, Weert et al. 2003; Theunissen, Vermeeren et al. 2004; 
Vuurman, Rikken et al. 2004; Tashiro, Horikawa et al. 2005; Theunissen, Vermeeren et al. 2006; 
Vuurman, Eef et al. 2007; Conen, Theunissen et al. 2011).  Conen et al conducted a study of Bilastine and 
Hydroxyzine in a group of 22 healthy participants and determined that Hydroxyzine affected driving 
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while Bilastine did not (Conen, Theunissen et al. 2011).  Hindmarch et al conducted a study of 
Clemastine in a group of 21 healthy volunteers and found that Clemastine did not affect driving ability 
(Hindmarch 1976).  Potter et al evaluated Fexofenadine in 255 healthy volunteers and determined that 
driving errors were not increased compared to placebo (Potter, Schepers et al. 2003).  Ramaeker et al 
evaluated Acrivastine, Terfenadine, and Diphenhydramine in 18 healthy volunteers and found that high 
doses of Acrivastine and regular doses of Diphenhydramine affected driving performance while 
Terfenadine had no significant effects on driving compared to placebo (Ramaeker and O'Hanlon 1994).  
Ramaeker et al tested the effects of Cetirizine and Loratadine in 16 healthy volunteers and found that 
Cetirizine caused mild driving impairment while Loratadine did not (Ramaekers, Uiterwijk et al. 1992).  
Ridout et al evaluated Fexofenadine and Hydroxyzine in 18 healthy volunteers and found that 
Fexofenadine did not cause impairment while Hydroxyzine did cause impairment compared to placebo 
(Ridout, Shamsi et al. 2003).  Tashiro et al also evaluated Fexofenadine and Hydroxyzine in healthy 
volunteers and found Fexofenadine did not impair performance while Hydroxyzine increased reaction 
time compared to placebo (Tashiro, Horikawa et al. 2005).  Theunissen et al conducted two studies of 
Mequitazine, Cetirizine and Dexchlorpheniramine in 16 and 18 healthy volunteers and found that only 
Cetirizine did not impair driving performance in either study (Theunissen, Vermeeren et al. 2004; 
Theunissen, Vermeeren et al. 2006).  Vermeeren et al evaluated the effects of Fexofenadine and 
Clemastine in 24 healthy volunteers and found that Fexofenadine did not impair performance compared to 
placebo (Vermeeren and O'Hanlon 1998).  Vermeeren et al evaluated the effects of Emedastine and 
Cetirizine in a group of 19 healthy volunteers and found that both drugs are sedating compared to placebo 
(Vermeeren, Ramaekers et al. 2002).  Vermeeren et al tested a combination of Chlorpheniramine and 
Terfenadine in a group of 24 healthy volunteers and found no significant differences in driving 
performance compared to placebo (Vermeeren, Ramaekers et al. 1998).  Verster et al studied both 
Levocitirizine and Diphenhydramine in a group of 48 healthy volunteers and determined that 
Levocitirizine does not affect driving performance while Diphenhydamine does compared to placebo 
(Verster, Weert et al. 2003).  Volkerts et al tested Cetirizine and Triprolidine in 27 healthy male 
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volunteers and found Ceterizine did not affect driving while Triprolidine significantly impaired 
performance (Volkerts, Van et al. 1992).  Vuurman et al studied Rupatadine and Hydroxyzine in a group 
of 20 healthy subjects and found that Rupatadine, but not Hydroxyzine, does not impair driving 
performance (Vuurman, Eef et al. 2007).  Vuurman et al evaluated the effects of Desloratadine and 
Diphenhydramine in 18 healthy volunteers and found that therapeutic doses of Desloratadine do not affect 
driving performance while Diphenydramine caused participants to swerve with their driving lanes 
(Vuurman, Rikken et al. 2004).  Vuurman et al studied the effects of Mizolastine and Clemastine in 24 
healthy volunteers and found that Mizolastine does not appear to affect driving ability (Vuurman, 
Uiterwijk et al. 1994). 
Benzodiazepines are the most studied drug class when it comes to evaluating their effects on 
driving performance.  At least 22 randomized, placebo-controlled, experimental studies have been 
conducted to date in healthy, depressed, and/or anxious volunteers; the results of these studies show that 
some benzodiazepines are associated with decreased driving ability while others are not (Hindmarch, 
Hanks et al. 1977; Hindmarch and Gudgeon 1980; De Gier, Hart et al. 1981; O'Hanlon, Haak et al. 1982; 
Hindmarch and Subhan 1983; Laurell and Tornros 1986; Schmidt, Brendemühl et al. 1986; Stevenson, 
Pathria et al. 1986; Riedel, Quasten et al. 1988; Brookhuis, Volkerts et al. 1990; Willumeit, Ott et al. 
1991; Van Laar, Volkerts et al. 1992; Volkerts, Laar et al. 1992; Van Laar, Van Willigenburg et al. 1993; 
Mercier-Guyon, Lejay et al. 1999; Van Laar, Volkerts et al. 2001; Verster, Volkerts et al. 2002; 
Hindmarch, Trick et al. 2005; Leufkens, Vermeeren et al. 2007; Leufkens and Vermeeren 2009; Daurat, 
Sagaspe et al. 2013; Moták, Bayssac et al. 2014).  The following benzodiazepines have been associated 
with decreased driving performance:  Lormetazepam (Brookhuis, Volkerts et al. 1990), Flurazepam 
(Brookhuis, Volkerts et al. 1990), Lorazepam (Hindmarch and Gudgeon 1980; Mercier-Guyon, Lejay et 
al. 1999; Van Laar, Volkerts et al. 2001; Daurat, Sagaspe et al. 2013; Moták, Bayssac et al. 2014), 
Diazepam (De Gier, Hart et al. 1981; O'Hanlon, Haak et al. 1982; Stevenson, Pathria et al. 1986; Van 
Laar, Volkerts et al. 1992), Alprazolam (Verster, Volkerts et al. 2002; Hindmarch, Trick et al. 2005; 
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Leufkens, Vermeeren et al. 2007), Nitrazepam (Laurell and Tornros 1986), Oxazepam (Volkerts, Laar et 
al. 1992; Van Laar, Van Willigenburg et al. 1993), and Flunitrazepam (Schmidt, Brendemühl et al. 1986).  
The following benzodiazepines have been shown to not significantly affect driving performance 
compared to placebo:  Clobazam (Hindmarch, Hanks et al. 1977; Hindmarch and Gudgeon 1980), 
Midazolam (Hindmarch and Subhan 1983; Riedel, Quasten et al. 1988), Triazolam (Laurell and Tornros 
1986; Riedel, Quasten et al. 1988), and Temazepam (Schmidt, Brendemühl et al. 1986; Riedel, Quasten et 
al. 1988; Leufkens and Vermeeren 2009).  Lormetazepam has shown to be relatively safe as long as 
patients sleep a full night prior to driving (Willumeit, Ott et al. 1991; Volkerts, Laar et al. 1992; Van Laar, 
Van Willigenburg et al. 1993). 
1.7 Illicit drugs and motor vehicle collision risk 
While licit drugs, such as prescription and over-the-counter medication, can influence driving 
ability or collision risk, so can illicit drugs.  Illicit drugs can be defined as drugs with no real medical 
benefit that are taken for recreational purposes.  Current research suggests that illicit drug use, particularly 
opiates and stimulants, are increasing among older adult populations across the U.S. and Europe (Beynon 
2009).  Despite this fact, to the author’s knowledge, no studies to date have investigated illicit drug use 
among older adult drivers.  Only one study conducted by Vanderbilt University during the 1990’s showed 
that illegal drug use was virtually non-existent among drivers over 65 years of age who were admitted to 
their level-1 trauma center after motor vehicle collision (Higgins, Wright et al. 1996).  While the research 
in this area is extremely limited, it is possible that those older adults who use illicit drugs do not drive or 
do not drive regularly.  Despite the lack of research in older adult populations, the following section 
highlights the current research surrounding the effects on illicit substances on collision risk and/or 
affected driving ability. 
1.7.1 The effects of individual illicit drugs on motor vehicle collision risk 
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The associations between illegal drug use and motor vehicle collision have been studied 
extensively for marijuana, but also to a lesser extent for cocaine and heroin.  Other studies have looked at 
broad groups of illegal drugs, such as opiates, stimulants, and depressants. 
The association between marijuana and motor vehicle collision has been studied extensively in 
different populations among different countries using different study designs; of the 11 studies that have 
investigated this drug, all have found statistically significant increases of motor vehicle collision when 
drivers use this substance (Ferguson and Horwood 2001; Laumon, Gadegbeku et al. 2005; Mura, Brunet 
et al. 2006; Bedard, Dubois et al. 2007; Mann, Adlaf et al. 2007; Lasebikan 2010; Mann, Stoduto et al. 
2010; Pulido, Barrio et al. 2011; Mu-Chen, Joanne E. et al. 2012; Li, Brady et al. 2013; Asbridge, Mann 
et al. 2014).   
One study investigated the use of heroin and motor vehicle collision.  In this survey of heroin 
addicts, 34% claimed to have been involved in a motor vehicle collision when high (Edwards and 
Quartaro 1978)  As for cocaine, a survey of adults in Ontario, Canada (n=8,107), found that self-reported 
cocaine use was associated with a two-time increase of motor vehicle collisions (Stoduto, Mann et al. 
2012).  A self-reported survey conducted in Spain also found a significant increase of motor vehicle 
collisions among drivers who used cocaine at least once per week (Pulido, Barrio et al. 2011). 
As for broad categories of drugs, two studies have been conducted (Kuypers, Legrand et al. 2012; 
Li, Brady et al. 2013)  In a population-based case-control study conducted in the Netherlands, the risk of 
motor vehicle collision was highest among drivers who combined stimulants with sedatives (Kuypers, 
Legrand et al. 2012).  In a case-control study conducted in the U.S., which used data obtained from fatal 
traffic crashes, those who used stimulants, depressants, narcotics, and marijuana were all at a significantly 
increased risk fatal motor vehicle collision while using these substances (Li, Brady et al. 2013). 
1.7.2 The effects of illicit drugs on actual driving ability 
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Several studies in Europe have actually assessed the effects of certain illegal drugs on actual 
driving ability.  The drugs that have been studied are marijuana and 3, 4-
methylenedioxymethamphetamine (MDMA).  Gramekers et al performed a cross-over study among 18 
subjects treated with marijuana then placebo using an instrumented vehicle in normal traffic.  Marijuana 
significantly impaired driving performance (Gramaekers, Robbe et al. 2000).  Bosker et al conducted a 
double-blind, placebo-controlled, randomized, three-way cross-over study among occasional (n=12) and 
heavy cannabis users (n=12) using an instrumented vehicle (Bosker, Kuypers et al. 2012).  Weaving 
within the lane and reaction time were the outcome measures.  Driving performance was affected in both 
groups while taking marijuana (Bosker, Kuypers et al. 2012).  Three studies have used cross-over designs 
to assess the effects of MDMA on driving performance using instrumented vehicles (Kuypers, Samyn et 
al. 2006; Ramaekers, Kuypers et al. 2006; Bosker, Kuypers et al. 2012).  Two of the three studies 
investigated the effects a short time after use (Kuypers, Samyn et al. 2006; Ramaekers, Kuypers et al. 
2006), while the third study tested how sleep loss mediates the drug’s effects (Bosker, Kuypers et al. 
2012).  MDMA affected driving performance in all studies but even more when sleep loss was taken into 
account (Kuypers, Samyn et al. 2006; Ramaekers, Kuypers et al. 2006; Bosker, Kuypers et al. 2012). 
1.8 Challenges of studying the association between drug use and motor vehicle collisions 
The fundamental challenge of studying the association between licit or illicit drug usage and 
driving ability is that the relationships are not always lucid.  For example, it is well-established in the 
literature that alcohol effects everyone’s driving ability to some extent even in small doses.  This is not 
always the case with drugs, particularly in an older adult population.  There are several reasons for this.  
First, the relationships between aging, existing medical conditions, and drug usage are often difficult—if 
not impossible—to separate.  It is difficult to determine exactly which is more responsible for declines in 
driving ability and/or motor vehicle collision risk as each can affect individuals.  Second, it can be how 
the drugs and their effects are studied.  Differences in study designs and inherent biases, such as 
confounding, misclassification, and selection bias, can also skew study findings (Rothman, Greenland et 
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al. 2008).  Lastly, drugs can elicit their effects differently amongst individuals.  There is a plethora of 
research that shows various endogenous and exogenous factors that affect drug metabolism among 
individuals.  Some of these factors include, but are not limited to:  pharmacokinetic or pharmacodynamic 
properties of the drug (Jusko 2013), the drug’s half life (Brown, Milavetz et al. 2013), developed 
tolerance (Stein and Baerwald 2014), elimination rate (Bushardt, Massey et al. 2008), dosage (Brown, 
Milavetz et al. 2013), route of administration (Bushardt, Massey et al. 2008), drug solubility (Augustijns, 
Wuyts et al. 2014), hormonal fluctuations (Berta, Harangi et al. 2014), alcohol use (Brown, Milavetz et al. 
2013), age (Brzaković, Vezmar Kovačević et al. 2012), weight (Brzaković, Vezmar Kovačević et al. 
2012), multiple drug use (Bushardt, Massey et al. 2008), gender (Chu 2014), diet (Cingi, Toros et al. 
2013), genetics (Daly 2014), circadian rhythms (Innominato, Roche et al. 2014), disease complications 
(Joy, Frye et al. 2014), supplement use (Markert, Ngui et al. 2014),  race/ethnicity (Spokoyny, Barazangi 
et al. 2014), and smoking status (Unterecker, Hiemke et al. 2012).    
1.9 Extant gaps in the literature 
As seen in this review, a scarcity of information is available in the U.S. regarding driving under 
the influence of drugs, particularly among senior drivers (Lotfipour and Vaca 2007).  Generally, most of 
the research has focused on broad categories of drugs (LeRoy and Morse 2008) or medical conditions in 
older adults that are associated with an increased risk of motor vehicle collision (Koepsell, Wolf et al. 
1994; Foley, Wallace et al. 1995; McGwin, Sims et al. 2000).  To the author’s knowledge, no studies 
have examined which specific licit, illicit, or combinations of these drugs are most common among senior 
drivers.  Few studies have tried to assess the risk of motor vehicle collision posed by individual 
medications in this age group. 
1.10 Rational and purpose of study 
The overarching goal of this dissertation research is to characterize licit and illicit drug use and to 
explore which individual licit drugs and combinations may affect driving ability and/or the risk of motor 
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vehicle collision among drivers 65 years of age and older in the U.S.  The approach to investigating this 
issue will involve a systematic review of the literature (Chapter 2), a cross-sectional analysis of a national 
traffic fatality database (Chapter 3), and a case-crossover study using electronic medical records 
(Chapter4).  Results of all three studies will be discussed in Chapter 5.  The purpose of the systematic 
review is to systematically search published and unpublished studies pertaining to specific medication use 
and motor vehicle collision.  This study will help to synthesize the information and help determine which 
individual medications are associated with driver impairment.  The purpose of the cross-sectional analysis 
is to determine which specific and broad categories of licit and illicit drugs and subsequent combinations 
are most prevalent among a nationally representative population of fatally injured drivers.  This study will 
allow the demographic characteristics to be compared between drivers who were found drug positive to 
those who were not.  It will also allow for the comparison of prevalence rates of individual drugs and 
combinations through the use of a referent population of 30-50 year old drivers.  The purpose of the case-
crossover study is to explore which individual medication exposures may be associated with increased 
risk of motor vehicle collision among West Virginia drivers 65 years of age and older who were admitted 
for medical treatment post-collision. Because this study is utilizing electronic medical records, the study 
will enable population demographics to be characterized, to distinguish which licit drugs and 
combinations are most prevalent in this population, discern illicit drug use via laboratory test results, and 

















Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review 
ABSTRACT 
Objectives: Driving under the influence of prescription and over-the-counter medication is a growing 
public health concern. A systematic review of the literature was performed to investigate which specific 
medications were associated with increased risk of motor vehicle collision (MVC).   
 
Methods: The a priori inclusion criteria were: 1) studies published from English-language sources on or 
after January 1, 1960, 2) licensed drivers 15 years of age and older, 3) peer-reviewed publications, 
master’s theses, doctoral dissertations, and conference papers, 4) studies limited to randomized control 
trials, cohort studies, case-control studies, or case-control type studies 5) outcome measure reported for at 
least one specific medication, 6) outcome measure reported as the odds or risk of a motor vehicle collision 
or some affected aspect of driving ability during an on the road assessment or driving simulation.  The 
last search was conducted in June 2014.  Fourteen databases (i.e. Medline, PubMed, Scopus, International 
Pharmaceutical Abstracts, Cochrane Central Register of Controlled Trials, CINAHL, AgeLine, Web of 
Science, PsychInfo, Transportation Research Information Services, Academic Search Complete, EconLit, 
SafetyLit and ProQuest Dissertations and Theses) were examined along with hand-searching. 
Independent, dual selection of studies and data abstraction was performed.  
 
Results: After the removal of duplicate studies, 4,578 articles were identified.  Of these studies, 4,134 
were excluded after the first screen for eligibility.  Of the 444 full text articles remaining, fifty-three 
medications were investigated by 27 studies included in the review.  Fifteen (28.3%) were associated with 
an increased risk of MVC.  These included Buprenorphine, Codeine, Dihydrocodeine, Methadone, 
Tramadol, Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, 
Carisoprodol, Zolpidem, and Zopiclone.   
 
Conclusions: Several medications were associated with an increased risk of MVC and decreased driving 
ability. The associations between specific medication use and the increased risk of MVC and/or affected 


























While the number of motor vehicle collisions (MVC) and subsequent fatalities has steadily 
declined over the past decade (Sise, Calvo et al. 2014), MVC still remains one of the leading causes of 
mortality in the United States (U.S.) (Rockett, Regier et al. 2012).  In 2010, this equated to approximately 
one death per collision every fifteen minutes (Oster and Strong 2013).  Besides the inherent risks to 
morbidity and mortality, MVCs are estimated to cost the U.S. over $300 billion dollars per year (Oster 
and Strong 2013). 
It is well-established in the literature that alcohol can negatively influence driving ability, even 
when consumed in small quantities.  It is estimated that over one-third of all MVC are a result of driver 
intoxication (Hayman and Crandall 2009).  While driving under the influence of alcohol is a well-
documented area of study, driving under the influence of drugs (DUID) is also an emerging public health 
and traffic safety concern (Morland 2000; Movig, Mathijssen et al. 2004; Walsh, de Gier et al. 2004).  
Driving under the influence of drugs entails the use of illicit drugs, i.e. drugs that are obtained illegally 
and with no real medical benefit, such as cocaine and methamphetamine.  Driving under the influence of 
drugs can also entail the use of licit substances, such as common prescription or over-the-counter 
medications, whose effects impair the driver’s ability to safely operate a motor vehicle from one 
destination to another.  However, it’s important to realize that while licit drugs can be obtained illegally, 
abused, or misused, the intent of use by the driver is often difficult to determine.  In 2009, approximately 
28% of all fatally injured U.S. drivers that were tested for either illicit or licit drugs tested positive for one 
or more of these substances (National Highway Traffic Safety Administration 2010).  In addition, recent 
research suggests that DUID is increasing nationally (Wilson, Stimpson et al. 2014).   
Due to the complexity of DUID, the primary focus of this paper pertains to the association 
between licit drug use and MVC.  However, one of the fundamental challenges to studying the effects of 
licit drugs on driving ability is that the relationship is not always as apparent when compared to alcohol 
(National Highway Traffic Safety Administration 2010).  For example, some drugs may not noticeably 
impair the skills (cognition, psychomotor function, physical ability) necessary to operate a motor vehicle 
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(Coopersmith, Korner-Bitensky et al. 1989; Carr 2000; Carr, Duchek et al. 2006; Cheung and McCartt 
2011).  Drugs that are perceived to affect the central nervous system may exhibit different effects among 
individuals; this may be attributed to the pharmacokinetic or pharmacodynamic properties of the drug 
(Jusko 2013), the drug’s half-life (Brown, Milavetz et al. 2013), interactions with other consumed drugs 
(Bushardt, Massey et al. 2008), tolerance (Stein and Baerwald 2014), drug elimination rate (Bushardt, 
Massey et al. 2008), dosage (Brown, Milavetz et al. 2013), route of administration (Bushardt, Massey et 
al. 2008), solubility (Augustijns, Wuyts et al. 2014), intestinal pH (Augustijns, Wuyts et al. 2014), current 
health status of the individual (Bushardt, Massey et al. 2008), genetics (Daly 2014), etc.  It may also be 
difficult to partition out the effects of the licit drug and the medical condition for which it was taken to 
remedy (Bushardt, Massey et al. 2008).  For example, several medical conditions have been associated 
with an increased risk of MVC. These include, but are not necessarily limited to, sleep apnea (Ellen, 
Marshall et al. 2006), dementia (Brown and Ott 2004), arthritis (Cross, McGwin et al. 2009), diabetes 
(Hansotia and Broste 1991), epilepsy (Hansotia and Broste 1991), anxiety (Sagberg 2006), depression 
(Sagberg 2006) and Parkinson’s disease (Uc, Rizzo et al. 2006). 
Numerous reviews and meta-analyses have investigated the association between licit drug use and 
MVC and/or driving ability.  These reviews have focused predominately on opioids (Fishbain, Cutler et 
al. 2002; Fishbain, Cutler et al. 2003; Kress and Kraft 2005; Borgeat 2010; Leung 2011; Jones, Mogali et 
al. 2012; Mailis-Gagnon, Lakha et al. 2012; Strand, Fjeld et al. 2013; Soyka 2014), benzodiazepines (van 
Laar and Volkerts 1998; Rapoport, Lanctôt et al. 2009; Smink, Egberts et al. 2010; Dassanayake, Michie 
et al. 2011; Leung 2011; Jones, Mogali et al. 2012), antihistamines (Roberts 2005; Popescu 2008) 
psychoactive drugs (Rapoport and Baniña 2007; Joris C. and Monique Anna Johanna 2009; Verster and 
Mets 2009; Krueger 2010; Cooper, Meuleners et al. 2011), antidepressants (Ramaekers 2003; Verster and 
Ramaekers 2009; Dassanayake, Michie et al. 2011; Ravera, Ramaekers et al. 2012; Brunnauer and Laux 
2013), hypnotics (Verster, Veldhuijzen et al. 2006; Krueger 2010), anxiolytics (Verster, Veldhuijzen et al. 
2005; Vermeeren, Leufkens et al. 2009) and sleep medications (Verster, Volkerts et al. 2007; Verster, 
Volkerts et al. 2007; Gunja 2013; Leufkens and Vermeeren 2014).  Some reviews have also examined 
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multiple drug categories (Kelly, Darke et al. 2004; Orriols, Salmi et al. 2009; Elvik 2013; Amanda and 
David B. 2014).  However, the majority of these studies have reviewed or analyzed licit drugs in broad 
groups (Fishbain, Cutler et al. 2002; Kress and Kraft 2005; Joris C. and Monique Anna Johanna 2009; 
Rapoport, Lanctôt et al. 2009; Dassanayake, Michie et al. 2011; Leung 2011; Jones, Mogali et al. 2012; 
Ravera, Ramaekers et al. 2012).  There is the potential that if the drugs within these groups were reviewed 
individually, the outcome measures of interest may be varied as some drugs may be more or less driver-
impairing than others.  Therefore, the purpose of this study was to perform a systematic review of the 
literature to investigate which specific medications, including typical prescription or over-the-counter 
drugs, may be associated with an increased risk or odds of MVC and/or driving ability among licensed 
drivers 15 years of age and older.   
2.2 Methods 
Study eligibility 
The inclusion criteria for studies, which were defined a priori, were as follows: 1) English-
language studies published on or after January 1, 1960, 2) licensed drivers 15 years of age and older, 3) 
studies published in a peer-reviewed journal or non-published (i.e. “grey literature”), which included 
master’s theses, doctoral dissertations, and conference papers, 4) studies limited to randomized control 
trials, cohort studies, case-control studies, or case-control types of studies , i.e. case cross-over, case-time 
series, etc. 5) outcome measure reported for at least one specific medication, 6) outcome measure reported 
as the odds or risk of a motor vehicle collision or some affected aspect of driving ability during an on-
road assessment or driving simulation (e.g. brake reaction time, weaving, standard deviation of lateral 
position, etc.).  If the study reported outcome measures for both specific medications and illicit drugs or 
specific medications combined with alcohol, only outcome measures for specific medications alone were 
reported.  A ‘medication’ was defined as a substance either available by prescription or over-the-counter 
to remedy a medical condition.  Therefore, caffeine, nicotine, vitamins, and nutraceuticals were excluded.  
If the medication usage was combined with a medical procedure, then the study was excluded to avoid 
bias.  While marijuana has been legalized for medicinal purposes in several states, it was not considered a 
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medication in this analysis as it is still defined as an illegal substance by federal law.  Because of the vast 
difference in the fidelity of driving simulators, a driving simulator must have consisted of a screen, 
pedals, and steering wheel.  If the study did not specify the components of the simulator, an attempt was 
made to search the make and model of the simulator noted in the study to see if it was comprised of these 
constituents.  The search date of January 1, 1960 was arbitrarily chosen as no DUID studies existed or 
were published prior to this time.  Because of the complexity of the initial study question, it was decided 
post-hoc to only present the studies whose outcomes reported the association between a specific 
medication and the odds or risk of a motor vehicle collision.   
Data sources 
Studies were acquired from the following fourteen databases: 1) Medline (within EBSCO host), 
2) PubMed, 3) Scopus, 4) International Pharmaceutical Abstracts (IPA), 5) Cochrane Central Register of 
Controlled Trials (CENTRAL), 6) CINAHL (within EBSCO host), 7) AgeLine, 8) Web of Science 
(WOS), 9) PsychInfo, 10) Transportation Research Information Services (TRID), 11) Academic Search 
Complete, 12) EconLit 13) SafetyLit, and 14) ProQuest Dissertations and Theses (ProQuest).  All 
searches were performed by TMR with the assistance of a Health Sciences Librarian from West Virginia 
University.  The last search was performed in June 2014.  All searches were conducted using Medical 
Subject Headings (MESH) terminology.  Each search contained the phrases, “drug”, “medication”, 
“traffic collision”, and “motor vehicle”.  In addition to the fourteen databases, studies from TMR’s 
personal library were also reviewed for eligibility.  Hand searches from the reference lists of included 
studies were also examined.  Government websites, such as the National Highway Traffic Safety 
Administration, were also searched for relevant government-performed studies. 
Selection of studies 
All included studies were independently selected by TMR and BR.  Any discrepancies regarding 
the inclusion of studies were resolved through discussion.  If a consensus could not be reached, MZ acted 
as the arbitrator.  All studies, whether included or excluded in the review, were stored in EndNote, 




A codebook was developed by TMR in Microsoft Excel 2007.  The codebook included variables 
regarding study characteristics, study population, medications investigated, outcome measures, and study 
quality.  All studies were coded by TMR and CP independent of one another.  After coding was 
completed, both authors met to compare the entries for accuracy and/or precision.  Any discrepancies 
were resolved through discussion.  If disagreements could not be rectified, MZ acted as the arbitrator.   
Study quality 
The included studies were evaluated for quality by TMR and CP independent of one another.  An 
abbreviated version of the checklist for measuring study quality designed by Downs and Black was used 
to score the studies for quality (Downs and Black 1998).  The original checklist designed by Downs and 
Black, which has been deemed both valid and reliable, is a 27 question, qualitative check-list to evaluate a 
study for internal and external validity, quality of reporting, and power; for every positive 
attribute/response, a study receives one point (Downs and Black 1998).  At the end of assessment, the 
points are tallied; the more points a study earns, the higher the study’s quality (Downs and Black 1998).  
After all coding and quality assessments were completed, the authors met to compare their entries for 
accuracy and/or precision.  Any discrepancies were resolved through discussion.  If disagreements could 
not be reached, MZ acted as the arbitrator.  No studies that met the eligibility criteria were excluded based 
on quality.   
Data synthesis 
All studies were synthesized qualitatively. No meta-analysis was performed given the a priori 
assumption that excessive statistical and/or methodological heterogeneity would be observed (Purgato 
and Adams 2012).  However, the overall odds or risk ratio for each medication and outcome was 
presented graphically and included the point estimate and corresponding 95% confidence intervals.  Post 
hoc, it was realized that some included studies only presented crude estimates (Nelson 1992; Koepsell, 
Wolf et al. 1994; Neutel 1998; Cui 2001; Mura, Kintz et al. 2003; Mathijssen 2006; Bramness, Skurtveit 
et al. 2007; Gustavsen, Bramness et al. 2008; Lonnen, Powell et al. 2008; Bachs, Engeland et al. 2009; 
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Bramness, Skurtveit et al. 2009; Gibson, Hubbard et al. 2009; Skurtveit, Strøm et al. 2009; Coupland, 
Dhiman et al. 2011; Gjerde, Normann et al. 2011; Orriols, Philip et al. 2011; Bramness, Skurtveit et al. 
2012; Corsenac, Lagarde et al. 2012; Hansen 2012; Gjerde, Christophersen et al. 2013), while others 
adjusted their outcome measures for various potential confounders such as age, gender, miles driven, day 
of the week, etc (Foley, Wallace et al. 1995; McGwin, Sims et al. 2000; Sims, McGwin et al. 2000; 
Etminan, Hemmelgarn et al. 2004; Delaney, Opatrny et al. 2006; Hemmelgarn, Lévesque et al. 2006; 
Yang, Lai et al. 2011).  For those studies that presented adjusted estimates or did not include 95% 
confidence intervals for crude estimates (Foley, Wallace et al. 1995; McGwin, Sims et al. 2000; Sims, 
McGwin et al. 2000; Etminan, Hemmelgarn et al. 2004; Delaney, Opatrny et al. 2006; Hemmelgarn, 
Lévesque et al. 2006; Yang, Lai et al. 2011), then the adjusted point estimates and 95% confidence 
intervals for the population were reported.  If a study’s point estimate was greater than one, this indicated 
that there was excess risk of collision; a point estimate less than one indicated that the medication use was 
associated with a decreased risk of collision (i.e. it was protective against MVC). Results were considered 
statistically significant if the 95% confidence intervals did not include one.  
2.3 Results 
Study characteristics 
The search processes for the selection of studies, as well as reasons for excluding studies, are 
presented in Figure 1.  Of the 6,516 records obtained, 208 studies met the original study question.  Of 
these 208 studies, 27 pertained to the association of specific medications and the odds or risk of motor 
vehicle collision, while the others pertained to the association of specific medications and affected driving 
ability determined through the use of driving simulators (n=90) or actual driving assessments (n=91).   
The characteristics of the 27 studies included in this review are presented in Table 1 (Nelson 1992; 
Koepsell, Wolf et al. 1994; Foley, Wallace et al. 1995; Neutel 1998; McGwin, Sims et al. 2000; Sims, 
McGwin et al. 2000; Cui 2001; Mura, Kintz et al. 2003; Etminan, Hemmelgarn et al. 2004; Delaney, 
Opatrny et al. 2006; Hemmelgarn, Lévesque et al. 2006; Mathijssen 2006; Bramness, Skurtveit et al. 
2007; Gustavsen, Bramness et al. 2008; Lonnen, Powell et al. 2008; Bachs, Engeland et al. 2009; 
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Bramness, Skurtveit et al. 2009; Gibson, Hubbard et al. 2009; Skurtveit, Strøm et al. 2009; Coupland, 
Dhiman et al. 2011; Gjerde, Normann et al. 2011; Orriols, Philip et al. 2011; Yang, Lai et al. 2011; 
Bramness, Skurtveit et al. 2012; Corsenac, Lagarde et al. 2012; Hansen 2012; Gjerde, Christophersen et 
al. 2013).  The included studies spanned from 1992-2013.  Of these studies, eight (29.6%) were 
conducted in Norway (Bramness, Skurtveit et al. 2007; Gustavsen, Bramness et al. 2008; Bachs, 
Engeland et al. 2009; Bramness, Skurtveit et al. 2009; Skurtveit, Strøm et al. 2009; Gjerde, Normann et 
al. 2011; Bramness, Skurtveit et al. 2012; Gjerde, Christophersen et al. 2013), six (22.2%) in the U.S. 
(Nelson 1992; Koepsell, Wolf et al. 1994; Foley, Wallace et al. 1995; McGwin, Sims et al. 2000; Sims, 
McGwin et al. 2000; Hansen 2012), five (18.5%) from Canada (Neutel 1998; Cui 2001; Etminan, 
Hemmelgarn et al. 2004; Delaney, Opatrny et al. 2006; Hemmelgarn, Lévesque et al. 2006), three 
(11.1%) from England (Lonnen, Powell et al. 2008; Gibson, Hubbard et al. 2009; Coupland, Dhiman et 
al. 2011), three (11.1%) from France (Mura, Kintz et al. 2003; Orriols, Philip et al. 2011; Corsenac, 
Lagarde et al. 2012), one (3.7%) from the Netherlands (Mathijssen 2006), and one (3.7%) from Taiwan 
(Yang, Lai et al. 2011).  Eleven (40.7%) of these studies were cohort designs, while the rest consisted of 
case-control or variations of a case-control design.  Only one study was limited to females (Nelson 1992).  
Nine (33.3%) of the studies were limited to older adult drivers typically 60 years of age and older, nine 
(33.3%) included drivers aged approximately 18-70 years, and the remaining nine (33.3%) covered all 
licensed drivers from the country of origin.  Three studies (11.1%) were doctoral dissertations (Nelson 
1992; Cui 2001; Hansen 2012), one study (3.7%) was a conference paper (Mathijssen 2006), and the 
remaining 23 studies (85.2%) were published in peer-reviewed journals.  Among these studies, 53 
specific medications were evaluated.  Diazepam, Zolpidem, Zopiclone, and Insulin were the most 
commonly studied medications.  With respect to study quality, 23 of the 27 studies (85.2%) received a 
score of 5 (Table 1). The studies that were scored 4 out of 5 typically did not explain their statistical 
methodology in sufficient detail, i.e., did not mention or explain what types of regression they utilized to 





The medications that were investigated by the studies included in this review are presented by 
drug category in Figures 2-9.  The drug categories consisted of analgesics, anticonvulsants, 
antidepressants, antihistamines, antihyperglycemics, benzodiazepines, and sleep-enhancing medications; 
if a drug could not be categorized into any of these groups, it classified as ‘Other Medications’.  Studies 
were adjusted by the original study authors for age and gender (Foley, Wallace et al. 1995), age, sex, 
gender, and annual mileage (McGwin, Sims et al. 2000), age, sex, gender, and days driven per week 
(Sims, McGwin et al. 2000), and age, gender, residence in the country, previous injurious MVC, chronic 
disease score, exposure to antidepressants, anti-epileptics, benzodiazepines, antipsychotics, anti-migraine, 
muscle relaxants, and narcotic analgesics (Etminan, Hemmelgarn et al. 2004).  Another study was 
adjusted for cardiac or stroke events within the past year as well as the following drug classes in the 
previous 60 days:  antidepressants, anti-epileptics, benzodiazepines, antipsychotics, anti-migraine, 
narcotic analgesics, muscle relaxants (Delaney, Opatrny et al. 2006).  Another study was adjusted for age, 
gender, previous MVC, and place of residence (Hemmelgarn, Lévesque et al. 2006), while another was 
adjusted for concomitant use of the following medications:  Zolpidem, Zopiclone, long and short acting 
benzodiazepines, antihistamines, anticonvulsants, antidepressants, other sedatives/hypnotics, other 
psychoactive drugs, muscle relaxants, and opioid analgesics (Yang, Lai et al. 2011).   
Analgesics 
Among the included studies, the associations between seven analgesic medications and the odds 
or risk of MVC were investigated (Figure 2).  These medications included Aspirin (Foley, Wallace et al. 
1995), Buprenorphine (Corsenac, Lagarde et al. 2012), Codeine (Mathijssen 2006; Bachs, Engeland et al. 
2009; Gibson, Hubbard et al. 2009), Dihydrocodeine (Gibson, Hubbard et al. 2009), Methadone 
(Bramness, Skurtveit et al. 2012; Corsenac, Lagarde et al. 2012), Morphine (Gibson, Hubbard et al. 
2009), and Tramadol (Bachs, Engeland et al. 2009; Gibson, Hubbard et al. 2009).  As shown in Figure 2, 
those taking Aspirin (Foley, Wallace et al. 1995) and Morphine (Gibson, Hubbard et al. 2009) did not 
experience a statistically significant increase in MVC; contrarily, those taking Buprenorphine (Corsenac, 
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Lagarde et al. 2012), Dihydrocodeine (Gibson, Hubbard et al. 2009), and Methadone (Bramness, 
Skurtveit et al. 2012; Corsenac, Lagarde et al. 2012) did experience an increase in MVC risk.  The results 
for both Codeine and Tramadol were mixed.  Three studies investigated the effects of Codeine on the risk 
of MVC; two of these studies reported a statistically significant increase in MVC (Bachs, Engeland et al. 
2009; Gibson, Hubbard et al. 2009), while one study did not (Mathijssen 2006).  The study that did not 
report an association for the increased risk of MVC and Codeine may be because of sample size 
(Mathijssen 2006); the study may not have had the statistical power to detect a difference.  As for 
Tramadol, two studies investigated its effects and only one (Gibson, Hubbard et al. 2009) reported a 
statistically significant increase in MVC.  This, too, may have been attributed to sample size.  Out of 181 
collisions, only 20 people were found positive for Tramadol in the study conducted by Bachs et al (Bachs, 
Engeland et al. 2009).  
Anticonvulsants 
Three studies investigated the effects of anticonvulsants, which included Carbamazepine 
(Etminan, Hemmelgarn et al. 2004), Phenytoin (Nelson 1992), and Valproate (Bramness, Skurtveit et al. 
2009).  As seen in Figure 3, none of these medications were associated with a statistically significant 
increase of MVC (Nelson 1992; Etminan, Hemmelgarn et al. 2004; Bramness, Skurtveit et al. 2009).  
Though not significant, Carbamazepine and Valproate were trending towards being protective against the 
risk of MVC. 
Antidepressants 
Antidepressant medications were the most studied class of drug.  Twelve medications were 
investigated amongst three studies, which included Amitriptyline (Gibson, Hubbard et al. 2009; 
Coupland, Dhiman et al. 2011), Cetirizine (Gibson, Hubbard et al. 2009), Citalopram (Gibson, Hubbard et 
al. 2009; Coupland, Dhiman et al. 2011), Doselupin (Gibson, Hubbard et al. 2009; Coupland, Dhiman et 
al. 2011), Escitalopram (Coupland, Dhiman et al. 2011), Fluoxetine (Gibson, Hubbard et al. 2009; 
Coupland, Dhiman et al. 2011), Lofepramine (Gibson, Hubbard et al. 2009; Coupland, Dhiman et al. 
2011), Mirtazapine (Coupland, Dhiman et al. 2011), Paroxetine (Gibson, Hubbard et al. 2009; Coupland, 
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Dhiman et al. 2011), Sertraline (Coupland, Dhiman et al. 2011), Trazodone (Gibson, Hubbard et al. 2009; 
Coupland, Dhiman et al. 2011; Hansen 2012) and Venlafaxine (Coupland, Dhiman et al. 2011).  As seen 
in Figure 4, with the exception of one outcome for Doselupin and two for Trazodone, virtually all of these 
medications were found to not be associated with a statistically significant increase of MVC.  Though not 
significant, several of these medications were trending towards being protective against a MVC; this 
included Amitriptyline, Fluoxetine, Mirtazapine, Paroxetine, Sertraline, and Venlafaxine.  In one study, 
Doselupin was found protective (Coupland, Dhiman et al. 2011) against MVC while another study 
(Gibson, Hubbard et al. 2009) found no association.  This may be attributed to the differences in study 
design or possibly the study population as the study that found Doselupin protective was limited to older 
adult drivers (Coupland, Dhiman et al. 2011).  All three studies investigated Trazodone and the findings 
for this medication were mixed.  Two studies found Trazodone to not be statistically significant for the 
increased risk of MVC (Gibson, Hubbard et al. 2009; Coupland, Dhiman et al. 2011).  Hansen found that 
both new (HR=2.15; 95% CI 1.83-2.51) and prevalent users (HR=1.47; 95 % CI 1.18-1.85) of Trazodone 
to be at increased risk of MVC (Hansen 2012).  These differences may be attributed to the study 
population or possibly the study design. 
Antihistamines 
One study investigated the effects of nine antihistamines on the odds of MVC, which included 
Astemizole, Brompheniramine, Chlorphenamine, Desloratidine, Fexofenadine, Hydroxyzine, 
Levocitirizine, Loratadine, and Terfenadine (Gibson, Hubbard et al. 2009).  As seen in Figure 5, only 
Levocitirizine was associated with an increased risk of MVC (Gibson, Hubbard et al. 2009).   
Antihyperglycemics 
Six studies investigated three antihyperglycemic medications which included Insulin (McGwin, 
Sims et al. 2000; Sims, McGwin et al. 2000; Cui 2001; Hemmelgarn, Lévesque et al. 2006; Lonnen, 
Powell et al. 2008; Skurtveit, Strøm et al. 2009), Metformin (Hemmelgarn, Lévesque et al. 2006), and 
Sulfonylurea (Hemmelgarn, Lévesque et al. 2006) (Figure 6).  Of the six studies that reported outcome 
measures for Insulin, only two reported a statistically significant increase in MVC (Cui 2001; Skurtveit, 
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Strøm et al. 2009).  The other four studies reported no statistically significant associations (McGwin, 
Sims et al. 2000; Sims, McGwin et al. 2000; Hemmelgarn, Lévesque et al. 2006; Lonnen, Powell et al. 
2008).  This may be attributed to the adjustment of covariates.  One study which included the odds of 
having any crash or a not-at-fault crash was adjusted for age, sex, race, and annual mileage (McGwin, 
Sims et al. 2000), while another study was adjusted for age, gender, and days driven per week (Sims, 
McGwin et al. 2000).  Other studies were adjusted for age, sex, previous MVC, and place of residence 
(Hemmelgarn, Lévesque et al. 2006), or unadjusted but stratified by the following ages: <25, 25-44, 45-
64, 65-74, and 75-84 years of age (Lonnen, Powell et al. 2008).  Since two studies were not adjusted and 
the other studies were adjusted or stratified by age, it is possible that these two studies were statistically 
significant because they were left unadjusted (Cui 2001; Skurtveit, Strøm et al. 2009).  In addition, one 
study found that Metformin was not associated with an increased risk of crash, while Sulfonylurea was 
protective against MVC (Hemmelgarn, Lévesque et al. 2006). 
Benzodiazepines 
Nine benzodiazepines were investigated amongst seven studies which included Chlordiazepoxide 
(Gibson, Hubbard et al. 2009), Diazepam (Neutel 1998; Bramness, Skurtveit et al. 2007; Gibson, 
Hubbard et al. 2009; Gjerde, Normann et al. 2011; Gjerde, Christophersen et al. 2013), Flunitrazepam 
(Gustavsen, Bramness et al. 2008), Flurazepam (Neutel 1998), Lorazepam (Neutel 1998), Nitrazepam 
(Gustavsen, Bramness et al. 2008; Gibson, Hubbard et al. 2009), Oxazepam (Neutel 1998), Temazepam 
(Gibson, Hubbard et al. 2009; Hansen 2012), and Triazolam (Neutel 1998) (Figure 7).  Chlordiazepoxide 
and Oxazepam were not found to be statistically significant for the increased risk of MVC (Neutel 1998; 
Gibson, Hubbard et al. 2009).  Flunitrazepam, Flurazepam, Lorazepam, Temazepam, and Triazolam were 
found to be statistically significant for an increased risk of MVC (Neutel 1998; Gustavsen, Bramness et 
al. 2008; Gibson, Hubbard et al. 2009).  The findings for Diazepam were slightly mixed.  Of the five 
studies investigating the effects of Diazepam, four found a statistically significant increase in MVC 
(Neutel 1998; Bramness, Skurtveit et al. 2007; Gibson, Hubbard et al. 2009; Gjerde, Christophersen et al. 
2013), while only one did not (Gjerde, Normann et al. 2011).  Since the confidence intervals for one study 
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was quite large, this estimate was likely not precise (Gjerde, Normann et al. 2011).  The findings were 
also mixed for Nitrazepam.  One study found it to be associated with an increased risk of MVC 
(Gustavsen, Bramness et al. 2008), while another did not (Gibson, Hubbard et al. 2009).  It should be 
noted that the study that did not report a statistically significant increase in MVC trended towards an 
increased risk (Gibson, Hubbard et al. 2009).  This discrepancy may have been attributed to different 
study designs. 
Sleep Medications 
Zolpidem and Zopiclone were the only two strictly sleep-enhancing medications to be 
investigated (Figure 8).  Five studies explored Zolpidem’s effects (Gustavsen, Bramness et al. 2008; 
Gibson, Hubbard et al. 2009; Orriols, Philip et al. 2011; Yang, Lai et al. 2011; Hansen 2012), while six 
studies examined Zopiclone (Gustavsen, Bramness et al. 2008; Gibson, Hubbard et al. 2009; Gjerde, 
Normann et al. 2011; Orriols, Philip et al. 2011; Yang, Lai et al. 2011; Gjerde, Christophersen et al. 
2013).  Both medications appeared to be associated with an increased risk of MVC.  Four (Gustavsen, 
Bramness et al. 2008; Orriols, Philip et al. 2011; Yang, Lai et al. 2011; Hansen 2012) of five studies 
found Zolpidem to be statistically significant for an increased risk of MVC.  Two (Gustavsen, Bramness 
et al. 2008; Gjerde, Normann et al. 2011) of six studies found Zopiclone to be statistically significant for 
an increased risk of MVC, while the other four were trending towards an increased risk, but not 
statistically significant (Gibson, Hubbard et al. 2009; Orriols, Philip et al. 2011; Yang, Lai et al. 2011; 
Gjerde, Christophersen et al. 2013). 
Other Medications 
Eight medications could not be grouped into any of the other drug categories (Figure 9).  These 
included Atenolol (i.e. a beta-blocker) (Gibson, Hubbard et al. 2009), Carisoprodol (i.e. a muscle 
relaxant) (Bramness, Skurtveit et al. 2007), Estrogen (i.e. a hormone) (Sims, McGwin et al. 2000), 
Lithium (i.e. an antipsychotic) (Etminan, Hemmelgarn et al. 2004; Bramness, Skurtveit et al. 2009), 
Methyldopa (i.e. an antihypertensive) (Nelson 1992), Propranolol (i.e. a beta-blocker) (Gibson, Hubbard 
et al. 2009), Salbutamol (i.e. an antispasmodic) (Bramness, Skurtveit et al. 2007), and Warfarin (i.e. an 
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anticoagulant) (Delaney, Opatrny et al. 2006).  Of these medications, Carisoprodol was associated with a 
statistically significant increase in MVC (Bramness, Skurtveit et al. 2007).  The findings for Lithium and 
Warfarin were mixed.  One study reported an increased risk of MVC for Lithium (Etminan, Hemmelgarn 
et al. 2004), while another reported no statistically significant association (Bramness, Skurtveit et al. 
2009).  This may have been attributed to differences in study design or the age of the population.  As for 
Warfarin, one study found that Warfarin was initially protective against MVC for new users, but if taken 
for an extended period of time, no association was found (Delaney, Opatrny et al. 2006).  All other 
medications were not found to be statistically significant for the increased risk of MVC.  
2.4 Discussion 
Findings 
The principal finding of this study is that among the 53 specific medications investigated by the 
27 studies included in this review, 15 medications (28.3%) were associated with an increased risk of 
motor vehicle collision.  The medications that were associated with an increased risk of collision were: 
Buprenorphine, Codeine, Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, 
Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and 
Zopiclone.  Two (3.8%) of the 53 medications, Sulfonylurea and Warfarin, may be protective against 
MVC.  All other 36 medications (67.9%) were not significantly associated with MVC.  The findings of 
this review illustrate that certain medications, even within the same class or drug category, may be more 
associated with crash risk than others.   
These findings are consistent with the current literature.  With the exception of Carisoprodol, 
Dihydrocodeine, and Tramadol, 12 of the 15 medications that were associated with increased MVC have 
also been studied in either driving simulations or actual driving assessments.  Both types of studies use 
common measures to assess one’s ability to safely navigate a vehicle; these measures include the ability 
to maintain position within the lane [i.e. standard deviation of lateral position (SDLP)], tracking (i.e. 
following an object), missed instructions or directions, actual collisions with cars or objects, the ability to 
maintain constant speed, reactions or reaction time to stimuli, the ability to keep the vehicle on the road, 
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steering wheel angle, divided attention (i.e. performing a task, such as acknowledging a sign or symbol, 
while driving), and gap acceptance (i.e. ability to judge distance between objects). There is evidence from 
both driving simulation and driving assessment studies that eight of these medications may also affect 
some aspects of driving ability; this includes Diazepam, Flunitrazepam, Flurazepam, Lorazepam, 
Temazepam, Triazolam, Zolpidem, and Zopiclone.   
Diazepam, an anxiolytic, has been studied more extensively than any other of the medications.  
Six driving assessments (Biehl 1979; de Gier, t Hart et al. 1981; O'Hanlon, Haak et al. 1982; De Gier 
1984; van Laar, Volkerts et al. 1992; O'Hanlon, Vermeeren et al. 1995) and ten simulation studies 
(Linnoila and Hakkinen 1974; Moskowitz and Smiley 1982; Willumeit, Ott et al. 1984; Willumeit, Ott et 
al. 1984; Smiley and Moskowitz 1986; Friedel, Joo et al. 1991; Kuitunen 1994; Vanakoski, Mattila et al. 
2000; Takahashi, Iwamoto et al. 2010; Tamaji, Iwamoto et al. 2012) have investigated its effects on 
driving ability.  The majority of studies have been randomized, double-blind, and cross-over by design.  
Participants in these studies have involved both genders of different age ranges.  Professional drivers have 
also been used to study its effects (O'Hanlon, Haak et al. 1982).  Diazepam has been shown to negatively 
affect driving ability in virtually all the studies whether the source is an actual driving assessment or 
driving simulation.  Collectively, Diazepam has affected nearly every aspect of driving ability including 
braking, SDLP, incidence of collisions, driver behavior, tracking, steering, car following, and reaction 
time, compared to placebo conditions (Linnoila and Hakkinen 1974; Biehl 1979; de Gier, t Hart et al. 
1981; Moskowitz and Smiley 1982; O'Hanlon, Haak et al. 1982; De Gier 1984; Willumeit, Ott et al. 1984; 
Willumeit, Ott et al. 1984; Smiley and Moskowitz 1986; Friedel, Joo et al. 1991; van Laar, Volkerts et al. 
1992; Kuitunen 1994; O'Hanlon, Vermeeren et al. 1995; Vanakoski, Mattila et al. 2000; Takahashi, 
Iwamoto et al. 2010; Tamaji, Iwamoto et al. 2012).   
Flunitrazepam, a benzodiazepine, has been studied in one simulation (Meskali, Berthelon et al. 
2009) and one driving assessment (Schmidt, Brendemühl et al. 1986).  In the simulation study, 16 healthy 
subjects underwent a double blind cross-over study where they took Flunitrazepam the night before than 
completed the simulation the next morning to assess residual effects of the drug.  Participants tended to 
48 
 
speed when taking Flunitrazepam (Meskali, Berthelon et al. 2009).  In the driving assessment, 32 
outpatients with sleep disorders received either 2 mg of Flunitrazepam or 20 mg of Temazepam daily for 
seven days and partook in a driving test on day one and day seven (Schmidt, Brendemühl et al. 1986).  
Steering, lateral acceleration, and velocity were used to assess driving ability.  Those taking 
Flunitrazepam experienced greater decreases in steering ability compared to Temazepam (Schmidt, 
Brendemühl et al. 1986). 
Flurazepam, a benzodiazepine derivative, has been investigated in two driving assessments (Betts 
and Birtle 1982; Brookhuis, Volkerts et al. 1990) and two simulations (Willumeit, Neubert et al. 1983; 
Willumeit, Ott et al. 1984).  In a blinded, cross-over trial, 12 female volunteers received placebo or 
Flurazepam the night before and then drove a course the following morning.  Under Flurazepam, 
participants incorrectly performed passable gaps (Betts and Birtle 1982).  In another double-blind, cross-
over study, 16 patients treated for insomnia performed a 75km driving assessment.  When treated with 
Flurazepam, SDLP was decreased, but was more pronounced in female subjects during morning 
assessments (Brookhuis, Volkerts et al. 1990).  In a double-blind, cross-over simulation using 12 healthy 
volunteers, general reaction time to signals was impaired under Flurazepam compared to control periods 
(Willumeit, Neubert et al. 1983).  In another placebo-controlled, double-blind simulation using 54 healthy 
volunteers, executed tasks while driving were decreased in those taking Flurazepam compared to placebo 
periods (Willumeit, Ott et al. 1984).  
Lorazepam, a benzodiazepine, has been evaluated in seven driving assessments (Hindmarch and 
Gudgeon 1980; Irving and Jones 1992; O'Hanlon, Vermeeren et al. 1995; Mercier-Guyon, Lejay et al. 
1999; van Laar, Volkerts et al. 2001; Daurat, Sagaspe et al. 2013; Moták, Bayssac et al. 2014) and one 
simulation (Mattila, Kuitunen et al. 1993).  All of the studies were randomized, double-blind, and cross-
over by design.  Four of the driving assessments were limited to males (Mercier-Guyon, Lejay et al. 1999; 
van Laar, Volkerts et al. 2001; Daurat, Sagaspe et al. 2013; Moták, Bayssac et al. 2014), two to females 
(Hindmarch and Gudgeon 1980; Irving and Jones 1992), and one to a group of clinically anxious and 
non-anxious participants of mixed gender (O'Hanlon, Vermeeren et al. 1995).  The simulation study 
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encompassed healthy volunteers (Mattila, Kuitunen et al. 1993).  Driving ability (i.e. SDLP, inappropriate 
line crossings, car handling, lane-keeping, speed, following distance, and tracking) was affected in all 
driving assessments and simulations (Hindmarch and Gudgeon 1980; Irving and Jones 1992; Mattila, 
Kuitunen et al. 1993; O'Hanlon, Vermeeren et al. 1995; Mercier-Guyon, Lejay et al. 1999; van Laar, 
Volkerts et al. 2001; Daurat, Sagaspe et al. 2013; Moták, Bayssac et al. 2014). 
Temazepam, a benzodiazepine prescribed to treat short-term insomnia, has been evaluated in five 
driving assessments (Betts and Birtle 1982; O'Hanlon and Volkerts 1986; Schmidt, Brendemühl et al. 
1986; Riedel, Quasten et al. 1988; Leufkens and Vermeeren 2009) and one simulation study (Partinen, 
Hirvonen et al. 2003).  All of the driving assessments and simulations were randomized, double-blind, 
and cross-over by design.  The driving assessments used female volunteers in two studies (Betts and 
Birtle 1982; O'Hanlon and Volkerts 1986), one used rotating shift workers (Riedel, Quasten et al. 1988), 
one used healthy volunteers (Leufkens and Vermeeren 2009), and one used insomniacs (Schmidt, 
Brendemühl et al. 1986).  The driving simulation used only female participants (Partinen, Hirvonen et al. 
2003).  Temazepam affected driving ability (i.e. participants hit more bollards) in only one study, but 
none of the others (Betts and Birtle 1982). 
Triazolam, a sedating benzodiazepine used to treat severe insomnia, has been studied in three 
driving assessments (Laurell and Tornros 1986; Riedel, Quasten et al. 1988; Riedel 1991) and three 
driving simulations (Deits, Boyle et al. 2011; Morrison, Boyle et al. 2011; Brown, Milavetz et al. 2013).  
All three driving assessments were randomized, double-blind, and cross-over by design (Laurell and 
Tornros 1986; Riedel, Quasten et al. 1988; Riedel 1991).  Two of the studies used rotating shift workers 
(Riedel, Quasten et al. 1988; Riedel 1991), while the third used healthy volunteers (Laurell and Tornros 
1986).  In the two driving assessments using shift workers, Triazolam severely affected driving ability 
(Riedel, Quasten et al. 1988; Riedel 1991); driving performance was not as affected among the healthy 
volunteers (Laurell and Tornros 1986).  In the simulation studies, all three were similar in design and used 
commercial bus drivers as the study population (Deits, Boyle et al. 2011; Morrison, Boyle et al. 2011; 
Brown, Milavetz et al. 2013).  Driving ability (i.e. lane keeping, driving path, steering, braking, and 
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SDLP) was affected in all of the simulation studies simulations (Deits, Boyle et al. 2011; Morrison, Boyle 
et al. 2011; Brown, Milavetz et al. 2013).  
Zolpidem and Zopiclone, two sleep-promoting medications, were evaluated simultaneously in 
two driving assessments (Leufkens, Lund et al. 2009; Verster, Bervoets et al. 2014) and four driving 
simulations (Bocca, Le Doze et al. 1999; Staner, Ertlé et al. 2005; Meskali, Berthelon et al. 2009; Bocca, 
Marie et al. 2011).  The two driving assessments were randomized, double-blind, and cross-over by 
design that used healthy participants of all age ranges (Leufkens, Lund et al. 2009; Verster, Bervoets et al. 
2014).  In both studies, Zopiclone and Zolpidem affected driving ability.  In the simulation studies, all 
four were randomized, double-blind, and cross-over by design; three studies used participants 55 years of 
age and older (Bocca, Le Doze et al. 1999; Meskali, Berthelon et al. 2009; Bocca, Marie et al. 2011), 
while the mean age in the fourth study was 38 years (Staner, Ertlé et al. 2005).  Zopiclone affected driving 
ability in all four simulations (Bocca, Le Doze et al. 1999; Staner, Ertlé et al. 2005; Meskali, Berthelon et 
al. 2009; Bocca, Marie et al. 2011); Zolpidem affected driving ability in three simulations (Staner, Ertlé et 
al. 2005; Meskali, Berthelon et al. 2009; Bocca, Marie et al. 2011), but not in the fourth (Bocca, Le Doze 
et al. 1999).  Zolpidem and Zopiclone were studied individually in three additional studies each.  
Zolpidem affected driving ability in all three studies (Verster, Volkerts et al. 2002; Partinen, Hirvonen et 
al. 2003; Otmani, Demazières et al. 2008), while Zopiclone affected driving ability in two of the three 
studies (Vermeeren, Riedel et al. 2002; Leufkens and Vermeeren 2009; Mets, Vries et al. 2011).  
In addition to the eight medications described, four of the other 15 medications associated with 
increased risk of MVC have not been associated with affected driving ability during driving assessments 
or simulation studies; this includes Buprenorphine, Methadone, Levocitirizine, and Codeine.  One driving 
simulation study investigated the effects of Buprenorphine and Methadone in a group of former heroin 
addicts whom were stabilized for at least three months and compared them to a group of healthy controls 
(Lenné, Dietze et al. 2003).  SDLP, speed, steering wheel angle, and reaction time were used to assess 
driving ability.  There was no difference in driving ability between the placebo group and those treated 
with either Buprenorphine or Methadone (Lenné, Dietze et al. 2003).  Another study investigated the 
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effects of Levocitirizine through an on-the-road assessment, which measured SDLP and speed to evaluate 
driving ability (Verster, Weert et al. 2003).  No difference in performance was detected among those 
treated with Levocitirizine and the control group (Verster, Weert et al. 2003).  Codeine has been studied 
in three driving simulations (Linnoila and Hakkinen 1974; Nilsen, Landr et al. 2011; Leung, Chapman et 
al. 2013).  A randomized, double-blind, placebo-controlled, crossover study of 13 healthy volunteers were 
administered therapeutic levels of Codeine and assessed on SDLP and time to collision under simulation.  
There were no differences between exposure and control periods (Leung, Chapman et al. 2013).  In 
another simulation study, 70, 16-22 year old professional drivers from the Finnish Army were 
randomized to various treatment and control groups and assessed on numerous factors during simulation 
(Linnoila and Hakkinen 1974).  The only difference among the Codeine treated group was that they 
caused slightly more collisions (Linnoila and Hakkinen 1974).  In another simulation study, which 
compared chronic pain users with Codeine, chronic pain users not using Codeine, and placebo group of 
healthy controls, participants were assessed on reaction time and missed reactions (Nilsen, Landr et al. 
2011).  No differences were detected in the Codeine treated group (Nilsen, Landr et al. 2011).  
While the remaining three medications, Carisoprodol, Dihydrocodeine, and Tramadol, have not 
been evaluated in driving assessments or driving simulations, their effects on psychomotor performance 
and/or cognition have been evaluated in laboratory settings.  Carisoprodol, a muscle relaxant, can cause 
users to feel sedated, sluggish, and distracted, especially at high dosages (Zacny, Paice et al. 2011; Zacny, 
Paice et al. 2012).  At therapeutic doses, Carisoprodol users often report feeling no effects of the 
medication even though their psychomotor functioning is decreased; this situation may cause users of this 
medication to underestimate its effects and partake in behaviors, such as driving, when they may be 
impaired (Zacny, Paice et al. 2012).  Dihydrocodeine, an opioid prescribed for mild to moderate pain, is 
known to cause dizziness and mild euphoria especially in new users (Ammon, Hofmann et al. 1999), 
which may interfere with their ability to drive.  Tramadol, an opioid for mild to moderate pain, has been 
shown to be fairly safe in respect to cognition and psychomotor function, though at higher doses, 
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Tramadol has been linked to the worsening of balance (Mintzer, Lanier et al. 2010).  It should be noted 
that poor balance has been linked to higher incidences of MVC (Huisingh, McGwin et al. 2013).  
Implications for research 
From these findings, it is apparent that some medications that are associated with an increased 
risk of MVC do not appear correlated with decreased driving ability.  Conversely, while the majority of 
the medications included in this review were not found to be statistically associated with increased risk of 
MVC, the inference that these medications are innocuous on one’s ability to drive is not advised.  There 
are several plausible reasons why the association between MVC and driving ability were not congruent 
with all medications presented in this review.  First, this incongruence may be attributed to study design.  
The 27 studies investigating the risk or odds of MVC were observational in nature, whereas the studies 
investigating driving ability were all randomized control trials (RCT) and therefore, experimental.  The 
studies investigating driving ability were comprised of small sample sizes and were occasionally limited 
to certain age groups or genders.  Therefore, the findings of the RCTs may not be generalizable to the 
entire population, which is a known limitation of this type of study design (Rothman, Greenland et al. 
2008).  In addition, the observational studies may not have been adjusted for key confounders whereas 
this would not have affected the RCTs’ results if participants were randomized properly (Rothman, 
Greenland et al. 2008).  Also, most of the RCTs only investigated one or two aspects of driving ability.  
The act of driving is quite complex in nature.  It is possible that other aspects of driving ability may not 
have been affected by the medication being investigated.  It is also plausible that even if driving ability is 
partially affected by a medication, some drivers may compensate their driving behaviors to avoid a 
potential collision, which is a known phenomenon (Marottoli, Ostfeld et al. 1993; Martinez 1995; Kelly, 
Warke et al. 1999).  Second, epidemiological research investigating the associations between specific 
medications and MVC is lacking; this is evident by the number of studies included in this review.  Some 
medications that have been studied via RCTs may not have been investigated observationally in larger 
populations.  Third, many of the RCTs used healthy volunteers.  This is problematic as disease-
medication relationships are often difficult to distinguish.  It is entirely possible that the disease in which 
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the medication is prescribed is affecting an individual’s ability to drive or their risk of MVC. It is also 
possible that driving ability is only affected for a short period of time and that an individual who takes a 
medication for an extended period of time develops a tolerance.  This may not have been detected as the 
RCTs were often short in duration. 
Implications for clinical practice 
The findings of this review have several key clinical implications.  First, the association between 
a specific medication and increased risk of MVC and decreased driving ability is not always clear.  There 
are some specific medications that are most likely driver-impairing as both experimental and 
observational research has associated them with decreased driving ability and increased risk of MVC, 
respectively.  These include Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, 
Zolpidem, and Zopiclone.  For other medications, such as Buprenorphine, Codeine, Methadone, and 
Levocitirizine, there appears to be an association between the medication and increased risk of MVC, but 
not driving ability.  As for Tramadol, Carisoprodol, and Dihydrocodeine, they appear to be associated 
with increased risk of MVC, but have not been evaluated in driving assessments or simulations.  
Secondly, some specific medications belonging to the same category or class may be more detrimental 
than others.  For example, among the ‘Other Medications” included in this review, Carisoprodol had a 
strong association with MVC while the other medications in this category did not.  Thirdly, some of these 
medications are widely prescribed.  For example, Buprenorphine was the 39
th
 most sold drug in the U.S. 
during the fourth quarter of 2013 (IMS Health 2014).  Therefore, careful consideration of the patient and 
their lifestyle must be given when these medications are prescribed.  Possible alternatives within a drug 
category or class should be considered for patients that frequently drive as certain medications may be 
more driver-impairing than others.  Education efforts are needed to ensure that patients are aware that 
certain medications may increase their risk of MVC. 
Strengths and limitations of this review 
The strengths of this review are that over 50 years of data among fourteen different databases 
were searched for potential studies.  This review also included relevant ‘grey literature’ as evidenced by 
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the inclusion of three doctoral dissertations and one conference paper.  Despite its strengths, this review is 
not without its limitations.  For example, publication bias is a known limitation of systematic reviews 
(Rothman, Greenland et al. 2008).  It is also possible that some studies may have been missed despite two 
authors independently reviewing studies for inclusion.  As much of the DUID research arises from Europe 
(Kelly, Darke et al. 2004), it is likely that several studies were not included or missed as they were not 
available in the English language, a requirement of the a priori inclusion criteria.  In some instances, only 
abstracts and not complete studies could be retrieved, especially with reports or conference papers that 
were dated.  The findings of this review also indicate that future research opportunities in this area of 
study are plentiful.  Future research could entail, 1) RCTs of medications found to be associated with 
increased risk of MVC that were never evaluated in a driving assessment or simulation, 2) 
epidemiological studies investigating the effects of other medications or new medications that may be 
driver-impairing, 3) investigating different methods of measuring driving ability in simulations and actual 
assessments, and 4) pursuing patient or clinician educational efforts to raise awareness about the possible 
effects of specific medications on MVC or affected driving ability.   
Conclusions 
This systematic review sought to determine which specific medications were associated with 
increased risk of motor vehicle collision among licensed drivers.  While the majority of medications 
investigated were found to not be significantly associated with increased MVC, several medications were 
associated with such risks.  It was also determined that some medications may be more driver-impairing 
than others.  These findings pose numerous clinical implications.  Due to the increasing public health and 
traffic safety concerns regarding driving under the influence of drugs, future research in this area of study 
is worthy of investigation as the associations between specific medication use and the increased risk of 














Objectives: Adults 65 years of age and older comprise the fastest growing demographic in the U.S.  As 
drug use is projected to increase in this population, there is concern that more seniors will be driving 
under the influence of impairing drugs.  The purpose of this analysis is to explore licit and illicit drug use 
among senior drivers fatally injured in traffic collisions. 
 
Methods: Data from the Fatality Analysis Reporting System were analyzed from 2008-2012. Commonly 
used classes and specific drugs were explored. Rates of drug use, multiple drugs, concomitant drug and 
alcohol use, and alcohol use alone were generated using Poisson regression with robust error variance 
estimation.  Rates for fatally injured senior drivers were compared to those of fatally injured middle-aged 
drivers (30 to 50 years old) using rate ratios. 
 
Results: Licit and illicit drug use among senior drivers occurred in 17.8% of those tested.  Among drug-
positive senior drivers, benzodiazepines and narcotics were frequent.  The rates of testing positive for any 
drug, multiple drugs, combined drug and alcohol, and alcohol use alone among seniors were 47% 
(RR=0.53, 95% CI 0.50, 0.57), 57% (RR=0.43, 95% CI 0.39, 0.48), 88% (RR=0.12, 95% CI 0.10, 0.15) 
and 79% (RR=0.21, 95% CI 0.19, 0.24) less, respectively, compared to middle-aged drivers.  
 
Conclusions: Overall licit and illicit drug use is less common among fatally injured senior drivers relative 
to middle-aged drivers.  As narcotics and benzodiazepines were frequently found in drug-positive senior 






























According to the National Center for Injury Prevention and Control, a person dies nearly every 
hour in the United States (U.S.) from a motor vehicle collision involving an impaired driver (Centers for 
Disease Control and Prevention 2015).  Despite decades-worth of traffic safety campaigns and nearly 60 
billion dollars of annual costs (Centers for Disease Control and Prevention 2015), impaired driving still 
remains an important public health and traffic safety concern (Kelly, Darke et al. 2004; Walsh, de Gier et 
al. 2004).  While the term ‘impairment’ traditionally referred to an individual’s diminished driving ability 
resulting from alcohol consumption, impairment also includes driving under the influence of drugs 
(DUID).  Driving under the influence of drugs is not limited to traditional illicit or recreationally used 
substances, such as cocaine or methamphetamines, which have no real medical benefit.  Impairment can 
be a result of licit drugs, including common prescription and over-the-counter medications, whose effects 
interfere with one’s cognitive, physical, or psychomotor ability to safely operate a motor vehicle from one 
destination to another (Coopersmith, Korner-Bitensky et al. 1989; Carr 2000; Carr, Duchek et al. 2006; 
Cheung and McCartt 2011).  Between 2007 and 2014, the National Highway Traffic Safety 
Administration (NHTSA) reports that while alcohol-impaired driving appears to be declining, DUID 
increased ~4% nationally (National Highway Traffic Safety Administration 2015).  Other studies also 
report increases in the prevalence of prescription drugs among fatally injured drivers (Rudisill, Zhao et al. 
2014; Wilson, Stimpson et al. 2014). 
While drug-impaired driving has steadily increased in the U.S., so has the number of licensed 
drivers over 65 years of age.  Adults 65 years of age and older (i.e. seniors) comprise the most rapidly 
growing sub-group of the U.S. population (McGwin, Sims et al. 2000). Should this population trend 
persist through 2030, 1 in 5 drivers will be 65 or older (Braver and Trempel 2004).  Seniors are the largest 
consumers of both prescription and over-the-counter medications (Bushardt, Massey et al. 2008), and the 
current generation of older adults reports a higher prevalence of lifetime licit and illicit drug use (Colliver, 
Compton et al. 2006).  Furthermore, it is projected that illicit drug use and non-medical use of 




In spite of these projections, there are numerous gaps in the extant literature.  Licit and illicit drug 
use among drivers, particularly seniors (Lotfipour and Vaca 2007), is largely understudied in the U.S. 
(Kelly, Darke et al. 2004; Walsh, de Gier et al. 2004).  Therefore, the purpose of this analysis is to explore 
both licit and illicit drug use among drivers 65 years of age or older who were fatally injured in motor 
vehicle collisions in the U.S. from 2008-2012.  While licit substances, such as prescription and over-the-
counter medications, can be obtained illegally, misused, or abused, the intent of use is impossible to 
determine given the decedent nature of the population.  The question that this study seeks to answer is, 
“what are the most common specific and broad groups of licit and/or illicit substances and combinations 
found in this population of drivers?” Describing the licit and illicit drug use in this demographic may 
elucidate potential avenues for public health intervention among aging U.S. drivers. 
3.2 Methods 
Data Source 
Data for this analysis were obtained from the Fatal Analysis Reporting System (FARS).  FARS is 
a publicly available database maintained by the NHTSA (National Highway Traffic Safety 
Administration 2012).  All 50 states and the District of Columbia are required to report traffic collisions 
to the NHTSA when at least one person injured in a traffic collision dies within 30 days of the incident 
(National Highway Traffic Safety Administration 2012).  Trained NHTSA analysts abstract the data from 
these state reported files using strict quality control procedures (National Highway Traffic Safety 
Administration 2012).  Currently, the FARS database contains over 100 variables relating to the crash, 
vehicles, and people involved in the incident (National Highway Traffic Safety Administration 2012).  In 
the database, blood alcohol concentration and up to three drug test results can be recorded for each 
individual involved in a collision.  In cases of multiple drug involvement, the possibility exists that 
drivers can have more than three drugs detected in their system at time of collision, yet only the first three 
are reported.  FARS lists drug test results in the following priority order:  1) narcotics, 2) depressants, 3) 
stimulants, 4) marijuana, and 5) other drugs (Centers for Disease Control and Prevention 2006).  Nicotine, 
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aspirin, and/or drugs administered to an individual as part of post-collision medical treatment are 
excluded from the drug test results (National Highway Traffic Safety Administration 2010; National 
Highway Traffic Safety Administration 2012).  Drug testing can be performed using urine and/or blood.  
The consistency of drug testing varies greatly by state (National Highway Traffic Safety Administration 
2010).  Some states routinely test fatally injured drivers for licit and illicit substances, while others do not 
(National Highway Traffic Safety Administration 2010).  Furthermore, states may not consistently report 
their results to the NHTSA (National Highway Traffic Safety Administration 2010). 
Study Population 
Due to the variability in states’ drug testing practices and reporting, this analysis was limited to 
states with acceptable data quality.  Each state’s data quality was examined from 2008-2012 for a 
combination of factors set a priori including the overall percentage of fatally injured drivers who were 
tested, the percentage of population found drug-positive, and the proportion of drug results listed as 
“Other”.  For inclusion in this analysis, the state had to test at least 50% of fatally injured drivers.  A 
state’s data quality was considered insufficient if the drug-positive percentage was unusually high (>70%) 
or low (<5%) and/or the percentage of results described as “Other” was high (>70%).  The following 
states (n=28) met the inclusion criteria--Alaska, Arizona, California, Colorado, Florida, Hawaii, Illinois, 
Indiana, Kentucky, Maryland, Massachusetts, Michigan, Nevada, New Hampshire, New Jersey, New 
Mexico, New York, North Dakota, Ohio, Pennsylvania, Rhode Island, South Carolina, Vermont, Virginia, 
Washington, West Virginia, and Wyoming—along with the District of Columbia.   
The study population was further limited to fatally injured drivers with a known drug test result 
from states meeting the inclusion criteria.  The traffic collision must have occurred between January 1, 
2008 and December 31, 2012. The study population was also limited to those drivers 65 years of age or 
older at time of collision.  For comparison purposes, middle-aged drivers (i.e. drivers 30-50 years of age 
at time of collision) were included as the referent population for the analysis.  The rationale of using 30-
50 year olds as the referent group was two-fold: 1) 30-50 year olds are generally safer behind the wheel, 
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and 2) they represent the average age of all drivers on the road (Foley, Heimovitz et al. 2002; Cheung and 
McCartt 2011).  The overview of participant selection, along with sample sizes, is described in Figure 1. 
Covariates 
Covariates of interest included age group; gender; race; ethnicity; type of drug test administered 
post-collision; blood alcohol concentration (BAC); a driving while intoxicated (DWI) conviction within 
the past 3 years; a previous crash within the past 3 years; day; time; and year of the crash; the number of 
vehicles involved in the collision; weather conditions at time of collision; and how long the individual 
survived after the crash.  With the exception of the type of drug test administered, weather conditions at 
time of collision, and survival time, all variables were characterized similarly to previously published 
work (Brady and Li 2013).  The type of drug test administered post-collision was categorized as urine, 
blood, or a combination of urine and blood.  Weather condition at time of collision was categorized as 
adverse (i.e. rain, wind, snow, sleet, hail, fog, freezing rain, or blowing debris) or clear.  Survival time 
was dichotomized into death within one hour of collision or beyond.   
BAC, which was measured in grams per deciliter (g/dl), was based on multiple imputed levels 
dictated by NHTSA if the value was missing for a driver (National Highway Traffic Safety 
Administration 2012).  The NHTSA’s multiple imputation method for missing BAC of drivers involved 
in fatal traffic collisions has been extensively published in the literature (Rubin, Schafer et al. 1998; 
Subramanian 2002).  The NHTSA’s validated model imputes 10 specific values of BAC across a range of 
possible values which allows for the estimation of statistics including measures of central tendency and 
dispersion (Rubin, Schafer et al. 1998; Subramanian 2002).  The overall BAC estimates were generated 
by combining these 10 specific values via the PROC MIANALYZE procedure using SAS/STAT software 
(SAS Institute 2010). 
Outcome Variables and Definitions 
Several terms pertaining to the outcomes of this analysis, which are presented throughout this 
paper, include:  licit drugs, illicit drugs, any drug use, multiple drug use, drug and alcohol use, alcohol use 
only, other drugs, broad drug groups, specific/types of drugs, and cannabinoids.  The term ‘licit drug’ is 
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defined as prescription and/or over-the-counter medications typically taken to remedy a medical 
condition.  The term ‘illicit drug’ refers to drugs that are commonly illegal or used recreationally with no 
real medical benefit; in this analysis, cannabis and cannabis metabolites were considered illicit as they are 
deemed illegal by federal law.  ‘Any drug use’ is defined as testing positive for at least one licit or illicit 
drug.  ‘Multiple drug use’ is defined as testing positive for two or more drug categories.  ‘Drug and 
alcohol use’ is classified as testing positive for at least one licit or illicit drug and having a BAC greater 
than 0.01 g/dl.  ‘Alcohol use only’ is characterized as testing negative for illicit and licit drugs but having 
a BAC greater than 0.01 g/dl.  ‘Other drugs’ refers to illicit or licit drugs that cannot be categorized as 
narcotics, depressants, cannabinoids, stimulants, hallucinogens, phencyclidine, anabolic steroids, or 
inhalants. 
‘Broad drug categories’ are overarching groups of drugs which include narcotics, depressants, 
cannabinoids, stimulants, hallucinogens, phencyclidine, anabolic steroids, inhalants, and ‘Other drugs’.  
‘Specific/types of drugs’ are narrower drug classifications which include substances such as 
benzodiazepines, hydrocodone/oxycodone, barbiturates, cocaine, and methadone.  The term ‘cannabinoid’ 
refers to cannabis and its metabolites, which include Delta 9, Hashish, Marinol, and 
Tetrahydrocannabinol.  
Statistical analysis 
Descriptive characteristics of senior drivers testing positive for at least one drug were compared 
to senior drivers testing negative.  An additional analysis was conducted to quantify which covariates 
were associated with drug-positive results in this population of drivers.  Drug prevalence rates were 
assessed for any drug use, multiple drug use, drug and alcohol use, and alcohol use alone in both senior 
and middle-aged drivers.  The drug prevalence rates were calculated by dividing the number of fatalities 
per drug group by the total number of drivers tested for each age group.  The prevalence ratio was then 
determined by dividing the drug prevalence rates of senior drivers by the drug prevalence rates of middle-
aged drivers for each drug category or class.  Drug prevalence ratios were calculated using hierarchical 
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Poisson regression with robust error variance estimation, where random effects were used to account for 
correlations among state reporting (Zou 2004).  
The proportions of select broad drug categories and specific drugs that were identified in both 
senior and middle-aged drivers who tested positive for licit and illicit drugs were also explored.  
Frequencies of the most commonly used specific and broad drug categories were also obtained for both 
senior and middle-aged drivers that tested positive for licit and/or illicit drugs.  These findings were 
presented for each age group and by the number of drugs detected.  The purpose of this analysis was to 
determine which broad and specific drugs were most often detected in each group of drivers.  It should be 
noted that the a priori level of statistical significance was set at 0.05 and SAS/STAT ® software (SAS 
Institute 2010) version 9.3 was used for all analyses.  
Sensitivity Analysis 
Due to the variability of reporting among states, a sensitivity analysis was conducted. The 
purpose of the sensitivity analysis was to determine if the effects of states’ overall drug testing 
percentages biased the results.  All analyses previously described were re-run using data from states that 
routinely tested 80% or more of their fatality injured drivers.  The states (n=10) that met these criteria 
were California, Hawaii, Maryland, New Hampshire, New Jersey, New Mexico, North Dakota, Vermont, 
Washington, and West Virginia. To determine if a bias existed, the results from the original analysis and 
the sensitivity analysis were qualitatively compared. 
3.3 Results 
The descriptive characteristics of the fatally injured senior drivers with complete toxicological 
testing are presented by drug test status in Table 1.  Of the 5,828 senior drivers included in this analysis, 
1,039 (17.8%) were found drug-positive.  Among this group of drivers, 28.5% were between 65-69 years 
of age, 39.7% were between 70-79 years of age, 27.6% were between 80-89 years of age, and 4.2% were 
90 years of age or older.  The sample consisted mainly of white, non-Hispanic males.  The majority of 
drivers were administered a blood test (91.2%).  Many of the drivers tested were found to have a zero 
blood alcohol concentration (90.0%). Of the drivers testing positive for drugs, 62.9% tested positive for 
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only one drug while 23.2% tested positive for two drugs.  Only 14.0% of those found drug-positive had 
three or more drugs detected.  Over 99% of the drivers tested had not been recently convicted of a DWI 
offense and 10.7% were involved in a recent collision.  Among the drivers tested, most collisions 
occurred between Monday and Thursday between 7:00AM-6:59PM.  The collisions typically involved 
two or more vehicles as opposed to single-vehicle crashes (62.4% vs. 37.6%, respectively) and occurred 
when the weather was either clear or cloudy (89.3%).  Approximately 57% of the drivers tested died 
within one hour of the collision.  Over the 5 year span, the total number of drivers tested declined, but the 
number of drivers testing positive for drugs increased.  The sensitivity analysis showed similar results 
(data not shown).   
Table 2 presents the prevalence and prevalence ratios of drug presence among population sub-
groups of senior drivers.  The purpose of this analysis was to determine which of the demographic 
characteristics previously described were associated with an increased or decreased occurrence of a drug-
positive test.  As drivers aged, the prevalence of drug-positive tests decreased.  For example, compared to 
those aged 65-69 years, fatally injured drivers 70-79, 80-89, and ≥90 years of age were approximately 
13% (PR=0.87, 95% CI 0.76, 1.01), 33% (PR=0.67, 95 % CI 0.57, 0.79), and 50% (PR=0.50, 95% CI 
0.34, 0.75), respectively, less likely to have a drug-positive test.  There did not appear to be a statistically 
significant difference concerning gender, race, or ethnicity.  Individuals with a BAC of 0.01-0.07 g/dl 
were 36% more likely (PR=1.36; 95% CI 1.01, 1.82) to have a positive drug result compared to those 
with a BAC equal to zero.  Those that received a previous DWI conviction within the past 3 years tended 
to test positive for drugs.  Individuals testing positive were 16% more likely (PR=1.16; 95% CI 1.03, 
1.32) to be involved in single vehicle relative to multiple vehicle collisions.  The prevalence rate of drug-
positive tests steadily increased from 2008-2012. The prevalence rate rose from 135.8 per 1,000 in 2008 
to 215.3 per 1,000 individuals testing positive in 2012. The sensitivity analysis showed similar results 
(data not shown). 
The prevalence rates and ratios of drug involvement among fatally injured senior and middle-
aged drivers are presented in Table 3.  Drug-positive results were 47% less in senior drivers compared to 
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middle-aged drivers (RR=0.53; 95% CI 0.50, 0.57).  Senior drivers were 57% less likely to test positive 
for two or more drug classes (RR=0.43; 95% CI 0.39, 0.48) and 88% less likely to test positive for drugs 
and alcohol compared to middle-aged drivers (RR=0.12, 95% CI 0.10, 0.15).  Fatally injured senior 
drivers were also 79% less likely to drink and drive relative to middle-aged drivers (RR=0.21; 95% CI 
0.19, 0.24).  The results of the sensitivity analysis were comparable (data not shown).   
The proportions of broad drug categories and specific drugs identified in both senior and middle-
aged drivers that tested positive for licit and/or illicit drugs are presented in Table 4.  Among senior 
drivers who were drug-positive, 43.4% tested positive for “Other” drugs.  Among drug-positive senior 
drivers, 37.2% tested positive for narcotics while 31.8% tested positive for depressants.  Testing positive 
for cannabinoids (6.4%) and stimulants (5.5%) was considerably less frequent among senior drug-positive 
drivers.  The drug use among middle-aged drivers that tested drug-positive differed from drug-positive 
senior drivers.  Among drug-positive middle-aged drivers, 34.6% and 30.4% tested positive for 
cannabinoids and stimulants, respectively.  While slightly less than drug-positive senior drivers, 25.5% 
and 23.9% of middle-aged drug-positive drivers tested positive for narcotics and depressants, 
respectively.  As for specific drugs, 26.1% of fatally injured drug-positive senior drivers tested positive 
for benzodiazepines and 17.7% tested positive for either oxycodone or hydrocodone.  Only 1.8% and 
1.4% of drug-positive senior drivers tested positive for cocaine and methadone, respectively.  Among 
drug-positive middle-aged drivers, 17.4% tested positive for cocaine, 21.4% tested positive for 
benzodiazepines, and 16.4% tested positive for hydrocodone or oxycodone.  The results of the sensitivity 
analysis were comparable (data not shown).   
The most common broad groups of drugs detected in drug-positive drivers are presented in Table 
5a by age group and by the number of drugs detected.  In regards to drug-positive senior drivers, the 
majority only had one drug identified post-collision.  Among drug-positive senior drivers with one drug 
detected, “Other” drugs were most commonly detected (42.3%), followed by narcotics (25.7%) and 
depressants (20.1%).  Among drug-positive senior drivers with two drugs detected, approximately 19% 
tested positive for a narcotic and a depressant while 18.3% tested positive for two narcotics or a narcotic 
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combined with an “Other” drug (16.2%).  The drugs detected in fatally injured drug-positive middle-aged 
drivers differed greatly from drug-positive senior drivers.  Among these drug-positive drivers, 
cannabinoids (37.0%), stimulants (27.2%), and “Other” (13.9%) drugs were the most common broad drug 
groups, if only one drug was detected.  In drug-positive middle-aged drivers with two drugs detected, 
combinations of a stimulant and cannabinoid (17.6%) or a narcotic and a depressant (12.1%) were most 
often identified.  In the sensitivity analysis, the results of the broad drug categories were virtually 
identical (data not shown).   
The most common specific drugs identified in the drug-positive fatally injured drivers are 
presented in Table 5b by age group and by number of drugs detected.  Among senior drivers testing 
positive for one drug, benzodiazepines [specific type-unknown (7.0%)], cannabis (6.6%), hydrocodone 
(5.4%), and morphine (2.9%) were common.  Among senior drivers testing positive for two drugs, 
combinations of two “Other” drugs, followed by combinations of hydrocodone and hydromorphone 
(4.2%), hydrocodone and an “Other” drug (4.2%) and morphine and an “Other” drug (2.9%) were most 
common.  Conversely, middle-aged drivers testing positive for one drug tended to have cannabis (37.0%) 
and cocaine (14.7%) most commonly detected.  For those with two drugs detected, the most prevalent 
combinations included cocaine and cannabis (9.4%), amphetamines and cannabis (8.2%), and cocaine and 
an “Other” drug (5.7%).   The results of the sensitivity analysis were comparable (data not shown).  
Among senior drivers testing positive for one drug, “Other” drugs (41.3%) followed by cannabis (8.5%), 
diazepam (6.5%), hydrocodone (6.5%), and morphine (5.5%) were most common.  Among seniors testing 
positive for two drugs, two “Other” drugs (21.2%), diazepam and an “Other” drug (3.5%), and 
dihydrocodeine and hydrocodone (3.5%) were the most prevalent combinations.  In middle-aged drivers 
testing positive for one drug, cannabis (35.4%) and amphetamines (21.5%) were the most commonly 
identified drugs.  In middle-aged drivers testing positive for two drugs, amphetamine and cannabis 





The principal finding of this study is that drug use among fatally injured drivers 65 years of age 
and older was detected in 17.8% of those tested.  Among the drivers testing positive, the majority were 
confirmed to have only consumed one or two drugs prior to collision.  Depressants, such as 
benzodiazepines, and narcotics, such as hydrocodone, were commonly consumed both separately and in 
combination.  The rates of drug involvement, multiple drug use, drug and alcohol use, and alcohol use 
alone were considerably less in senior drivers compared to middle-aged drivers. Another interesting 
finding was that while the number of senior drivers tested gradually decreased over the 5-year period, the 
prevalence of drug use steadily increased from 2008 to 2012.  These findings suggest that while drug use 
is less frequent among fatally injured senior drivers compared to middle-aged drivers, narcotic and 
depressant consumption is prevalent among drug-positive senior drivers; there is also evidence that drug 
use may be increasing in this population.   
These findings are consistent with the current literature.  It is estimated that approximately 60% 
of all adults over 65 years of age consume one prescription medication daily (Fulton and Allen 2005), 
while only 20% of seniors use three or more prescriptions each day (Jorgensen, Johansson et al. 2001).  In 
this analysis, the majority of senior drivers were found negative for both licit and illicit drugs, which was 
surprising considering that prescription drug use generally increases with age.  There may be several 
potential explanations for this result.  First, previous research demonstrates that drivers self-regulate and 
alter their traffic behaviors when they feel that their driving ability is compromised due to poor health 
(Marottoli, Ostfeld et al. 1993; Martinez 1995; Kelly, Warke et al. 1999).  Such drivers will typically 
avoid situations involving traffic congestion, complex intersections, adverse weather, driving alone, 
and/or driving at night (Ball, Owsley et al. 1998; Blanchard, Myers et al. 2010).  Because the participants 
in this study were still driving, it is possible that the drivers included in this analysis were healthier and 
consequently consuming fewer medications than their less healthy counterparts.  An alternative 
explanation may involve gender differences.  Through the aging process, women typically drive less 
and/or cease driving sooner than men (Stewart, Moore et al. 1993).   Research also suggests that women 
typically consume more medications and have higher rates of multiple medication use compared to males 
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(Jorgensen, Johansson et al. 2001).  As the study population was comprised predominately of men, the 
rates of medication use may have naturally been lower than if it were equally comprised of males and 
females.  A third, though unlikely, explanation for the number of negative drug tests, may have been the 
timing of the collisions and/or medication adherence.  The majority of the collisions occurred on 
weekdays during daylight hours.  It is possible that some drivers had prescriptions but did not yet take 
their medications or were non-adherent to their medication regimen on the day of their collision.  While 
age and gender are not believed to be predictors of medication adherence, the number of prescriptions are; 
medication adherence varies inversely with the number of prescriptions an individual takes each day 
(Hughes 2004).  Hence, if an individual has multiple prescriptions, their medication adherence may be 
low.      
The high prevalence of negative drug test results for illicit substances and alcohol is also 
consistent with the current literature.  Previous research suggests that illicit drug and alcohol use may not 
be commonplace among senior drivers.  A study conducted during the 1990’s in Tennessee revealed that 
only 14% of Level 1 trauma patients over 60 years of age whom were involved in motor vehicle collisions 
tested positive for alcohol over the five year study period.  In this same study, less than 1% of these 
patients tested positive for illicit drugs (Higgins, Wright et al. 1996).   
While alcohol and illicit drug use appears atypical among senior drivers, the high prevalence of 
narcotics, depressant, and “Other” drugs use among fatally injured senior drivers is not unprecedented 
given the following recent trends: 1) increased retail drug sales, 2) elevated emergency department visits,  
3) increased hospital admissions,  and 4) high death rates due to these substances.  Among all written 
prescriptions, cardiovascular, central nervous system, and gastrointestinal medications are typically the 
most prevalent pharmacologic agents prescribed to elderly individuals (Jorgensen, Johansson et al. 2001).  
It is possible that the medications listed as “Other” were these types of pharmacological agents; it is also 
possible that these substances were over-the-counter medications as elderly adults are the largest 
consumer of such products based on retail drug sales (Fulton and Allen 2005).  Unfortunately, due to the 
constraints of the FARS database, discerning what type of pharmacologic agent the “Other” drugs were 
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remains unknown.  As for the high prevalence of opioid analgesics and benzodiazepines among fatally 
injured senior drivers, their use in the U.S. has dramatically increased over the past two decades 
(Joranson, Ryan et al. 2000; Paulozzi, Ballesteros et al. 2006). The retail sales of oxycodone and 
hydrocodone rose almost 600% and 200%, respectively, between 1997 and 2005 (Manchikanti 2007).  
The number of emergency department visits due to opioid and benzodiazepine use increased 111% and 
89%, respectively, between 2004 and 2008 (Centers for Disease Control and Prevention 2010), which 
may be partially attributed to the concomitant use of these medications (Jones, Mogali et al. 2012).  
Hospitalizations due to opioids and benzodiazepines increased 400% and 39%, respectively, between 
1999 and 2006 (Coben, Davis et al. 2010), while death rates attributed to opioid analgesics was almost 
four times higher in 2008 compared to 1999 (Centers for Disease Control and Prevention 2011).  These 
trends may be attributed to several factors such as the rise and popularity of internet pharmacies 
(Manchikanti 2007), increases in generic drug manufacturing (Adis International 2002; Bailey, Barton et 
al. 2006; Srihari, Padmaja et al. 2009),  and national initiatives to address the under-treatment of pain 
which have been associated with increases in opioid prescriptions (Manchikanti 2007; Pletcher, Kertesz et 
al. 2008).  
While licit drugs were detected in a portion of this population, the findings of this analysis are not 
suggesting causation.  The fundamental challenge of studying the association between licit drugs and 
driving ability is that the relationship is not as clear as compared to alcohol (National Highway Traffic 
Safety Administration 2010) for numerous reasons.  First, drugs may affect individuals differently.  This 
could be attributed to a myriad of factors such as an individual’s genetics (Daly 2014), current health 
status (Bushardt, Massey et al. 2008), drug dosaging (Brown, Milavetz et al. 2013), drug interactions 
(Bushardt, Massey et al. 2008), or developed tolerance (Stein and Baerwald 2014).  Secondly, not all 
drugs affect driving ability.  Although, several drugs, including some of those found in this analysis, have 
been linked to increased motor vehicle collisions including barbiturates (Christensen, Nielsen et al. 1990), 
insulin (Hours, Fort et al. 2008), antihistamines (Verster and Volkerts 2004), narcotics (Bachs, Engeland 
et al. 2009), antipsychotics (Carr 2000), and muscle relaxants (Carr 2000).  Third, disease-medication 
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relationships are nearly impossible to distinguish.  It is possible that disease may be affecting an 
individual’s driving ability and not the medication taken to mitigate symptoms or disease progression.  
Several medical conditions have been associated with increased risk of motor vehicle collision including 
sleep apnea (Ellen, Marshall et al. 2006), dementia (Brown and Ott 2004), arthritis (Cross, McGwin et al. 
2009), diabetes (Hansotia and Broste 1991), epilepsy (Hansotia and Broste 1991), anxiety (Sagberg 
2006), depression (Sagberg 2006), and Parkinson’s disease (Uc, Rizzo et al. 2006). Given the decedent 
nature of the population, these points could not be explored. 
Limitations 
The strengths of this analysis are the use of multi-state data over a 5-year period.  The weaknesses 
of this study are the limitations imposed by the FARS data.  As previously mentioned, FARS does not list 
every drug in existence and many substances are listed as “Other”.  Therefore, it is unknown what type of 
pharmacologic agent (i.e. over-the-counter, prescription, etc.) an “Other” drug was.  Future research will 
likely involve trying to discern what other types of specific medications and combinations senior drivers 
involved in motor vehicle collisions consume.  A second limitation of the FARS data involves 
metabolites.  FARS simply lists the drugs detected in individuals; some of these reportable substances 
may be metabolites.  It may be difficult to determine the parent drug an individual consumed based on the 
metabolite reported, particularly if the parent drug was not detected or if a certain pharmacologic agent is 
a metabolite of more than one drug.  A third limitation of the FARS data is that not all drivers killed in 
fatal crashes are tested for drugs, and differences in state reporting do exist.  The sensitivity analysis 
sought to address these issues.  Additionally, a maximum of three drugs can be reported per person in 
FARS, which could be a bias in instances of extreme multiple-drug involvement.   Furthermore, the 
results of this analysis also do not prove that the drugs identified were the cause for collision or that—in 
the case of legal, prescription drugs—they were being misused or abused by the driver.  Also, the study 
population included more males than females; future studies could investigate gender differences in licit 




While the rates of licit and illicit drug use were considerably less among fatally injured senior 
drivers compared to fatally injured middle-aged drivers, some individuals in this population consumed 
medications which may have impaired their driving ability.  Among drug-positive senior drivers killed in 
U.S. traffic collisions, narcotic analgesics and benzodiazepines were often detected separately or in 
combination.  These findings suggest that driving under the influence of prescription medication may be a 
growing public health and traffic safety concern for the aging U.S. population.  Discernment must be 
raised amongst the public and healthcare providers that driving under the influence of commonly 
prescribed medications may be perilous not only to drivers, but to their passengers, pedestrians, and 





































Medication use and the risk of motor vehicle collision in West Virginia drivers 65 years of age and 
older: a case-crossover study 
Abstract 
Background: The current generation of older adults reports a higher lifetime prevalence of prescription, 
over-the-counter and recreational drug usage.  As older adults continue to drive later in life, concerns 
regarding how specific drugs affect driving ability are beginning to accrue.  The purpose of this analysis 
is to characterize the drug usage and determine the risk of motor vehicle collision associated with 
individual medications in a population of drivers ≥ 65 years of age. 
Methods: A case-crossover study was conducted at West Virginia University Healthcare’s facilities using 
data obtained from the electronic health records (n=611) of drivers aged ≥ 65 years who were admitted 
for treatment following a motor vehicle collision which occurred between Jan. 1, 2009 and June 30, 2014.  
Medication usage 14 days before the collision was matched to the medication usage which occurred 
during four control periods 350-365 days, 255-270 days, 165-180 days, and 75-90 days before the crash 
using conditional logistic regression. 
Results:  Analgesic, cardiovascular and gastrointestinal medicines were prevalent.  Few drivers tested 
positive for drugs.  Of those testing positive, benzodiazepines and opiates were the most common.  After 
adjusting for the number of medications taken during case and control periods, drivers consuming 
Tramadol (OR: 11.41; 95% CI 1.27, 102.15) were at a significantly increased risk of motor vehicle 
collision while taking this medication 14 days prior to collision compared to control periods. 
Conclusions: Older adult drivers who have a prescription for this medication should be made aware of its 
potential risks.  Further research is necessary in a larger, more nationally representative population as 
many other drugs were trending toward being associated with motor vehicle collision though were not 

























The United States (U.S.) is experiencing an unprecedented demographic shift as the number of 
adults 65 years of age and older (i.e. seniors) are the most rapidly growing subgroup of the population 
(McGwin, Sims et al. 2000).  By 2020, it is estimated that the number of licensed drivers over 65 years of 
age will exceed 40 million (Awadzi, Classen et al. 2008).  This demographic shift poses a unique 
challenge to both public health and traffic safety officials as senior drivers experience more motor vehicle 
fatalities (Massie, Campbell et al. 1995) and an increased rate of injurious crashes per mile driven 
compared to any other age group (Keall and Frith 2004).  
It is also well-established in the literature that medication usage increases with age; in the U.S., 
adults over 65 years of age consume more than 30% of all annual written prescriptions (Bushardt, Massey 
et al. 2008).  The current generation of older adults reports a higher prevalence of both lifetime licit (i.e. 
prescription and over-the-counter medications used to treat a medical condition) and illicit drug use (i.e. 
drugs used recreationally with no real medical benefit) compared to previous generations (Colliver, 
Compton et al. 2006).  As more adults continue to drive later in life compared to previous generations, 
concerns regarding how these drugs affect driving ability are beginning to amass (Kelly, Darke et al. 
2004; Walsh, de Gier et al. 2004).  While alcohol is a known contributor of motor vehicle collisions, the 
extent to which drugs other than alcohol contribute to crashes is less lucid.(Centers for Disease Control 
and Prevention 2006) There is evidence that driving under the influence of drugs is increasing nationally 
and that prescription medication, some of which may interfere with central nervous system functioning, 
are becoming more ubiquitous than illicit drugs among fatality injured drivers (Rudisill, Zhao et al. 2014; 
Wilson, Stimpson et al. 2014).   
The association between medications and motor vehicle collisions is largely understudied in the 
U.S. (Kelly, Darke et al. 2004; Walsh, de Gier et al. 2004), particularly among senior drivers (Lotfipour 
and Vaca 2007).  This issue may be of particular importance to West Virginia residents.  The population 
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of West Virginia is more mature compared to other states with more than 16% of the state’s residents 
being over 65 years of age (West Virginia Department of Health Bureau of Family Planning 2010).  
Previous research has also shown that both licit and illicit drug use contribute greatly to motor vehicle 
collisions in West Virginia (Centers for Disease Control and Prevention 2006).  The traffic fatality rate is 
also starkly higher—nearly 45% more--compared to other non-Appalachian states (Zhu, Zhao et al. 
2013).  Therefore, the purpose of this analysis is to explore which prescription and over-the-counter 
medications are most common, if illicit drug use is prevalent, and which prescription and over-the-counter 
medications are associated with an increased risk of motor vehicle collision among West Virginia drivers 
65 years of age or older.  Discerning this information may help guide future interventional and 
educational efforts to minimize death and disability from motor vehicle collisions in this population. 
4.2 Methods 
Study Design 
The design for this analysis is a case-crossover.  Developed by Maclure in 1991, case-crossover 
studies are similar to matched case-control studies in theory; the fundamental difference between the two 
study designs is that cases serve as their own controls in a case-crossover study (Maclure 1991).  The 
case-crossover design compares (i.e. matches) a case’s exposure during a time period immediately 
preceding an event (i.e. the case or ‘risk’ period) to the exposure in a time period when the event did not 
occur (i.e. control period) (Maclure 1991).  These designs are useful for studying the relationship between 
transient exposures and acute outcomes; they are commonly used in air pollution studies, traffic safety, 
and pharmacoepidemiology (Wang, Schneeweiss et al. 2004).  A benefit of the case-crossover design is 
that fixed confounders, such as age, race, sex, etc, are controlled for regardless if they were actually 
measured (Greenland 1996).  The sampling schema for this analysis is depicted in Figure 1.  The event of 
interest is a motor vehicle collision in which the driver required medical treatment.  The exposure of 
interest is the driver’s medication usage leading up to the collision.  The risk period is defined as the 14 
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days preceding the motor vehicle collision.  The reason as to why 14 days was chosen as the risk period 
as opposed to one of shorter duration is because medications may take time to accumulate and/or cause 
side-effects in an individual which may interfere with their driving ability.  Additionally, this length of 
risk period has been used in previous studies (Barbone, McMahon et al. 1998).  In order to increase 
statistical efficiency (Mittleman, Maclure et al. 1995), there are four matched control periods, each 15 
days long, at 350-365 days, 255-270 days, 165-180 days, and 75-90 days before the collision.  Control 
periods were chosen to be disjoint from one another to avoid possible correlation (Lumley and Levy 
2000). 
Study setting 
All cases received medical treatment from West Virginia University (WVU) Healthcare’s 
facilities located in Morgantown, WV.  Morgantown is a city with approximately 29,600 residents 
situated in Monongalia County in north-central West Virginia (West Virginia Department of Health and 
Human Resources 2010).  The size of the town can fluctuate throughout the year as it is home of West 
Virginia University, the state’s largest institution of higher education.  In 2012, approximately 25.1% of 
the patients served by WVU Healthcare resided in Monongalia county, while an additional 21.5% of 
patients lived in surrounding counties (i.e. Preston, Marion, and Taylor counties) (West Virginia 
University Healthcare 2013).  Approximately 38% of patients who sought treatment from WVU 
Healthcare were from other West Virginia counties, while another ~15% of patients were from 
surrounding states (i.e. Pennsylvania, Maryland, Ohio, Virginia and Kentucky) (West Virginia University 
Healthcare 2013).  Therefore, the population served by WVU Healthcare is fairly representative of the 
state.  The population of West Virginia is predominately of white non-Hispanic race/ethnicity and is 
comprised largely of older individuals (West Virginia Department of Health and Human Resources 2010).  
In 2010, heart disease, cancer, and chronic lower respiratory disease were the leading causes of death in 
this population (West Virginia Department of Health and Human Resources 2010). 
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Data sources and collection 
All data for this analysis were collected from the electronic medical records of eligible cases and 
obtained through Medsite and Epic (Merlin), WVU Healthcare’s electronic medical record systems.  Data 
was collected through a combination of manual data abstraction and through the assistance of the West 
Virginia University Clinical and Translational Science Institute’s (WVCTSI) Integrated Data Repository.  
In order to ensure the congruence of the data obtained from WVCTSI and the actual medical records, 
several electronic records were pulled and compared to ensure accuracy.  This study was approved by 
West Virginia University’s Institutional Review Board (protocol #1401165743).  
Case selection 
The sampling frame consisted of individuals 65 years of age and older at time of treatment and 
received treatment from emergency or trauma services or urgent care facilities from January 1, 2009 to 
June 30, 2014.  Cases had to be designated as a driver involved in a motor vehicle collision by the 
International Classification of Disease, Ninth Revision, Clinical Modification codes (ICD 9-CM) E810.0, 
E811.0, E812.0, E813.0, E814.0, E815.0, E816.0 and E819.0.  The E-codes used to identify the incident 
cases could have been listed as the primary or secondary diagnosis in the electronic medical record.   
Medication exposures 
Medications of interest were those considered potentially driver-impairing, meaning that they 
could possibly alter a driver’s cognition, psychomotor function, or physical functioning as suggested by 
the American Medical Association (American Medical Association 2010).  Medication usage up to a year 
before each case’s admittance for treatment was assessed.  Medications that were started up to 24 hours 
before admittance for treatment were not included in the analysis; this was done to avoid potential bias in 
the event that a medication was administered to a patient by emergency medical services (i.e. the 
medication was consumed after the collision occurred).  The duration of time that an individual was 
taking a particular medication was obtained directly from the medical record.  If the duration of 
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medication usage could not be determined or was not documented in the record, the medication was not 
included in the analysis as to avoid misclassification.  As many of the cases were existing patients of 
WVU Healthcare and/or due to the severity of the incurred injuries, medication records were fair in terms 
of completeness.  Of the 611 case visits included in this analysis, 581 cases had medications noted in their 
electronic health record at any point, while 292 cases had medication usage in the year preceding their 
motor vehicle collision.  An individual was considered ‘exposed’ if they were taking a medication at any 
point during the case and/or individual control periods.   
While the purpose of this analysis was to explore the risk of motor vehicle collision due to 
individual medication exposures, an analysis of more encompassing pharmaceutical sub-classes was also 
conducted.  This included anticholesteremics, anticoagulants, antidepressants (non-benzodiazepines), 
antihyperglycemics, antihypertensives, narcotic analgesics, and benzodiazepines.  In this particular 
analysis, anticholesteremics included 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors.  
Anticoagulants included both coumarin type and platelet aggregation inhibitors.  Antidepressants included 
tricyclic antidepressants, selective serotonin re-uptake inhibitors, serotonin antagonist and reuptake 
inhibitors, serotonin–norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, 
and noradrenergic and specific serotonergic antidepressants.  Antihyperglycemics included insulin, 
biguanides, insulin-release stimulants, combination biguanides and insulin-release stimulants, and 
thiazolidinediones.  Antihypertensives included angiotensin-converting-enzyme inhibitors, angiotensin 
receptor antagonists, and sympatholytic vasodilators.  Narcotic analgesics also included narcotic-
nonsalicylate combinations, and anesthetic adjunct agents. 
Other covariates 
Other variables of interest included age, gender, race, day, time, year, and season of admittance, 
how the patient was transported to medical treatment, treatment location, injury severity, insurance status 
of the patient, county and state of residence, employment status, length of hospital stay, health status, and 
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whether the patient was tested for drugs and/or alcohol at time of admittance.  Age was categorized as 65-
69, 79-79, 80-89 and ≥90 years.  Due to the homogeneity of the population, race was classified as white 
or other.  Day of admittance was categorized as weekday (i.e. Monday thru Thursday) or weekend (i.e. 
Friday thru Sunday).  Time of admittance was classified as daytime (7:00 AM to 6:59 PM) or night (7:00 
PM-6:59 AM).  For season of admittance, winter included December, January, and February, while spring 
comprised March, April, and May.  Summer included June, July, and August while fall included 
September, October, and November.  For method of transport, this was categorized as ambulance, 
helicopter, or self-transport.  Treatment location was grouped into trauma, emergency or urgent care 
departments; because so few patients were seen by urgent care (i.e. less than 10), urgent care and 
emergency were reported together to protect patient confidentiality.  Patient’s injury severity was based 
on acuity level at time of arrival for treatment.  Patient acuity levels that were noted as emergent or 
immediate were classified as severe injuries.  Acuity levels that were urgent were classified as moderate 
injuries.  Acuities that were less urgent or non-urgent were classified as minor injury severity.  Since 
acuity is not assigned within the Urgent Care facility, these were left unassigned.  Insurance status of the 
patient was grouped as government, private, none, or other/unknown.  Government insurance included 
Medicare or Medicaid programs.  Private insurance indicated that a patient had a commercial insurance 
plan.  If patient’s self paid, insurance status was noted as none.  Because there were few other types of 
insurance, these were grouped with unknown.  Because many patients resided in West Virginia, 
particularly Monongalia County, county and state of residence were grouped as Monongalia or other and 
West Virginia or other, respectively, to protect patient confidentiality.  Employment/work status was 
categorized as retired or employed.  If a patient reported that they were still working full, part-time or 
were self-employed, employment status was categorized as employed.  Chronic disease status was 
categorized as 0, 1-3, or 4 or more based on the number of chronic conditions patients were noted to have 
in their medical records.  For patient confidentiality purposes, these conditions were grouped as opposed 
to listing each individually.  The chronic conditions of interest, along with Clinical Classification 
Software codes or ICD 9-CM codes used to identify them in patients’ records, were as follows: heart 
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disease (96, 97, 100, 101, 103-108, 114, 117), stroke (109, 111, 112, 113), dementia (653), Alzheimer’s 
disease (331.0), diabetes (49,50), cancer (11-44), arthritis (201-203), Parkinson’s disease (79), 
hypertension (98-99), asthma (128), chronic obstructive pulmonary disease (127), alcoholism (660), 
depression (296.2, 296.3, 311), anxiety (651), chronic kidney disease (158), and substance 
abuse/dependency (661).  As part of the admission process, patient’s urine may have been laboratory 
tested for the presence of alcohol and/or drugs.  The drugs that can be detected are amphetamines, 
barbiturates, benzodiazepines, buprenorphine, cannabis, cocaine, opiates, phencyclidine and 
propoxyphene.  Results of drug testing were also noted. 
Statistical methods 
Because of the 1:4 matching of case to control periods, conditional logistic regression was used to 
calculate the odds of motor vehicle collision for each medication exposure (Greenland 1999).  Because of 
the study design (i.e. known longitudinal medication exposure over time), the odds ratio approximated the 
incidence rate ratio (i.e. risk) (Rothman, Greenland et al. 2008).  To account for the slight difference in 
exposure lengths of case and control periods (i.e. 14 days versus 15 days, respectively), the natural log of 
exposure time in days was used as the variable offset as suggested by Greenland (Greenland 1999).  
Because case-crossover studies are not immune to within person confounding, all regression models were 
adjusted for the number of medications a case was taking during each risk and control period.  The 
number of medications used served as a proxy of health status as a case’s health may have been time-
varying (i.e. improved or declined) over the study period.  All analyses were run using SAS/STAT 
Software version 9.3 (SAS Institute 2010), with α=0.05. 
4.3 Results 
The characteristics of cases and the circumstances surrounding their medical visits (n=611) are 
presented in Table 1.  The majority of cases were aged 65-69 (36.8%) or 70-79 years (41.2%) at time of 
treatment.  More males (54.0%) than females (46.0%) were admitted for treatment post-collision and 
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most were of white race (97.0%).  Over 60% of the medical visits occurred during the week and during 
daylight hours (75.7%).  More collisions occurred during the spring time (30.9%) and more patients were 
admitted during 2012 (25.2%) as opposed to other years.  While the method of transport to medical 
services was unknown for a large portion of the population (43.2%), ambulance was the primary method 
of transfer among those with known transportation.  As less than 10 patients were seen at urgent care, 
most patients were treated in the emergency department as opposed to trauma service (22.1%), though 
many of the injuries sustained were moderate to severe.  Most patients had government (54.2%) or private 
(29.6%) insurance coverage.  The majority of patients were West Virginia residents (80.4%).  While most 
patients were no longer working, 12.4% still held some form of employment.  Chronic conditions (i.e. 1 
or more) were common (82.4%).  Only 32% of patients were tested for drugs at time of admittance, while 
slightly more (44%) were tested for alcohol.           
Table 2 elaborates on the findings associated with the drug testing of cases.  Among those tested 
for drugs at time of admittance, 17% tested positive for benzodiazepines and 15.5% tested positive for 
opiates.  Of those that tested positive for benzodiazepines and opiates, nearly 50% had a traceable 
prescription for the substance during the past year.  It is possible that the other 50% received a 
prescription for these substances outside of the WVU Healthcare network, consumed pills left over from 
older prescriptions, possibly from sharing medications, or simply had incomplete documentation in their 
medical record.  Overall, drug use was not common in those tested as drug tests were negative for 
amphetamines, barbiturates, buprenorphine, cocaine, and phencyclidine.  
Table 3 lists the most common broad therapeutic groups of medications, individual medications, 
and combination drugs found in the population.  Analgesic, cardiovascular and gastrointestinal 
medications were the most prominent therapeutic groups.  As for specific medications, Aspirin, 
Metoprolol, Lisinopril, and Furosemide were the most common.  A combination of Oxycodone and 
Acetaminophen was the most common dual-drug compound. 
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Table 4 lists the most prevalent medications by therapeutic class along with subsequent 
unadjusted and adjusted odds ratios and 95% confidence intervals (CI) to approximate the risk of an 
individual’s involvement in a motor vehicle collision. After adjusting for the number of medications a 
driver was taking during each case and control period, individuals who were taking Tramadol (OR=11.41; 
95% CI 1.27, 102.15) were at a significantly increased risk of motor vehicle collision while taking this 
substance during the risk period compared to control periods.  Though not statistically significant, those 
taking Clopidogrel, Gabapentin, Citalopram, Insulin, Hydrochlorothiazide, Metoprolol, Zolpidem, and 
Nitroglycerine were trending towards an increased risk of collision.   
Table 5 lists larger therapeutic classes of medications along with subsequent crude and adjusted 
odds ratios and 95% CI to approximate the risk of an individual’s involvement in a motor vehicle 
collision while taking these substances during the risk period compared to control periods. After adjusting 
for the number of medications a driver was taking during each case and control period, all therapeutic 
classes were found statistically insignificant.  Although those taking anticoagulants, antihyperglycemics, 
and antihypertensive medications during case periods were trending towards an increased risk of motor 
vehicle collision compared to control periods.  
4.4 Discussion 
This analysis sought to explore which licit drugs were most common, if illicit drug use was 
prevalent, and which licit drugs were associated with an increased risk of motor vehicle collision among 
drivers 65 years of age or older who received medical services at WVU Healthcare facilities post-motor 
vehicle collision using a case-crossover approach.  Two principal findings were generated as a result of 
this analysis.  First, while few patients were tested for drugs at time of medical treatment, the drivers 
found drug-positive tended to test positive for prescription medications.  Typical illegal drugs, such as 
cocaine or phencyclidine, were not common in this population.  Second, despite small sample sizes, those 
taking Tramadol were at a significantly increased risk of motor vehicle collision if they took this 
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substance 14 days prior to collision compared to other control times.  Numerous other medications were 
also trending towards an increased risk of motor vehicle collision but were likely not found statistically 
significant due to small sample sizes and low statistical power.  Consequently, these findings may be of 
important clinical relevance and worthy of further exploration in a larger population. 
The findings from this analysis are consistent with the current literature.  Trend analyses have 
shown that prescription medications, particularly benzodiazepines and narcotic analgesics, are being 
detected more frequently than traditional illicit substances, such as cocaine and methamphetamine, among 
drug-positive drivers in the U.S. (Rudisill, Zhao et al. 2014; Wilson, Stimpson et al. 2014).  While the 
literature regarding drug usage among older adult drivers is limited, previous research has suggested that 
illicit drug usage may not be common among this population.  A study of drug usage among level 1 
trauma patients over 60 years of age involved in motor vehicle collisions (n=180) was conducted by 
Vanderbilt University (Higgins, Wright et al. 1996).  Their analysis revealed that alcohol and illicit drugs 
were detected in only 14% and 1%, respectively, of their study participants (Higgins, Wright et al. 1996).  
Therefore, the findings from this analysis were similar.   
As for the risk of motor vehicle collision posed by individual medications, two previous studies 
have investigated the risk of motor vehicle collision associated with the use of Tramadol (Bachs, 
Engeland et al. 2009; Gibson, Hubbard et al. 2009).  In the study by Bachs et al, Tramadol use was not 
significantly associated with an increased risk of  motor vehicle collision among a Norwegian cohort of 
adult drivers aged 18-70 years, though it was trending in the direction of increased risk (Risk: 1.5; 95% 
CI 0.9,2.3).  In the study by Gibson et al, Tramadol was significantly associated with an increased risk of 
collision (Risk: 9.17; 95% CI 7.81, 10.77) in an English cohort of drivers aged18-74 years.  At high 
doses, Tramadol is also known to affect balance (Mintzer, Lanier et al. 2010).  Poor balance has also been 
linked to an increased risk of motor vehicle collision, particularly in older populations (Gustavsen, 
Bramness et al. 2008).  Therefore what this analysis adds to the extant literature is that the effects of 
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Tramadol are likely not age-dependent because this analysis was limited to older adult drivers whereas 
other studies investigated drivers less than74 years of age and the results were comparable.  
Numerous other medications were also trending towards an increased risk of motor vehicle 
collision but were likely not found statistically significant due to small sample sizes and low statistical 
power.  This included Clopidogrel, Gabapentin, Citalopram, Insulin, Hydrochlorothiazide, Metoprolol, 
Zolpidem, and Nitroglycerin. To the authors’ knowledge, no studies have investigated whether 
Clopidogrel affects driving ability.  Two studies have investigated the relationship between anticoagulants 
and the risk/odds of motor vehicle collision.  A case-control study conducted by McGwin et al showed 
that elderly drivers in Alabama during 1996 who consumed anticoagulants were 2.6 times more likely to 
be involved in a motor vehicle collision (OR 2.6; 95 % CI 1.0, 6.7) (McGwin, Sims et al. 2000).  As to 
which medications were included in this categorization was not described.  A case-control study 
conducted by Delaney et al in Quebec, Canada showed that those taking Warfarin, another anticoagulant, 
were not at an increased risk of motor vehicle collision (OR 0.74; 95% confidence interval 0.55, 1.05) 
(Delaney, Opatrny et al. 2006), which was similar to what was seen in this analysis.  Gabapentin, a newer 
anti-epileptic medication, is not known to affect driving ability, though it may.  In a study conducted by 
Martin et al, healthy senior adults (mean age 66.5 years) experienced mild cognitive effects during 
psychomotor testing conducted in a laboratory setting (Martin, Meador et al. 2001).  Common complaints 
regarding Gabapentin use include dizziness, nausea, and somnolence (Gupta and Li 2013), which could 
affect one’s ability to drive.  While Citalopram has not been associated with an increased risk of motor 
vehicle collision in two other studies (Gibson and Hubbard 2009; Coupland and Dhiman 2011), second-
generation antidepressants are known to effect driving ability possibly due to side effects produced after 
initial use (Chang, Wu et al. 2013).  It is possible that those taking Citalopram in this analysis were 
experiencing side-effects, though it is unknown.  Several studies have investigated the association 
between Insulin use and the risk of motor vehicle collision (McGwin, Sims et al. 2000; Sims, McGwin et 
al. 2000; Cui 2001; Hemmelgarn, Lévesque et al. 2006; Lonnen, Powell et al. 2008; Skurtveit, Strøm et 
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al. 2009).  Most of the findings concerning Insulin use are mixed.  Two studies have found significantly 
increased risks of motor vehicle collision with Insulin use (Cui 2001; Skurtveit, Strøm et al. 2009), while 
four others have found no significant associations (McGwin, Sims et al. 2000; Sims, McGwin et al. 2000; 
Hemmelgarn, Lévesque et al. 2006; Lonnen, Powell et al. 2008).  To the authors’ knowledge, no studies 
have investigated the risk of motor vehicle collision associated with individual antihypertensive 
medications.  One study by McGwin et al did investigate the use of angiotensin-converting enzyme 
(ACE) inhibitors, beta-blockers, and diuretics, which all can be used to treat hypertension (McGwin, Sims 
et al. 2000).  After adjusting for age, sex, race, and annual miles driven, the odds of motor vehicle 
collision were 1.6 (95% CI: 1.0, 2.7), 1.4 (95% CI: 0.8, 2.3), and 0.9 (95% CI: 0.5, 1.7) for ACE 
inhibitors, beta blockers, and diuretics, respectively (McGwin, Sims et al. 2000).  In this analysis, 
Hydrochlorothiazide, a diuretic, and Metoprolol, a beta blocker, were both trending toward being 
associated with an increased risk of motor vehicle collision.  While the pharmacokinetic properties of 
these drugs may be a potential explanation, the reason as to why the effects of Hydrochlorothiazide on 
motor vehicle collision were so pronounced is unknown.  Zolpidem, a sleep-promoting medication, has 
consistently shown in four other studies to be associated with an increased risk of motor vehicle collision 
(Gustavsen, Bramness et al. 2008; Orriols, Philip et al. 2011; Yang, Lai et al. 2011; Hansen 2012).  While 
no studies have investigated the effects of individual vasodilators, such as Nitroglycerin, on motor vheicle 
colllsion, only one study investigated them as a pharmaceutical sub-class.  Mcgwin et al found that 
vasodilators were not assocated with an increased risk of collision (Mcgwin, Sims et al. 2000).  The 
reason as to why Nitroglycerin use in this analysis was trending towards an increased risk of motor 
vehicle collsion remains unknown.   
The findings from this analysis have several key clinical implications.  First, this study found 
Tramadol to be associated with an increased risk of collision and numerous other substances such as 
Clopidogrel, Gabapentin, Citalopram, Insulin, Hydrochlorothiazide, Metoprolol, Zolpidem, and 
Nitroglycerin, use to be trending towards an increased risk of motor vehicle collision.  While these results 
83 
 
are not conclusive, it may be worthy of notifying older patients who have prescriptions for these 
medications of their potential risk, particularly if they drive frequently.  Future interventional efforts 
could involve raising patient awareness.  Secondly, the findings of this study may suggest that drugs 
within the same pharmaceutical class maybe more or less driver impairing than others. This may be 
worthy of consideration to clinicians when prescribing medications to patients who drive frequently.    
The findings from this analysis do need to be interpreted with caution as disease-medication 
relationships are often difficult, if not impossible, to distinguish.  It is entirely possible that the disease in 
which the medications were prescribed could be affecting one’s ability to drive or their risk of motor 
vehicle collision.  Numerous medical conditions have been associated with motor vehicle collision, 
particularly sleep apnea (Ellen, Marshall et al. 2006), dementia (Brown and Ott 2004), arthritis (Cross, 
McGwin et al. 2009), diabetes (Hansotia and Broste 1991), epilepsy (Hansotia and Broste 1991), anxiety 
(Sagberg 2006), depression (Sagberg 2006), and Parkinson’s disease (Uc, Rizzo et al. 2006).  In addition, 
drugs that affect the central nervous system may exhibit different effects among individuals.   There are 
numerous intrinsic and extrinsic factors that can alter medication effectiveness and/or side effects among 
individuals.  These include, but are not limited to, drug solubility (Augustijns, Wuyts et al. 2014), 
intestinal pH (Augustijns, Wuyts et al. 2014), drug interactions (Berta, Harangi et al. 2014), age 
(Brzaković, Vezmar Kovačević et al. 2012), sex (Brzaković, Vezmar Kovačević et al. 2012; Chu 2014), 
weight (Brzaković, Vezmar Kovačević et al. 2012) ,diet (Siegmund, Siegert et al. 2012; Cingi, Toros et 
al. 2013), genetics (Daly 2014), circadian rhythms (Innominato, Roche et al. 2014), supplement use 
(Markert, Ngui et al. 2014), health of the individual (Joy, Frye et al. 2014), developed tolerance (Stein 
and Baerwald 2014), dosage (Brown, Milavetz et al. 2013), route of administration (Brown, Milavetz et 
al. 2013), etc.   
Several of these factors which may alter drug effectiveness were controlled for by design; the 
strength case-crossover studies are that all fixed confounders are controlled.  Despite this strength, this 
study has several distinct limitations.  First, certain time-varying covariates were not adjusted for as many 
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of them were immeasurable.  For example, driving exposure (i.e. the amount that an individual drives), is 
a known and important confounder of traffic studies (Blanchard, Myers et al. 2010) and could not be 
accounted for in this analysis because it is absent from the medical records.  Second, there were 
limitations associated with the medical records.  Much of the information collected was self-reported by 
the patient or their legal guardian and subject to recall bias.  Some of the information, such as medication 
duration, may have been incomplete or was simply not documented.  Also, the accuracy of E-codes for 
identifying potential cases in this analysis may have been lacking (Bowman, Aitken 2011); therefore 
some potential cases may have been unnecessarily excluded particularly if the patient was not coded 
properly.  Third, patient behavior in terms of their medication usage was unknown; it was impossible to 
determine if the patient was taking their medication as prescribed by their healthcare provider.  Fourth, 
the sample sizes in this analysis were often small and many statistical tests were likely under-powered.  
Also, several regression analyses were run, so statistical significance could have been achieved by chance 
alone.  Fifth, as this study was conducted in only one state, the findings may not be generalizable to other 
locations.  Sixth, as previously mentioned, disease-medication relationships are often difficult to 
distinguish.  The findings of this analysis are not suggesting that the medications were the cause of the 
motor vehicle collision; the findings are associative.  Lastly, a known weakness of case-crossover studies 
is that they are subject to selection bias in terms of choosing proper control periods (Greenland 1996).  
Future research may involve replicating this study in a larger population that is nationally representative 
or in a different age group.  
Conclusion 
This analysis sought to explore which licit drugs were most common, if illicit drug use was 
prevalent, and which licit drugs were associated with an increased risk of motor vehicle collision among 
West Virginia drivers 65 years of age or older using a case-crossover approach.  It was determined that 
analgesics, cardiovascular and gastrointestinal drugs were prevalent in this population.  While few drivers 
were tested, illicit drug use was uncommon.  Those taking frequently prescribed medications, such as 
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Tramadol, were at a significantly increased risk of motor vehicle collision while taking these substances 
during the 14 day risk period compared to control periods.  Many medications were trending towards an 
increased risk of motor vehicle collision but statistical models were likely under-powered.  Future 
research in this area is necessary as different medications may pose more risk to patient safety than others.  
The association between medication use and the risk of motor vehicle collisions is particularly important 



















5.1 Summary of key findings 
This dissertation research sought to explore licit and illicit drug usage among drivers 65 years of 
age and older in the United States via a systematic review of the literature (Chapter 2), a cross-sectional 
analysis of traffic fatality database (Chapter 3), and a case-crossover study of senior drivers admitted to 
medical treatment following a motor vehicle collision (Chapter 4).  Each study contributed a different key 
piece of information in which the other two studies alone could not answer. 
The findings presented in Chapter 2 helped frame the research pursued in Chapters 3 and 4 by 
determining which individual medications were associated with the increased odds/risk of motor vehicle 
collision and/or impaired driving ability.  The key finding of Chapter 2 was that among the 53 specific 
medications investigated by the 27 studies included in the review, 15 medications (28.3%) were 
associated with an increased risk of motor vehicle collision.  The medications that were associated with 
an increased risk of collision were: Buprenorphine, Codeine, Dihydrocodeine, Methadone, Tramadol, 
Levocitirizine, Diazepam, Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, 
Carisoprodol, Zolpidem, and Zopiclone.  The findings of this review illustrated that certain medications, 
even within the same class or drug category, may be more associated with crash risk than others.   
The cross-sectional analysis presented in Chapter 3 provided a unique perspective of drug 
prevalence among fatally injured drivers 65 years of age and older across the United States.  Chapter 3 
helped determine which individual, broad groups, and combinations of licit and illicit drugs senior drivers 
had actually consumed prior to their motor vehicle collision; the prevalence of these drugs was compared 
to a referent population of middle-aged drivers.  The key finding of Chapter 3 was that overall licit and 
illicit drug usage was not common among fatally injured senior drivers.  Those who did test positive 
(17.8%) tended to test positive for ‘other drugs’, narcotic analgesics and/or benzodiazepines.  Based on 
the limitation of the FARS data, it could not be determined what the ‘other drugs’ were; it was 
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hypothesized that these were cardiovascular or gastrointestinal medications as these are the most common 
medication types that older adults consume based on retail drug sales (Fulton and Allen 2005). 
 The case-crossover study presented in Chapter 4 enabled the characterization of drug use and the 
risk of motor vehicle collision posed by individual medications among drivers in West Virginia 65 years 
of age and older (as indicated by their electronic medical records).  The key findings to Chapter 4 were 
that analgesic, cardiovascular and gastrointestinal drugs were common.  Few drivers were screened for 
drugs at time of admittance to medical treatment.  Of those testing positive, benzodiazepines and opiates 
were the most common.  As for the association between medications and motor vehicle collision risk, 
senior drivers consuming Tramadol were at a significantly increased risk of motor vehicle collision if they 
consumed this medication 14 days prior to their motor vehicle collision compared to other control 
periods.  Numerous other medications, such as Clopidogrel, Gabapentin, Citalopram, Insulin, 
Hydrochlorothiazide, Metoprolol, Zolpidem, and Nitroglycerine, were trending towards an increased risk 
of motor vehicle collision though were not statistically significant. 
5.2 Significance of study findings 
Collectively, the findings of this dissertation research pose numerous clinical and research 
implications.  From a clinical perspective, the findings raise concerns regarding patients’ safety, 
awareness and/or education.  Based on the findings of Chapters 2 and 4, it was determined that 
Buprenorphine, Codeine, Dihydrocodeine, Methadone, Tramadol, Levocitirizine, Diazepam, 
Flunitrazepam, Flurazepam, Lorazepam, Temazepam, Triazolam, Carisoprodol, Zolpidem, and Zopiclone 
may pose an increased risk of motor vehicle collision to drivers.  Many of these medications are widely 
prescribed to seniors.  Also, among drivers who did test positive for drugs either at death or upon 
admittance for medical treatment, illicit substances were infrequent whereas prescription medications, 
such as benzodiazepines and narcotics, were common.  Therefore, patient awareness and educational 
efforts are needed to ensure patients who continue to drive late in life are aware of the risk that their 
medications may pose to their driving ability.  Education of older patients is particularly important 
because it is known that health literacy declines with age, which is possibly attributed to cognitive 
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declines (Baker, Gazmararian et al. 2000).  Also, it is known that patient education of this age group is 
lacking.  A study conducted by Kelly et al showed that many patients were not given proper instruction 
from their primary health care provider to limit or stop driving due to a recent diagnosis and/or 
prescription for a medication which could be driver-impairing (Kelly, Warke et al. 1999).  Interventional 
efforts in this area appear abundant. 
The findings of this dissertation also have research implications.  It is possible that individual 
medications within the same ‘type’ may pose different risks to patients then others.  This was seen in 
Chapter 4 with anticoagulants and antihypertensive medications where certain drugs within these 
categories were trending towards being protective against motor vehicle collision while others were not.  
While the exact reason as to why this was observed is unknown.  These findings may suggest that the 
pharmacokinetic properties of these drugs augment motor vehicle collision risk.  Further exploration of 
this issue is necessary.   
Individually, the findings of this dissertation research are also significant because they contribute 
to the extant gaps in the literature.  As no reviews have looked at the risk of individual medications on 
motor vehicle collision, the systematic review answered this question.  The cross-sectional analysis 
characterized drug use among older adult drivers in the U.S. which has not been done to date.  The case-
crossover study contributed to the limited information that exists regarding Tramadol; comparing this 
study to others, it appears that the effects of Tramadol are not age-dependent.  Also, the case-crossover 
study investigated individual medication use and the risk of motor vehicle collision.  To the authors’ 
knowledge, this has not been done to date. 
5.3 Strengths and limitations 
The strength of the present study is that it utilized different approaches (i.e. a systematic review, a 
cross-sectional study using national data, and a case-crossover study) to explore overall drug use and the 
relationship between licit drug use and motor vehicle collision among senior drivers.  Each study was a 
complement of the others.  Despite this strength, as discussed previously in Chapters 2 thru 4, each study 
had their own innate limitations.  Briefly, the systematic review was subject to publication bias.  The 
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cross-sectional analysis was subject to limitations surrounding the FARS data.  The case-crossover study 
was subject to small sample sizes and the completeness of the electronic medical records.  Despite these 
limitations unique to each study, the overarching limitation of this dissertation research involves 
confounding.  First, the relationships between disease, the natural aging process, and medication use are 
extremely convoluted.  It is nearly impossible to differentiate which is the most ‘responsible’ for declines 
in driving ability and/or increased motor vehicle collision risk.  It is entirely possible that the natural 
aging process or the underlying medical condition in which the medications were prescribed caused the 
individuals in this analysis to be involved in their motor vehicle collisions.  It is possible that the 
collisions could have been attributed to a combination of the three.  Second, driving exposure (i.e. the 
amount someone drives in the time period of interest), a known confounder of traffic studies (Blanchard, 
Myers et al. 2010), and ‘self-regulation’ could not be assessed.  It is a known phenomenon among older 
adults that they will regulate where and how much they drive when they perceive their driving ability to 
be compromised (D’Ambrosio, Donorfio et al. 2008). Driving exposure and self-regulation could not be 
accounted for in any of the studies.  Also, driver fault could not be adequately assessed in Chapter 3 or 
Chapter 4, which could also have been a confounder.  Despite the efforts taken to control for 
confounding, it is virtually impossible to eliminate entirely which may have biased the results. 
5.4 Future research  
Future research in this area of study is plentiful.  Future studies may involve trying to separate the 
effects of confounding surrounding the relationship between the aging process, chronic medical 
conditions, and medications.  Future studies could also involve repeating the case-crossover study in a 
larger, more nationally representative population.  Other studies could involve seeing if age mediates the 
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Figure 2. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 
between specific analgesic medications and MVC.  Estimates by Foley et al (Aspirin-3) were adjusted for age and gender; all 




Figure 3. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 
between specific anticonvulsant medications and MVC. The study by Etminan et al (Carbazepine-9) was adjusted for age, sex, 
residence, previous MVC, chronic disease score, and exposure to antidepressants, antiepileptic, benzodiazepines, antipsychotics, 







Figure 4. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 
between specific antidepressant medications and MVC.  The study by Hansen (Trazadone-26) provided two estimates.  The first 





Figure 5. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 





Figure 6. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 
between specific antihyperglycemic medications and MVC.  The study by Lonnen et al provided five estimates of risk (Insulin-
15a-e).  These correspond to the risk of MVC for the following age groups respectively, <25, 25-44, 45-64, 65-74, and 75-84 
years of age.  The study by Mcgwin et al provided two estimates of risk (Insulin-5a-b), which corresponds with the odds of 
having any crash or a not-at-fault crash, respectively. The study by Mcgwin et al was adjusted for age, sex, and annual miles 
driven.  The study by Sims et al was adjusted for sex, age, and days driven per week (Insulin-6).  The study by Hemmelgarn et al 
was adjusted for age, gender, previous MVC, and place of residence (Insulin-11).  All other estimates are unadjusted. 
 
Figure 7. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 
between specific benzodiazepine medications and MVC.  Hansen provided two estimates of risk (Temazepam-26a-b) which 








Figure 8. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 
between specific sleep-promoting medications and MVC.  Hansen (Zolpidem-26a-b) provided two estimates of risk which 
correspond to new and prevalent users of Zolpidem, respectively.  The estimates provided by Yang et al (Zolpidem-23 and 
Zopiclone-23) were adjusted for concomitant use of the following medications: Zolpidem, Zopiclone, long and short acting 
benzodiazepines, antihistamines, anticonvulsants, antidepressants, other sedatives/hypnotics, other psychoactive drugs, muscle 
relaxants, and opioid analgesics.  All other estimates are unadjusted. 
 
Figure 9. Odds or risk ratios with corresponding 95% confidence intervals from included studies that investigated the association 
between MVC and specific medications that could not be grouped into the other drug categories.  Delaney et al provided two 
estimates of risk (Warfarin-10a-b) which correspond to both new and prevalent users, respectively, of Warfarin. The study by 
Delaney et al was adjusted for cardiac or stroke events within the past year and the following drug classes in the previous 60 
days: antidepressants, anti-epileptics, benzodiazepines, antipsychotics, anti-migraine, narcotic analgesics, muscle relaxants.  The 
study by Sims et al was adjusted for sex, age, and days driven per week (Estrogen-6).  The study by Etminan et al was adjusted 
for age, sex, residence, previous MVC, chronic disease score, and exposure to antidepressants, antiepileptic, benzodiazepines, 




































Table 1. Characteristics of fatally injured drivers ≥65 years with known drug test resultsa 
Characteristic Drivers 
≥65 years who tested 
negative for drugs 
(N=4,789) 
Drivers 
≥65 years who tested 
positive for drugs 
(N=1,039) 
Total Drivers 
≥65 years with 

















Age (in years)       
65-69 1,306 27.3 353 34.0 1,659 28.5 
70-79 1,885 39.4 431 41.5 2,316 39.7 
80-89 1,382 28.9 229 22.0 1,611 27.6 
≥90 216 4.5 26 2.5 242 4.2 
Gender       
Male 3,309 69.1 737 70.9 4,046 69.4 
Female 1,480 30.9 302 29.1 1,782 30.6 
Race       
White 3,466 91.3 804 92.3 4,270 91.5 
African American 239 6.3 49 5.6 288 6.2 
Asian 57 1.5 9 1.0 66 1.4 
Native American 30 0.8 6 0.7 36 0.8 
Other 3 0.1 3 0.3 6 0.1 
Unknown 994  168  1162  
Ethnicity       
Hispanic 132 3.5 21 2.4 153 3.3 
Non-Hispanic 3,642 96.5 850 97.6 4,492 96.7 
Unknown 1,015  168  1,183  
Type of drug test given       
Urine 172 3.7 40 3.9 212 3.7 
Blood 4,336 92.5 864 85.2 5,200 91.2 
Urine & Blood 180 3.8 110 10.9 290 5.1 
Unknown 101  25  126  
Blood alcohol concentration 
(g/dl) 
      
0 4,327 90.0 915 88.0 5,242 90.0 
0.01-0.07 149 3.0 46 4.0 195 3.0 
≥0.08 313 7.0 78 7.0 391 7.0 
Number of drugs detected at 
time of crashb 
      
0 4,789 100.0 NA  4,789 82.2 
1  NA  653 62.9 653 11.2 
2  NA  241 23.2 241 4.1 
3  NA  145 14.0 145 2.5 
DWI conviction within past 
3 yearsc 
      
No 4,717 99.5 1,023 99.2 5,740 99.5 
Yes 23 0.5 8 0.8 31 0.5 
Unknown 49  8  57  
Crash within past 3 years       
 No  4,127 89.4 908 88.8 5,035 89.3 
Yes 489 10.6 115 11.2 604 10.7 
138 
 
Unknown 173  16  189  
Day of crash       
Friday-Sunday 1,906 39.8 438 42.2 2,344 40.2 
Monday-Thursday 2,883 60.2 601 57.8 3,484 59.8 
 
Time of crash 
      
Day (7:00am-6:59pm) 3,928 82.4 831 80.4 4,759 82.0 
Night (7:00pm-6:59am) 839 17.6 203 19.6 1,042 18.0 
Unknown 22  5  27  
Number of vehicles 
involved 
      
1 1,762 36.8 428 41.2 2,190 37.6 
≥2 3,027 63.2 611 58.8 3,638 62.4 
Weather conditions at time 
of crashd  
      
Clear 4,267 89.1 937 90.2 5,204 89.3 
Adverse 522 10.9 102 9.8 624 10.7 
Survival time after crash       
Death within 1 hour 2,612 57.1 553 55.0 3,165 56.7 
Death beyond 1 hour 1,963 42.9 452 45.0 2,415 43.3 
Unknown 214  34  248  
Year of crash       
2008 1,056 22.1 166 16.0 1,222 21.0 
2009 956 20.0 191 18.4 1,147 19.7 
2010 960 20.1 194 18.7 1,154 19.8 
2011 924 19.3 243 23.4 1,167 20.0 
2012 893 18.7 245 23.6 1,138 19.5 
 
a:States included in this analysis are AK, AZ, CA, CO, FL, HI, IL, IN, KY, MD, MA, MI, MN, NV, NH ,NJ, NM, NY, ND, OH, 
PA, RI, SC, VT, VA, WA, WV, WY, and Washington, DC. 
b: N/A=not applicable 














Table 2.  Prevalence and prevalence ratios for drug presence among sub-groups of fatally injured drivers ≥65 yearsa 










Age (in years)    
65-69 353 212.8 1.00 (Reference) 
70-79 431 186.1 0.87 (0.76, 1.01) 
80-89 229 142.5 0.67 (0.57, 0.79) 
≥90 26 107.4 0.50 (0.34, 0.75) 
Gender    
Male 737 182.2 1.00 (Reference) 
Female 302 169.5 0.93 (0.81, 1.06)  
Race    
White 804 188.3 1.00 (Reference) 
African American 49 170.1 0.90 (0.68, 1.21) 
Asian 9 136.4 0.72 (0.38, 1.40) 
Native American 6 166.7 0.89 (0.40, 1.98) 
Other 3 500.0 2.66 (0.85, 8.25) 
Unknown 1,162   
Ethnicity    
Non-Hispanic 850 189.2 1.00 (Reference) 
Hispanic 21 137.3 0.73 (0.47, 1.12) 
Unknown 1,183   
Type of drug test given    
Blood 864 166.2 1.00 (Reference) 
Urine 40 188.7 1.14 (0.83, 1.56) 
Urine & Blood 110 379.3 2.28 (1.87, 2.78) 
Unknown 126   
Blood alcohol concentration 
(g/dl) 
   
0 915 174.6 1.00 (Reference) 
0.01-0.07 46 235.9 1.36 (1.01, 1.82) 
≥0.08 78 199.5 1.14 (0.90, 1.44) 
DWI conviction within past 
3 yearsc 
   
No 1,023 178.2 1.00 (Reference) 
Yes 8 258.1 1.45 (0.72, 2.90) 
Unknown 57   
Crash within past 3 years    
 No  908 180.3 1.00 (Reference) 
Yes 115 190.4 1.06 (0.87, 1.28) 
Unknown 189   
Day of crash    
Monday-Thursday 601 172.5 1.00 (Reference) 
Friday-Sunday 438 186.9 1.08 (0.96, 1.23) 
 
Time of crash 
   
Day (7:00am-6:59pm) 831 174.6 1.00 (Reference) 
Night (7:00pm-6:59am) 203 194.8 1.12 (0.96, 1.30) 
















a:States included in this analysis are AK, AZ, CA, CO, FL, HI, IL, IN, KY, MD, MA, MI, MN, NV, NH ,NJ, 
NM, NY, ND, OH, PA, RI, SC, VT, VA, WA, WV, WY, and Washington, DC. 
                                b: CI= confidence interval 





Number of vehicles 
involved 
   
1 428 195.4 1.16 (1.03, 1.32) 
≥2 611 168.0 1.00 (Reference) 
Weather conditions at time 
of crash 
   
Clear 937 180.1 1.00 (Reference) 
Adverse 102 163.5 0.91 (0.74, 1.11) 
Survival time after crash    
Death within 1 hour 553 174.7 1.00 (Reference) 
Death beyond 1 hour 452 187.2 1.07 (0.95, 1.21) 
Unknown 248   
Year of crash    
2008 166 135.8 1.00 (Reference) 
2009 191 166.5 1.23 (1.00, 1.51) 
2010 194 168.1 1.24 (1.01, 1.52) 
2011 243 208.2 1.53 (1.26, 1.87) 
2012 245 215.3 1.58 (1.30, 1.93) 
 





Drug Category  
 
Drivers ≥65 years 
(No. Drivers Tested=5,828) 
   














Rate ratioa, (95% CIb) 
 










0.53 (0.50, 0.57) 
 











0.43 (0.39, 0.48) 
 










0.12 (0.10, 0.15) 
 










0.21 (0.19, 0.24) 
 
 
a: Rates and ratios were attained through Poisson regression with robust error variance and controlled for the random 
effects of state 



















Table 4. Proportions of broad drug categories and specific drugs identified in fatally injured drivers  
 
Drug Category or Type 
 
Drivers ≥65 years old 
(No. Positive=1,039) 
  











Broad drug categories 
     
Others 451 43.4  917 17.8 
Narcotics 387 37.2  1,312 25.5 
Depressants 330 31.8  1,226 23.9 
Cannabinoid 66 6.4  1,778 34.6 
Stimulants 57 5.5  1,564 30.4 
      
Specific drugs 
 
     
Benzodiazepines 271 26.1  1,098 21.4 
Hydrocodone/Oxycodone 184 17.7  842 16.4 
Barbiturates 29 2.8  75 1.5 
Cocaine 19 1.8  896 17.4 
Methadone 15 1.4  200 3.9 
 



















Age (years)   
65-69 225  (36.8) 
70-79 252  (41.2) 
80-89 119  (19.5) 
≥90 15  (2.5) 
Gender   
Male 330  (54.0) 
Female 281  (46.0) 
Race   
White 560  (97.0) 
Other 17  (3.0) 
Missing 34  
Day of admittance   
Mon-Thurs 368  (60.2) 
Fri-Sun 243  (39.8) 
Time of admittance   
7:00AM-6:59PM 462  (75.7) 
7:00PM-6:59AM 148  (24.3) 
Season of admittance   
Winter 133  (21.8) 
Spring 189  (30.9) 
Summer 147  (24.1) 
Fall 142  (23.2) 
Year of admittance   
2009 102  (16.7) 
2010 87  (14.2) 
2011 89  (14.6) 
2012 154  (25.2) 
2013 110  (18.0) 
2014 69  (11.3) 
Method of transport   
Ambulance 248  (40.6) 
Helicopter 62  (10.2) 
Self 37  (6.1) 
Other/Unknown 264  (43.2) 
Treatment location   
Trauma 135  (22.1) 




Minor 29  (9.0) 
Moderate 43  (13.4) 
Severe 250 (77.6) 
Unknown 289  
Insurance status   
Government 331 (54.2) 
144 
 
Private 181 (29.6) 
None 30  (4.9) 
Other/Unknown 69  (11.3) 
   
County of residence   
Monongalia 92 (15.4) 
Other 506 (84.6) 
Missing 13  
State of residence   
WV 491  (80.4) 
Other/Missing 120  (19.6) 
Work status   
Employed 74  (12.4) 
Retired 523 (87.6) 
Missing 14  
Number of chronic conditions   
0 108 (17.6) 
1-3 314 (51.4) 
≥4 189 (31.0) 
 






Yes 61  (31.4) 
No 133 (68.6) 
Missing 417  
Alcohol detected   
Yes  12  (4.5) 
No 257 (95.5) 
Missing 342  
 
 
Table 2. Most common drugs identified in cases via laboratory testing 




Cases testing positive who have 




Total cases tested 194  
Benzodiazepines 33 (17.0) 16 (48.5) 








Table 3. Most frequently identified broad therapeutic groups, specific medications, and combinations among cases 
up to 365 days before collision 
Total cases  
(N=611) 




Broad therapeutic groups   
Analgesics 82 (13.4) 
Cardiovascular 81 (13.3) 
Gastrointestinal 74 (12.1) 
Psychotherapeutics 48 (7.9) 
Specific medications   
Metoprolol 38 (6.2) 
Aspirin 33 (5.4) 
Esomeprazole 30 (4.9) 
Lisinopril 27 (4.4) 
Furosemide 21 (3.4) 
Combinations   



















Table 4. The risk of involvement in a motor vehicle collision by medication exposure 
   









OR (95% CI) 
Model 2 
OR (95% CI) 
Anticholesteremic      
Simvastatin 12 1.00  (0.12, 8.17) 0.42 (0.03,07.23) 
Anticoagulants      
Clopidogrel 10 10.73  (1.19, 96.67) 7.62 (0.48, 122.10) 
Warfarin 10 0.72  (0.06, 9.04) 0.30 (0.08, 1.22) 
Anticonvulsants      
Gabapentin 15 2.69  (0.59, 12.32) 1.32 (0.24, 7.17) 
Antidepressants      
Citalopram 10 3.01  (0.31, 29.65) 3.21 (0.24, 42.50) 
Antihyperglycemics      
Insulin 12 15.76  (1.78, 139.61) 2.63 (0.14, 48.72) 
Antihypertensive      
Furosemide 12 0.50  (0.08, 3.22) 0.81 (0.06, 10.62) 
Hydrochlorothiazide 13 12.35  (1.35, 113.06) 15.01 (0.76, 296.60) 
Lisinopril 25 1.56  (0.43, 5.69) 0.27 (0.05, 1.60) 
Metoprolol 29 5.29  (1.31, 21.38) 1.16 (0.23, 5.79) 
Muscle Relaxants      
Albuterol 11 0.44  (0.06, 3.20) 0.25 (0.02, 3.34) 
Narcotic Analgesics      
Hydrocodone 15 1.32  (0.36, 4.92) 0.37 (0.04, 3.79) 
Tramadol 11 10.56  (1.17, 95.51) 11.41 (1.27, 102.15) 
Sleep Medications      
Zolpidem 10 4.20   (0.73, 24.13) 1.42 (0.66, 3.00) 
Steroids      
Fluticasone 11 0.56  (0.08, 3.89) 0.41 (0.04, 4.85) 
Prednisone 12 0.12  (0.01, 1.07) 0.19 (0.02, 1.82) 
Vasodilators      
Nitroglycerin 12 2.54  (0.42, 15.23) 1.27 (0.07, 23.82) 
Other Drugs      
Alendronate 10 1.15  (0.22, 6.04) 0.13 (0.01, 1.78) 
Combination Drugs      
Oxycodone and Acetaminophen 16 0.61  (0.18, 2.00) 0.17 (0.02, 1.63) 
 
a: Conditional logistic regression was used to calculate the odds ratios and 95% CI. Each case’s medication exposure during the 
14 day risk period immediately before the crash was matched to four separate control periods up to one year before the collision 
to assess if medication use during the risk period was associated with an increase of motor vehicle collision compared to control 
periods. Model 1 is the crude estimate (i.e. unadjusted) while Model 2 was adjusted for the number of medications a person was 




Table 5. The risk of involvement in a motor vehicle collision by medication exposure categorized by pharmaceutical 
sub-class 
   




Medication sub-class N 
 
Model 1  
Odds Ratio (95% CI) 
Model 2  
Odds Ratio (95% CI) 
Anticholesteremics 31 1.50 (0.44, 5.18) 0.42 (0.08, 2.21) 
Anticoagulants 20 3.59 (0.84, 15.28) 2.29 (0.35, 15.19) 
Antidepressants 30 2.05 (0.59, 7.16) 0.50 (0.09, 2.67) 
Antihyperglycemics 22 15.36 (1.79, 132.0) 2.24 (0.17, 29.84) 
Antihypertensives 39 3.32 (1.15, 9.62) 1.24 (0.29, 5.32) 
Benzodiazepines 21 1.96 (0.58, 6.62) 0.71 (0.15, 3.34) 
Narcotic Analgesics 41 1.56 (0.72, 3.39) 0.94 (0.32, 2.75) 
 
a: Conditional logistic regression was used to calculate the odds ratios and 95% CI. Each case’s medication exposure during the 
14 day risk period immediately before the crash was matched to four separate control periods up to one year before the collision 
to assess if medication use during the risk period was associated with an increase of motor vehicle collision compared to control 
periods.  Model 1 is the crude estimate (i.e. unadjusted) while Model 2 was adjusted for the number of medications a person was 
taking at each case and control period. 
 
 
 
 
 
 
 
 
 
 
 
 
